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Abstract 
Since the 1970s, cancer in children and young people has become both 
increasingly common and more survivable. Whilst physical late effects of 
cancer are well documented, less is known about long-term mental health. A 
systematic review highlighted increased mental ill health amongst childhood 
and young adult cancer survivors. However, few studies included clinician-
diagnosed mental health problems, and no population-based studies were 
found. 
The Yorkshire Specialist Register of Cancer in Children and Young People 
was used to identify 7253 long-term survivors of early-life cancer. Records 
from routinely collected mental health data sets were used to identify 
individuals who had had contact with specialist mental health services, or 
who had a recorded mental health condition during an inpatient hospital 
stay. These were compared with population rates of specialist mental health 
services use and recorded mental health conditions, and standardised 
incidence ratios were calculated. Logistic regression was used to identify 
sub-groups at increased risk of mental health difficulties. 
Cancer survivors were 73.7% more likely than the general population to 
have a recorded contact with specialist mental health services, but no more 
likely to have a recorded mental health diagnosis during an inpatient stay. 
Teenagers and young adults treated on specialist teenage and young adult 
units had more specialist mental health services contacts than those treated 
on standard wards. 
The increased risk of mental health services use amongst cancer survivors 
should prompt clinicians to routinely enquire about mental health during 
contacts with this cohort. The increased risk amongst teenagers and young 
adults treated on specialist units was surprising, and it is unclear whether 
this represents a true increase in prevalence of mental ill health, or simply 
improved access to specialist services. Further work to understand the 
reasons behind increased mental health services use is essential, and 
should include analysis of primary care records. 
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Chapter 1 Introduction  
1.1 Cancer in Children and Young People 
1.1.1 What is Cancer? 
Cancer is the term given to a group of diseases which are characterised by the 
uncontrolled proliferation of abnormal cells1,2.  
Cancer can occur in any tissue in the body, and may affect individuals of all 
ages and backgrounds. However, there are some factors which make the 
development of cancer more likely. In adult patients, these include lifestyle 
factors, such as tobacco usage3, excessive alcohol consumption4 and obesity5. 
Genetic factors may predispose to cancer in both adults and children. Genetic 
factors associated with increased risk of cancer include cancer predisposition 
syndromes such as Li Fraumeni6 and constitutional mismatch repair deficiency 
syndrome7, as well as other disorders where increased risk of malignancy is 
part of a wider clinical spectrum, such as Trisomy 21 (Down’s syndrome)8, 
neurofibromatosis type 1 (NF1)9 and Fanconi anaemia10.  
Approximately 50% of all people are expected to develop cancer during their 
lifetime11, and cancer is the cause of more than a quarter of all deaths in the 
United Kingdom12, although the majority of these cases and deaths occur in the 
adult population.  
1.1.2 Epidemiology 
Childhood cancer (diagnosed under the age of 15 years) is a rare entity, 
accounting for just 1% of all cancer cases13. However, incidence of cancer in 
children has been steadily rising globally since the late 1970s14. Incidence rates 
of childhood cancer have increased by around a quarter in this period, rising 
slightly more in girls than boys, although cancer remains more common in 
boys14. Between 2012 and 2014, there were 164 new cancer cases for every 
million boys and 147 for every million girls in the UK14. Figure 1.1a shows the 
increasing incidence of childhood cancer between 1993 and 2016. Teenage 
and young adult (TYA) cancer (diagnosed between the ages of 15 and 24 
years) has risen markedly in the same time period, with 280 new cancer cases 
for every million males and 307 for every million females in the UK between 
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2012 and 201415. Figure 1.1b shows the increasing incidence of TYA cancer 
between 1993 and 2016. 
Figure 1.1a Incidence of childhood cancer per million per year between 1993 
and 2016. Image from Cancer Research UK14 
4 
Figure 1.1b Incidence of TYA cancer per 100,000 between 1993 and 2016. 




Cancers in children and young people (CYP) present an important health issue, 
not just because of their increasing number but because they may result in 
considerable mortality. The term “children and young people” in this context 
refers to children plus TYA, i.e. all cancer patients 24 years of age and 
younger. Cancer is the leading cause of death in children, accounting for 
around 20% of deaths in 1 to 14 year olds16. Cancer is the leading cause of 
death in female TYA, and the leading cause of death from disease in male 
TYA, although transport accidents account for more deaths in this group17. 
Moreover, when cancer affects CYP, there are potentially many more years of 
life lost than when it affects older adults18. As well as being a leading cause of 
mortality, CYP’s cancer can result in marked morbidity and associated cost19, 
with much of this morbidity persisting for the duration of the CYP’s lives20.  
Since the late 1970s, in the same time period that CYP’s cancer rates have 
increased, survival rates have dramatically improved. The survival rates for 
childhood cancer have more than doubled21 and those for TYA have also 
improved considerably22. More than 80% of children and young adults 
diagnosed with cancer now survive for at least 5 years21,22 and three quarters 
of children diagnosed before the age of 15 survive for at least 10 years21. 
Figure 1.2a shows 1, 5 and 10 year survival for children diagnosed with cancer 
between 1971 and 2010, broken down by cancer type. Although TYA survival 
rates have not increased as sharply as childhood survival rates, this is offset 
against an already much higher baseline22. Figure 1.2b shows five-year 
survival estimates for TYA diagnosed with cancer between 1991 and 2005.  
The prevalence of adult survivors of CYP’s cancer is consequently ever 
increasing. It has been estimated that there are currently over 35,000 adult 
survivors of childhood cancer living in Great Britain23, although this estimate is 
based on somewhat dated information24. As a result, any morbidity burden 
experienced by this population takes on increasing importance to health and 





Figure 1.2a 1, 5 and 10 year survival for children diagnosed with different 
cancer types between 1971 and 2010. Image from Cancer Research UK21 
 
Figure 1.2b 5 year survival rates for TYA diagnosed with cancer between 1991 
and 2005. Image from Cancer Research UK22a
  
                                            
a CNS = central nervous system 
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1.1.3 Cancer Classification 
Cancer in CYPs is biologically distinct from adult cancer, and is therefore 
classified differently, according to morphological features. Childhood cancer is 
classified according to the International Classification of Childhood Cancer 
(ICCC)25, whilst TYA cancer is usually classified according to the Birch 
system26. The commonest cancers in children (under 15 at diagnosis) in the 
United Kingdom are leukaemias (approximately 434 new cases per year) and 
central nervous system (CNS) tumours (approximately 329 new cases per 
year)27,28 whilst carcinomas (576 new cases per year) and lymphomas (461 
new cases per year) are the most common cancers in TYA29. This is in contrast 
to adults, for whom breast, prostate, lung and bowel cancers are the most 
common diagnoses30. These differences in biology and classification mean that 
it is essential for CYP’s cancer to be studied thoroughly, and separately from 
cancer affecting older adults. Figures 1.3a and 1.3b show the most common 




Figure 1.3a Most common cancer types by age at diagnosis, for male patients. 





Figure 1.3b Most common cancer types by age at diagnosis, for female 






The term leukaemia refers to a malignant disease of the haematopoietic 
tissues31. Both the ICCC and Birch systems classify leukaemias as their first 
major diagnostic group. This group accounts for the greatest number of 
childhood cancer cases27, although a smaller number of TYA cancers15. As well 
as being common, leukaemias are survivable, with over 80% of children 
diagnosed between 2001 and 2005 surviving for at least 5 years32.  
Acute lymphoblastic leukaemia (ALL) is the commonest form of leukaemia, 
accounting for around 75% of leukaemia cases in children, and around 30% of 
all childhood cancers27. Incidence peaks at 1-4 years of age, at 80-85 cases 
per million per year14. In TYA, ALL accounts for 46% of leukaemias, but only 
9% of overall cancers15. The prognosis in ALL has improved dramatically over 
time33, and the 5 year survival rate for children in the UK is now well over 
90%34. Although survival is slightly lower in TYA, it is still approaching 80%35. 
Thus, a large proportion of long-term cancer survivors will have had an initial 
diagnosis of ALL. 
Acute myeloid leukaemia (AML) accounts for fewer leukaemia cases in CYP, 
but still comprises a substantial proportion36. Incidence has an early peak in the 
first year of life, at around 16 cases per million per year, and then falls to 4-7 
cases per million per year throughout childhood14. Incidence then increases 
with age, to 10-15 cases per million per year in TYA37. The prognosis for AML 
is less positive than for ALL, with mortality around 40%38. 
Other forms of leukaemia are much less common in the CYP population. 
1.1.3.2 Lymphomas 
Lymphomas, or malignant diseases of the lymphatic tissues, are considered as 
a distinct diagnostic group by both the ICCC and Birch systems. Some 
analyses and definitions will group leukaemias and lymphomas together as 
“haematological malignancies”39. Lymphomas account for a considerable 
proportion of TYA cancers29 and, like leukaemias, have a good prognosis, with 
5 year survival well above 80%32. 
Hodgkin’s lymphoma (HL) accounts for a large proportion of CYP lymphoma 
cases, accounting for 45% of cases in children14 and two-thirds of cases in 
TYA15 and has an excellent prognosis, with 5 year survival rates around 98%35. 
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HL has an incidence of under 10 per million per year in the under 10s, but this 
increases rapidly throughout the TYA age group to almost 50 cases per million 
per year in older TYA40. 
Non-Hodgkin’s lymphoma (NHL) has a less favourable prognosis, although 
survival still exceeds 80%35. Incidence is 1-3 cases per million per year 
throughout the CYP age group41. 
1.1.3.3 Central Nervous System Tumours 
CNS tumours are also a distinct group in both the ICCC and Birch systems, 
and are the commonest solid tumour type in children27. Survival from CNS 
tumours differs markedly amongst different tumour sub-groups. CNS tumours 
are classified according to the World Health Organisation (WHO) grading 
system42. Grading is from I to IV; grade I tumours are slow growing, non-
malignant tumours associated with good long term survival and grade IV 
tumours are highly aggressive, rapidly growing malignant tumours associated 
with much poorer outcomes. 
CNS tumours affect similar numbers of individuals throughout the CYP age 
group, with around 50 cases per million per year43. 
For the purposes of this thesis, grade I and II tumours have been grouped 
together as “low grade” tumours and grade III and IV tumours have been 
grouped as “high grade” tumours. 
1.1.3.4 Neuroblastoma 
Neuroblastomata are rare tumours of the primordial neural crest cells, which 
mainly affect very young children. The incidence of neuroblastoma in the under 
5s is 20-25 cases per million per year, but falls sharply thereafter to around 1 
per million per year in 10-14s28. Neuroblastomata are extremely rare in the TYA 
age group44. The ICCC classifies neuroblastoma as a distinct group, whereas 
under the Birch system they would be classified within “miscellaneous specified 
neoplasms”. Despite being classified as a single disease, and originating from 
the same cell type, there are major differences between sub-types of 
neuroblastoma. Some low-risk sub-types, commonly seen in infants, have an 
excellent prognosis with minimal or even no treatment, whilst high-risk disease 
is highly aggressive and has survival rates of less than 50%44. Risk 
stratification is based on factors including age at diagnosis, stage, cytogenetic 
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factors such as MYC-N amplification status, and histological features45. The  
International Neuroblastoma Risk Group have produced comprehensive 
guidelines to allow appropriate assessment of risk for individual patients46. 
MYC-N amplification always confers a poorer prognosis and all tumours with 
this finding are considered high risk. Localised and well differentiated tumours 
are lower risk than metastatic and poorly differentiated tumours45. 
1.1.3.5 Retinoblastoma 
Retinoblastoma is a very rare ocular tumour seen in very young children. Like 
neuroblastoma, it is classified as a distinct tumour group by the ICCC but would 
be classified within “miscellaneous specified neoplasms” by the Birch system. 
There are just over 10 cases per million per year in the under 5s annually in 
England, and almost no cases in older children or TYA28. Although survival is 
almost 100% in the developed world, retinoblastoma is often associated with 
constitutional mutations in the RB1 tumour suppressor gene. Individuals with 
this gene mutation have a 50% risk of a further malignancy by the age of 5047. 
1.1.3.6 Renal Tumours 
Using the ICCC, all tumours of the kidneys are classified together. Under the 
Birch system, renal tumours would fall into varying categories. Renal cell 
carcinomas (RCCs) would be categorised alongside other carcinomas, whilst 
Wilms tumours, which are the commonest renal tumour seen in children, are 
classified within “miscellaneous specified neoplasms”.  
Renal tumours have an incidence of 10-20 per million per year for children, but 
are rare in TYA, with under 10 cases per million per year annually in the UK48. 
Wilms tumours, which account for around 95% of renal tumours in children and 
about 5% of childhood cancers in total49, have an excellent prognosis, with 
survival of over 90%50. Although Wilms tumours are rarer in older patients, 
those aged over 16 with Wilms tumour have a worse prognosis, with 5 year 
survival being closer to 70%49.  
RCCs are extremely rare in the paediatric population, but become more 





1.1.3.7 Hepatic Tumours 
Like renal tumours, all tumours affecting the liver are classified into one group 
by the ICCC. Whilst the Birch system does not have a specific category for 
hepatic tumours, they are most likely to fall within either carcinomas (e.g. 
hepatocellular carcinoma) or “miscellaneous specified neoplasms” (e.g. 
hepatoblastoma). 
Liver tumours in childhood are rare, and only account for around 1% of 
paediatric cancers. Hepatoblastoma, the most common childhood liver tumour, 
is associated with a good prognosis and 5 year survival over 80%, although 
many patients require liver transplantation if the tumour cannot be surgically 
resected. Transplantation has considerable associated long-term morbidity52. 
Throughout the CYP age range, hepatic cancers have an incidence of fewer 
than 10 cases per million per year53. Liver cancers are extremely rare in the 
TYA population53. 
1.1.3.8 Bone Tumours 
Both the ICCC and Birch systems classify malignant bone tumours as distinct 
groups. Bone tumours account for 3-5% of cancers in children and 7-8% of 
cancers in TYA54. The commonest bone tumours in CYP are osteosarcoma 
and Ewing’s sarcoma. Survival from bone tumours is lower than many other 
cancer types, at just under 60% for children and just under 50% for 
adolescents54. Bone tumours have an incidence of 5-12 cases per million per 
year in children, but up to 190 cases per million per year in males aged 15-
1955. 
1.1.3.9 Soft Tissue Sarcomas 
Like bone tumours, soft tissue sarcomas (STSs) are classified as a distinct 
group by both the ICCC and Birch systems. STSs account for around 7% of 
paediatric cancers56. STSs have an incidence rate of 10-13 cases per million 
per year in the under 5s, this rate then falls in older children28 and then 
increases in TYA to just over 20 cases per million per year in older TYA57. 
Survival from STSs is between 75 and 80% across the CYP period58. 
1.1.3.10 Germ Cell Tumours 
Germ cell tumours (GCTs) are another distinct group in both the ICCC and 
Birch classification systems. In the paediatric population, GCTs are relatively 
12 
 
rare, comprising around 3% of cancers59, with incidence rates between 1 and 7 
cases per million per year28. In TYA, however, GCTs are amongst the more 
common cancer types, with an incidence around 35 per million per year29. 
Males are disproportionately affected, mostly due to the prevalence of testicular 
GCTs, which are the commonest cancers in young men. Prognosis is 
extremely good, with 20 year survival at 90%59. 
1.1.3.11 Skin Cancers 
Whilst skin cancers are categorised with “other malignant epithelial neoplasms 
and malignant melanomas” in the ICCC, they are a distinct category in the 
Birch system. Skin cancers are very rarely seen in children, but incidence 
increases steadily after the age of 2060, with rates of 35-40 per million per year 
in TYA29. Prognosis is excellent, with 30 year survival amongst CYPs at 93%61. 
1.1.3.12 Carcinomas 
Carcinomas are cancers arising from epithelial tissues. The Birch system has a 
distinct category for carcinomas, whilst in the ICCC they are largely categorised 
with “other malignant epithelial neoplasms and malignant melanomas”, 
although depending on their anatomical location, they may also fall within other 
categories, such as renal or hepatic tumours. They are rare tumours in the 
paediatric population, but are the commonest tumour type in the TYA age 
group29. Incidence of carcinoma in the TYA group is increasing year on year, 
and now exceeds 50 cases per million per year29. Much of this increase has 
been due to increasing rates of thyroid carcinomas, as well as smaller 
increases in rates of both cervical and ovarian carcinomas29. The reasons for 
the increase in thyroid cancer rates are unclear, although this trend has been 
noted globally62. There has been some suspicion that the increased rate is due 
to over diagnosis of small, indolent tumours which are unlikely to cause much 
morbidity, however it has also been noted that larger, more aggressive tumours 
have become more common, meaning that any increase cannot be explained 
solely by over diagnosis63.  
Survival from carcinomas is varied and depends upon factors such as 
anatomical location and disease stage. Thyroid carcinoma has a very good 
prognosis, with around 98% of affected individuals surviving for 5 years or 
more, whereas 5 year survival for bowel carcinoma is much lower, at around 
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65%15. In females in this age group, cervical, breast and ovarian carcinomas 
are not uncommon. 5 year survival is around 80% for breast and cervical 
carcinomas, and around 85% for ovarian carcinomas15. Amongst patients with 
breast cancers, survival is directly proportional to stage at diagnosis, with 
metastatic disease having a much poorer prognosis than localised, low stage 
disease64, and similar patterns are seen in colon cancer65. 
1.2 Cancer Registration 
Cancer registration is defined as “the systematic collection of data about cancer 
and tumour diseases”66. Cancer registration is an important way of gathering 
epidemiological data about cancer, and may help to identify groups who seem 
to be disproportionately affected by cancer and who would benefit from public 
health interventions such as screening programmes. Additionally, ongoing 
follow up of individuals with records on such registries may allow the study of 
the long-term health of affected individuals once they have recovered from their 
primary disease. 
1.2.1 The Yorkshire Specialist Registry of Cancer in Children and 
Young People 
The Yorkshire Specialist Register of Cancer in Children and Young People 
(YSRCCYP), which forms one of the main data sources for this thesis, has 
collected population-based data on cancer diagnoses in children within 
Yorkshire for over 40 years67. The history of, and methodology used by, the 
YSRCCYP are further described in Chapter 3: Data Sources and Methods. 
1.3 Childhood and Young Adult Cancer Treatment Centres 
1.3.1 Principal treatment centres for Children 
All children aged 17 and under with cancer who are treated in Great Britain will 
have their care co-ordinated by one of 19 paediatric principal treatment centres 
(PTCs)68. These are hospitals with specialist knowledge and experience of 
caring for these young patients. The co-ordination of care by these specialised 
centres developed in response to national guidance aiming to improve 
outcomes in children with cancer69, and there is evidence that specialist 
centres who treat a higher volume of patients do have better outcomes70. 
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Within Yorkshire, the two PTCs are Leeds Children’s Hospital and Sheffield 
Children’s Hospital.  
1.3.2 Principal treatment centres for Teenagers and Young Adults 
Young people have distinct needs when accessing healthcare. The government 
produces a set of “Quality criteria for young people friendly health services”, 
known colloquially as the “You’re Welcome” criteria, which set out principles for 
ensuring healthcare services meet the needs of teenagers and young people. 
The most relevant of these to the provision of cancer care are those falling 
under the “Environment” theme, which recommend that care is delivered in a 
safe, suitable, young-people friendly environment71. Additional 
recommendations include all staff members who deliver care to young people 
having suitable training in caring for this age group, services being accessible 
to all young people, and young people being routinely involved in the evaluation 
of services they access. 
In Britain, teenagers and young people aged 18 and over have the option of 
having their care co-ordinated by one of 15 PTCs specialising in young 
people’s care, or by having all of their care at a non-specialist oncology centre 
closer to their home69. Many young people in England receive the majority of 
care out-with one of these PTCs72. Both Leeds Teaching Hospitals NHS Trust 
and Sheffield Teaching Hospitals NHS Trust are PTCs for young adults73. 
1.3.3 Specialist Teenage and Young Adult Units 
The Teenage Cancer Trust (TCT) are a charitable organisation who specifically 
aim to improve the care and experiences for young people being treated for 
cancer between the ages of 13 and 2474. They fund specialist wards caring for 
patients within this age group, within hospitals which may or may not be 
designated PTCs. Within Yorkshire, there are five units at different locations; 
Castle Hill Hospital in Hull (for 18-24 year olds), Leeds Children’s Hospital (13-
18 year olds), Royal Hallamshire Hospital in Sheffield (16-24 year olds), St 
James’ University Hospital in Leeds (17-24 year olds) and Weston Park 
Hospital in Sheffield (16-24 year olds), which have opened between 1998 and 
2012, as shown in figure 1.475. In practice, these units provide a similar service, 
whether or not they are designated as PTCs, providing age-specific care, 
access to youth support workers and recreational facilities such as Wi-Fi and 
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games consoles75.There is some overlap between the age ranges catered for 
in these units, and whether a 17 year old patient is treated in a centre aimed 
more at young teenagers aged 13-17 or 18 or at young adults aged 17-24 is a 
complex decision made by a multi-disciplinary team, taking into account both 
clinical factors such as underlying diagnosis and social factors such as whether 
a young person is still in full time education and living with their parents69. 
 
Figure 1.4 Dates of opening of specialist TCT treatment centres across 
Yorkshire 
 
1.4 Treatment of Childhood and Young Adult Cancer 
Cancer treatment is constantly evolving as research is undertaken and more is 
learned about tumour biology and potential new therapeutic targets. The 
majority of cancer treatment, however, consists of therapies which fall into 
three broad categories; surgery, chemotherapy and radiotherapy. Newer 
therapies, such as immunotherapy and targeted antibody treatments, are also 
being developed and becoming a more standard part of some treatment 
regimes. 
1.4.1 Surgery 
Surgery to remove all or part of a tumour may be the only treatment required 
for a cancer or brain tumour, or it may be used in conjunction with 
chemotherapy and/or radiotherapy. Although more targeted than systemic drug 
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therapy, surgery is not without risk of long-term complications. Abdominal 
surgery, particularly on large masses presenting early in life, may result in 
difficulties with bladder and bowel function, including incontinence76. Surgery 
for brain tumours, even in the absence of other therapies, may result in 
neurocognitive difficulties, neurological deficit or visual impairment77. 
1.4.2 Chemotherapy 
Chemotherapy refers to the use of cytotoxic agents to treat cancer. 
Chemotherapy may be used as a sole treatment modality or in combination 
with radiotherapy, or may be used to shrink a tumour in order to make it more 
amenable to surgery or to treat residual tumour which cannot be surgically 
resected. Traditionally, chemotherapy is given systemically. This means that, 
as well as treating cancer cells, it also impacts on the bodies’ normal tissues. 
This results in side effects and potential long-term consequences78. 
Chemotherapy generally acts by inhibiting cell division, exploiting the fact that 
cancer cells often divide much more rapidly than healthy cells. Healthy cells 
which do divide rapidly, such as hair follicles and gastric mucosa, are at the 
greatest risk of damage from chemotherapy78.  
Over time, increased understanding of the long-term impact of chemotherapy, 
combined with greater knowledge of which cancers can successfully be treated 
with less intensive treatment, has led to some conditions being treated 
successfully with less intensive chemotherapy regimens79,80.  
Conversely, some conditions which were previously considered to have a very 
poor prognosis are now treated with more intensive treatments. Survival rates 
for high-risk neuroblastoma, for example, have improved considerably over 
time, partly due to the use of more intensive chemotherapy regimens81. 
1.4.3 Radiotherapy 
Radiotherapy is the use of targeted radiation to treat cancer. It is rarely used as 
a sole curative treatment modality, but is often used to treat residual tumour 
which cannot be surgically resected or as part of a combined regimen 
alongside chemotherapy. Although total body irradiation (TBI) is now rarely 
used (an exception being prior to haematopoietic stem cell transplant) and 
most radiotherapy is targeted, the radiation beam will always pass through 
some normal tissues. This can lead to severe side effects and damage which 
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may be long lasting. Factors including age at time of therapy and dose of 
radiotherapy affect the likelihood of side effects developing82. Skin changes are 
seen very frequently following radiotherapy, and can have a serious negative 
impact on quality of life83. Other side effects of radiotherapy include diarrhoea, 
nausea and fatigue84. Syndromes associated with DNA-repair defects are 
associated with considerable late effects from radiotherapy, particularly 
SPNs85. 
Like chemotherapy, there have been temporal changes in the way radiotherapy 
is used. Radiotherapy is used far less frequently in Wilms tumours and 
localised neuroblastoma80, and at reduced intensity for patients with HL86. 
Prophylactic cranial radiotherapy, which was once a routine part of treatment, is 
no longer used in ALL79.  
TBI continues to be used for conditioning prior to stem cell transplant, but 
concerns regarding considerable toxicity in both the long and short term87 have 
led to the development of lower-dose TBI regimens88,89. 
1.4.4 Immunotherapy 
Immunotherapy, which is the use of antibody treatments to target cancer cells, 
has been developed for childhood cancers such as neuroblastoma over the 
past 2 decades90. This has been pioneered in an attempt to produce treatment 
which is more targeted and less likely to damage healthy tissues and cause 
long-term compilations. Unfortunately, many of these compounds are highly 
immunogenic and therefore associated with risk of hypersensitivity and 
anaphylactic reactions. Acute toxicities range from headaches and myalgia to 
cytokine storm, which can be potentially fatal91. Due to their relatively recent 
development, less is known about potential long-term complications than more 
established therapies such as chemotherapy and radiotherapy. It is hoped that 
these treatments will be associated with fewer long-term complications than 
other therapies91. 
1.5 Late Effects of Childhood and Young Adult Cancer 
Although most CYP with cancer will survive21,22, this is not without 
complications or consequences. The non-specific and highly toxic nature of 
many cancer treatments means that the majority of children and young people 
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who survive cancer will go on to develop treatment-related complications, some 
of which may occur many years after treatment has ended92. One large British 
study found that adults who had survived childhood cancer had 11 times the 
expected mortality rate in the 20 years post diagnosis, and mortality rate 
remained elevated above that of the general population 45 years post 
diagnosis93. Over two thirds of survivors will have at least one chronic health 
condition 25 years after diagnosis94 and 80% have at least one serious chronic 
disease by the age of 4595 with some estimates even higher96. The majority 
self-report decreased quality of life, which has been directly attributed to these 
ongoing health problems; these reports come from patient-reported outcome 
measures such as the SF-36, which include reports on domains including pain, 
social functioning and mental health97.  
1.5.1 Risk of Late Effects 
Whilst the majority of long-term CYP’s cancer survivors are at risk of late 
effects (LEs), some are at a much higher risk and some are at minimal risk. A 
strategy for stratifying patients, and thus adapting their planned follow-up, 
based on risk of LEs was first proposed by Wallace et al in 200198. These 
levels of risk are based largely on the intensity of cancer treatment given, with 
those who have received minimal systemic treatment who are therefore at 
minimal risk of LEs being classified as level 1 and those who have received 
intensive therapies who are at the highest risk of LEs being classified as level 
3. The majority of patients will be classified as level 2 and be at moderate risk 
of LEs. Despite the relatively crude and simplistic nature of this classification 
system, it has been shown to accurately predict risks of physical ill health such 
as cardiac and renal failure in a large cohort of British CYP’s cancer 
survivors99. Further work by the National Cancer Survivor Initiative (NCSI)100 
has led to the development of guidelines on long-term follow up of CYP’s 
cancer survivors, based upon late effects risk, which have been adapted  
around the world101.   
1.5.2 Late Effects over Time 
As cancer treatments have become more targeted and treatment regimens 
have reduced in intensity where possible, it stands to reason that patients 
treated more recently should be at risk of fewer late effects than those treated 
longer ago. This has been demonstrated in a very large cohort study from the 
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United States, which found decreased risks of late morbidity in patients 
diagnosed and treated more recently compared with those treated longer 
ago102. However, survival rates of cancer are increasing, and some patients 
who may previously have died are now surviving, albeit with long-term 
morbidity. In some cases, survival is a result of more intensive therapy for 
diseases which would once have had extremely poor prognoses. Thus in one 
large cohort of leukaemia patients, there was no decrease in late effects in 
patients treated more recently compared to those treated longer ago103. It may 
be that the difference in late morbidity amongst leukaemia patients compared 
to those treated for other malignancies may relate to patients who are now 
surviving conditions which previously would have been fatal, and that the 
reduction in late effects for patients with lower- risk disease who have received 
less intensive treatment is somewhat ameliorated in large-scale studies by the 
prevalence of late effects in patients who received very intensive therapy but 
who would not previously have survived104. 
1.6 Physical Late Effects 
LEs of cancer vary widely, depending upon factors such as the type and dose 
of treatment used and the age the patient is when undergoing treatment. 
Survivors of TYA cancer are at greater risk of cardiovascular disease, second 
malignancy and pulmonary complications, as well as psychosocial difficulties, 
than survivors of childhood cancer105. 
Many LEs have been known about for many years and the majority are well 
documented. A number of longitudinal studies, such as the British Childhood 
Cancer Survivor Study (BCCSS)106, the Childhood Cancer Survivor Study 
(CCSS)107 and the St Jude Lifetime Cohort Study (SJLife)108 in the USA and 
the Swiss Childhood Cancer Survivor Study (SCCSS)109 have followed up 
patients for several decades and collated data from self-reports and 
questionnaires on the health problems survivors have developed. Due to their 
reliance on questionnaires and self-reporting, however, they are all at risk of 
potential bias as they will not capture data on non-responders. The Adult Life 
after Childhood Cancer in Scandinavia (ALiCCS) study110 is a retrospective 
cohort study which is aiming to gather data from hospitals and disease 
registries on late effects of CYP’s cancer on a population level, which should 
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enhance the quality of data available on late effects. This study should 
potentially have fewer issues with bias because data is from registries and 
hospitals, rather than relying on participants returning questionnaires. 
Known LEs include cardiovascular disease111, reproductive health problems112 
and subsequent primary neoplasms (SPNs)113. Respiratory104, renal114, 
endocrine115 and neurological116 complications have also been described in the 
literature. LEs vary depending on the treatment received; for example patients 
who received chest radiotherapy are at considerable increased risk of 
developing breast cancer117, whilst patients treated with anthracyclines may go 
on to develop cardiomyopathy118. Age at diagnosis and treatment of cancer 
also plays a role in the types of LEs which may develop.  
1.6.1 Cardiovascular disease 
Diseases of the cardiovascular system are 4-6 times more prevalent in CYP’s 
cancer survivors than the general population119,120. This includes conditions 
such as peripheral vascular disease, valvular heart disease, cardiac failure and 
myocardial infarction. Stroke risk is also elevated in CYP’s cancer survivors121, 
with a small but non-negligible subset experiencing recurrent stroke122. 
Survivors of both Hodgkin’s and non-Hodgkin’s lymphoma are at particular risk 
of cardiovascular diseases123, as are patients who have received thoracic 
radiotherapy or high dose anthracyclines124. 
1.6.2 Subsequent primary neoplasms 
Subsequent primary neoplasms are tumours which arise in differing locations, 
or are histologically distinct, from the initial cancer and are thus distinct from 
relapse113 and are a considerable source of anxiety for cancer survivors and 
their families125. Around 1 in 25 CYP’s cancer survivors will develop an SPN in 
the 25 years following their original diagnosis126. Survivors of childhood cancer 
are 3-6 times more likely to develop SPNs than older patients127, and survivors 
of TYA cancer are also at increased risk of SPNs compared to older adults128. 
Survivors of TYA cancer often develop an SPN relatively soon after their initial 
cancer treatment, and shorter intervals between cancer diagnoses are 
associated with poorer prognosis129. SPNs have been observed following 
treatment for a variety of cancers, including Burkitt’s lymphoma130, 
retinoblastoma131, thyroid cancer132 and malignant astrocytoma133. 
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1.6.3 Sexual and reproductive health 
Many chemotherapeutic agents, as well as radiotherapy to the lower abdomen 
and pelvis, may result in sub fertility112. Surgery may also result in difficulties 
achieving or carrying a pregnancy, either due to direct removal of the female 
reproductive organs134 or as a result of cervical incompetence following more 
targeted surgeries135. Sexual health problems such as erectile dysfunction136,137 
and decreased arousal138 are also seen commonly, and are particularly 
prevalent in those treated for cancer in the TYA period139. Difficulties with 
sexual health140,141 and sub fertility142,143 have a considerable negative impact 
on mental health and quality of life. Conversely, psychological difficulties are 
one potential cause of sexual dysfunction144. Although there are strategies 
available to try to mitigate sub fertility, there are also multiple potential 
complications which may occur even if a pregnancy can be successfully 
achieved145. 
1.6.4 Respiratory disease 
Diseases of the respiratory system affect CYP’s cancer survivors at a greater 
rate than the general population, with one in five having at least one respiratory 
diagnosis by 35 years post diagnosis146. Chest radiotherapy is strongly 
associated with pulmonary fibrosis, with a cumulative incidence of 3.5% by 20 
years after the original cancer diagnosis104. Cranio-spinal irradiation, which is 
likely to involve at least some radiation to the chest by virtue of the location of 
the spine, is also associated with increased risk of respiratory pathology147. 
Chemotherapy with bleomycin is also associated with lung fibrosis, which can 
be particularly problematic following exposure to high concentration oxygen 
and thus cause serious potential problems during future general 
anaesthesia148. 
1.6.5 Renal disease 
Many chemotherapeutic agents are nephrotoxic and can cause both acute and 
late decreases in renal function, particularly platinum compounds, alkylating 
agents and methotrexate114. Reported prevalence of renal dysfunction among 
long term CYP’s cancer survivors varies considerably, but some studies report 
rates of up to 84%, with nephrectomy and radiotherapy to the kidney being 
notable risk factors along with the aforementioned chemotherapeutic agents149. 
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1.6.6 Endocrine disease 
Endocrine disorders are prevalent in CYP survivors, with one study reporting 
that nearly half had at least one endocrine problem. The greatest risk is seen in 
those treated for CNS tumours, who are at risk of pituitary damage as a result 
of surgery or radiotherapy, and Hodgkin’s lymphoma150. High rates of obesity 
and metabolic syndrome amongst CYP’s cancer survivors, which are risk 
factors for the development of diabetes mellitus, may explain some of this 
pathology151. Patients exposed to total body irradiation, chest or abdominal 
radiotherapy, as well as high dose therapy and stem-cell transplants, are at 
particular risk for developing metabolic syndrome152,153.  
1.6.7 Neurological disease 
Aside from stroke, which has already been described in the cardiovascular 
disease section, neurological disease is not a major LE for many CYP’s cancer 
survivors. However, for survivors of CNS tumours, it can be a major issue. 
Seizures, motor impairment and sensorineural hearing loss will affect 41%, 
35% and 23% of survivors respectively by 30 years post tumour diagnosis116. 
1.7 Late Effects on Mental Health 
Despite the obvious emotional impact of a cancer diagnosis154, relatively little is 
known about the late effects of childhood cancer on mental health. Both 
psychological distress155 and psychiatric disorder156 have been investigated in 
long-term survivors of CYP’s cancer. Broadly speaking, for the remainder of 
this thesis, the term “psychological” will be used to refer to any difficulties with 
emotion or behaviour, whilst “psychiatric” refers specifically to clinical 
diagnoses. The terms "mental ill health” and “mental health problems” 
encompass both psychological and psychiatric issues.  
There is evidence that childhood cancer survivors are at increased risk of 
psychological distress in adult life155, with risk particularly high in those with 
chronic physical health needs157. However, these data come from self-reports 
and questionnaires rather than clinician-made diagnoses. Self-reporting of 
symptoms is known to have a low predictive value for psychiatric diagnoses 
such as depression158 and even well validated scores are less accurate in the 
presence of co-morbidity159. Patients who report higher levels of psychological 
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distress are also more likely to utilise mental health services, but again this is 
based on self-report and not medical records160. There are also data from 
parental reports to suggest adolescents who are survivors of childhood cancer 
have more behavioural, social and emotional issues than their unaffected 
siblings161. 
A large Danish study found that there was an increased likelihood of secondary 
care contact for psychiatric disorders in survivors of childhood, adolescent and 
young adult cancer compared with sibling controls162, with the highest risk 
being in those who were diagnosed under the age of 10. However, as the 
majority of healthcare contact for patients with psychiatric disorders occurs in 
primary care163, it is likely that looking only at hospital contacts will not reveal 
the true extent of these issues, although they probably provide a good estimate 
of the prevalence of the most severe mental health problems. 
Reports of psychological distress155,161 come from studies using sibling 
controls. Whilst siblings provide an obvious control group due to their shared 
genetics and upbringings, using siblings of cancer survivors in controls when 
investigating mental health issues is problematic. A diagnosis of any serious 
childhood illness impacts the whole family, and siblings of CYP diagnosed with 
cancer face a variety of challenges of their own164. Using them as a control 
group, therefore, is likely to underestimate the effects cancer has on the 
diagnosed individual. A lack of population-based studies, however, means that 
at present there are no better data available. 
It is known that survivors of childhood cancer are more likely to be prescribed 
antidepressants than the general population156,165. However, in the United 
Kingdom, first line therapy for mild to moderate depression is psychological 
therapy such as cognitive behavioural therapy166. It is therefore likely that 
looking at antidepressant prescribing alone will underestimate the prevalence 
of depression.  
Additionally, studies reporting increased antidepressant prescriptions156,165 
have looked purely at prescribing data and did not provide information on the 
indication for prescription. Various antidepressants, including tricyclics and 
selective serotonin reuptake inhibitors (SSRIs), have been used to treat 
neuropathic pain167. Pain is another commonly reported symptom in cancer 
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survivors168 and therefore without data on indication for prescriptions of 
antidepressant medication, it is difficult to know how much increased 
prescribing is actually a result of increased prevalence of depression. One 
study156Error! Bookmark not defined. did exclude prescriptions of tricyclic and selective 
noradrenaline reuptake inhibitors (SNRIs) in a bid to account for this, as these 
are the drug types most likely to be prescribed for pain, but this would not 
exclude all prescribing for this indication and data on actual diagnoses would 
still be valuable.  Antidepressant medications, in particular SSRIs, are also 
used for a number of psychiatric conditions, such as obsessive-compulsive 
disorder (OCD)169, generalised anxiety disorder (GAD)170 and eating 
disorders171. Whilst increased prescribing does likely indicate higher rates of 
psychiatric illness in this cohort, it would be useful to know specifically which 
conditions were more prevalent. 
Substance misuse has been shown to be lower in survivors of CYP’s cancer 
than the general population172, presumably as a result of health promotion 
aimed at reducing LEs. However, data from the referenced study came from a 
cohort of largely Hispanic patients, and thus may not reflect patterns in the UK. 
This study also found that depression was associated with an increased risk of 
marijuana use. The CCSS found lower rates of tobacco smoking and risky 
alcohol use in survivors of CYP’s cancer compared to their siblings173. Another 
American study found similar rates of risky behaviours, including illicit drug use, 
between cancer survivors and their siblings174. As already discussed, the use of 
siblings as a control group is not without problems and it is thus difficult to 
interpret these results. 
1.8 Link between Physical and Mental Ill Health  
Mental health problems are associated with an increased risk of premature 
mortality, even after adjustment for pre-existing physical conditions175,176. 
Although some mortality is a result of suicide, drug- or alcohol-related 
causes177,178,  there is also evidence of increased mortality from causes such 
as cardiovascular179,180, gastrointestinal, infectious181. and metabolic 
disease182,183. This is thought largely to be due to high prevalence of unhealthy 
lifestyle choices in this group184, although lack of concordance with medical 
advice in patients with poorer mental health may also play a role.  
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Riskier lifestyle choices in patients with mental health problems have also been 
demonstrated in survivors of CYP’s cancer; for example higher rates of 
marijuana use in survivors with depression172. 
Given the already increased risk of cardiovascular disease in CYP 
survivors93,111,118, as well as risk of other diseases which are affected by 
lifestyle such as SPNs113,117 and respiratory problems104, maintaining a healthy 
lifestyle is particularly important151, although not always adhered to185. 
It is therefore particularly important that psychiatric morbidity is identified in 
survivors, not only because it results in considerable distress and reduced 
quality of life155,160,161, but also because serious mental health issues may 
indirectly increase risk of other LEs. 
1.9 Young People’s Mental Health 
Improving the nation’s mental health is a key target for the UK government, 
with many indicators in the Public Health Outcomes Framework relating to 
mental health186. According to data from the Office for National Statistics, as 
many as 8.2% of adults had self-reported a mental health problem in 2017187. 
Although these data do not report on children under the age of 16, or include 
any breakdown by age, it does give some indication of the scale of the problem 
of mental ill health in the UK population. Another large scale survey in working-
age adults (16-64 years), which collected data on symptoms as well as 
diagnoses, estimates the prevalence to be much higher, at 17%188. 
Mental health problems in CYP are especially concerning, because there is 
evidence that mental health problems in early life are an important risk factor 
for poor mental health in adulthood, as well as poor educational and 
socioeconomic outcomes189–192. Additionally, mental health problems are 
strongly associated with premature mortality175. Approximately 50% of adult 
mental health disorders are thought to have their onset by the age of 14 years 
and approximately 75% by 24 years193,194, with some studies finding large 
numbers beginning even earlier, reporting onset of up to three quarters of adult 
mental health issues before the age of 18195. A large British cohort study also 
reports a 1.5 to 2 fold increase in mental health difficulties in later life in those 
individuals who had psychological difficulties in childhood and early 
adulthood196. It is estimated that fewer than half of young people with a mental 
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health problem receive appropriate therapy, which may explain why many of 
these disorders persist into later life197,198. 
Globally, mental health problems affect around 13.4% of children and 
adolescents; depression affects around 2.6% and anxiety affects around 
6.5%199. In the UK, approximately one fifth of young people develop mental 
health problems during adolescence177. In the latter quarter of the last century, 
there was also a considerable increase in suicides, particularly in older male 
teenagers 197.  
Risk factors for poor mental health in early life include bullying200, poor parental 
mental health201,202 , deprivation203 and low cognitive ability204. Poor diet quality 
has also been associated with risk of poor mental health amongst children and 
young people205, which may reflect the link between deprivation and diet. Being 
female is also a risk factor for mental health problems at any age, with some 
evidence that females are more likely to be adversely affected by triggers such 
as educational206 and financial stressors207. Early cessation of formal education 
and low attainment is both a risk factor for, and consequence of, poor 
adolescent mental health208. Students who were disengaged with education 
were more likely to have psychological problems, but directionality has not 
been clearly established209. As well as being associated with increased 
likelihood of developing mental health problems202, deprivation has also been 
linked to decreased rates of referral to specialist mental health care following 
episodes of self-harm177. 
1.9.1 Mental Health of Young People with Chronic Illness 
CYP with chronic physical health conditions are known to be at markedly 
increased risk of developing mental health problems compared to their 
physically healthy counterparts 210,211, and conversely, young people with 
mental health problems are at increased risk of physical health problems212. 
Adjusting to a chronic disease, particularly in adolescence, is challenging and 
physical health problems in young people are a strong predictor of future 
mental health service use212. Even in the absence of diagnosed psychiatric 
illness, physical illness is a risk factor for suicide213. 
There are a number of factors which may explain the increased risk of mental ill 
health in CYP with chronic illness. The diagnosis of a chronic illness in a child 
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or young adult is often a shock to the whole family and requires a period of 
adjustment for both the affected young person and their caregivers214.  CYP 
who struggle to adapt to the diagnosis of a chronic illness are at particular risk 
of mental health problems215. Patients with pre-existing alexithymia, who 
struggle to identify and express their emotions, are more likely to develop 
maladaptive coping strategies and also go on to experience worse mental 
health216. CYP whose parents struggle to adapt to their diagnosis and suffer 
from their own mental health problems as a result have worse health-related 
quality of life and more mental ill health than CYP whose parents cope well with 
the diagnosis and maintain good mental health217. This likely reflects the known 
link between poor parental mental health and risk of developing psychiatric 
illness in adolescence202.  
Like other chronic illnesses, a diagnosis of cancer can be hugely emotionally 
challenging154 and it stands to reason that similar challenges to those faced by 
CYP with other diagnoses are also applicable to CYP with cancer. 
Feelings of shame, unattractiveness and embarrassment are associated with 
some chronic illnesses, particularly those which lead to changes in physical 
appearance218. Treatment for cancer can lead to marked physical alterations, 
most obviously alopecia secondary to chemotherapy, but also potentially more 
permanent changes such as amputation, enucleation and surgical scarring. 
Radiotherapy can also result in skin and hair changes, with patients who have 
undergone cranial radiotherapy at risk of long-lasting hair thinning, which may 
be distressing219. Poor growth and subsequent short stature may develop as a 
result of prolonged illness as well as cancer treatments220–222. These physical 
changes are likely to lead to the same feelings of shame, unattractiveness and 
embarrassment encountered by young people with other conditions. 
Feelings of belongingness and “fitting in” at school are associated with better 
mental health, but young people with disabilities and ill health are less likely to 
feel a sense of belongingness than their physically healthy peers223. Bullying 
has a considerable negative impact on mental health200 and social exclusion 
has a stronger association with mental illness than other forms of bullying224. 
Bullying is also associated with more frequent relapse of mental health 
problems225. Bullying is known to be a major problem for young people with a 
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cancer diagnosis226, and it is likely that this has a major negative impact on 
subsequent mental health.  
Children with chronic illnesses may be bullied and feel different from their peers 
as a result of their health problems227,228 and experience greater feelings of 
loneliness and isolation during their school life229. Children with chronic ill 
health are also more likely to be victims of multiple forms of bullying230. 
Expectation of judgement and bullying from peers may also prevent CYPs from 
sharing their diagnosis with their peers and thus deprive them of potential 
support231. Additionally, many caregivers are more protective of chronically ill 
CYP than they would be of their healthy siblings, leading to a reduction in 
opportunities to gain independence and spend time socialising with their 
peers232. 
CYP who have experienced a cancer diagnosis may go on to have 
considerable difficulties with romantic attachments233. These may be in part 
due to the aforementioned physical changes, which result in feelings of shame 
and unattractiveness218. Anxieties regarding sub-fertility and sexual 
function139,234, as well as reduced libido and interest in dating235 may impact on 
the development of romantic relationships. Anxieties regarding when to 
disclose their history of cancer, and how this information will be received by a 
potential romantic partner, are also potentially problematic233. Absence of 
romantic relationships is strongly associated with poorer mental health236. 
1.9.2 Classification of Mental Illness 
Within most UK hospitals, the diagnosis and classification of mental illnesses is 
based on the International Statistical Classification of Diseases and Related 
Health Problems 10th Revision (known more commonly as the ICD-10)237. This 
differs to the USA, where the Diagnostic and Statistical Manual of Mental 
Disorders Fifth Addition (known as DSM-V) is used238. 
The ICD-10 classifies illnesses, including mental illnesses, by affected bodily 
system and then disease pattern. All mental illnesses have the prefix “F”.  
1.9.2.1 F00-F09 Organic, including symptomatic, mental disorders 
These are conditions characterised by a clear organic aetiology, and comprise 
largely of dementias and cognitive difficulties237. These disorders are not 
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considered within this thesis, as the cognitive late effects of CYP’s cancer have 
been comparatively well studied already239–241. 
1.9.2.2 F10-F19 Mental and behavioural disorders due to psychoactive 
substance use  
These conditions are those which occur as a result of substance use and 
misuse, including dependency and withdrawal of substances237. These 
conditions are of interest, at least in part due to their considerable impact on 
physical health174. 
1.9.2.3 F20-F29 Schizophrenia, schizotypal and delusional disorders  
These disorders are characterised by periods of psychosis237, a debilitating 
symptom where the patient suffers hallucinations and/or delusions without 
insight and has an impaired understanding of reality242. Whilst comparatively 
rare, with a prevalence around 1%, these disorders are important due to the 
marked functional impairment they can cause243. 
1.9.2.4 F30-F39 Mood [affective] disorders  
These disorders are primarily characterised by a change in affect, and include 
mania and depression237. Affective disorders in adolescence are associated 
with poor health outcomes in later life175 and are thus of interest amongst 
cancer survivors who are already at risk of long-term poor health108. Affective 
disorders are also the most common mental health conditions in the UK188. 
1.9.2.5 F40-F48 Neurotic, stress-related and somatoform disorders  
These disorders are characterised by stress and anxiety, either generally or in 
specific situations or in response to specific events; post-traumatic stress 
disorder (PTSD) is included within this classification237. These are also 
common within the UK188, and are likely to be common amongst cancer 
survivors244,245. 
1.9.2.6 F50-F59 Behavioural syndromes associated with physiological 
disturbances and physical factors  
These are a diverse group of disorders where mental symptoms and 
physiological disorders co-exist237. This thesis will consider F50: Eating 
Disorders, as these may be associated with poor body image seen in cancer 
survivors246,247, but not other disorders within this category such as sexual 
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dysfunction, as these are both relatively rare, and also complex, and thus were 
felt to be out with the remit of this work. 
1.9.2.7 F60-F69 Disorders of adult personality and behaviour  
These are a group of disorders characterised by clinically significant abnormal 
or maladaptive patterns of behaviour237. These conditions are common, and 
can be challenging to treat248. They have been included in this work, with the 
exceptions of F64: Gender Identity Disorders and F66: Psychological and 
behavioural disorders associated with sexual development and orientation, 
which have been excluded due to marked concerns from the psychiatric 
community that these should not be conceptualised as mental disorders249,250. 
1.9.2.8 F70-F79 Mental retardation  
These are disorders of cognitive function237. Like organic disorders, they have 
been excluded from this work as they have already been relatively well 
studied239–241. 
1.9.2.9 F80-F89 Disorders of psychological development  
These are disorders which are associated with delayed maturation of the 
nervous system, and include dyspraxia and dyslexia237. Because these 
conditions often diminish with age, they have been excluded from this thesis. 
1.9.2.10 F90-F98 Behavioural and emotional disorders with onset 
usually occurring in childhood and adolescence  
This is a diverse group of conditions which have onset in early life, but which 
may or may not persist into adulthood237. This thesis will include F90: 
Hyperkinetic disorders, F91: Conduct disorders (including oppositional defiant 
disorder; ODD), F92 Mixed disorders of conduct and emotions and F93: 
Emotional disorders with onset specific to childhood. The other listed disorders 
are a heterogeneous group which are generally not seen in adults, and have 
thus been excluded from this work. 
1.9.2.11 F99-F99 Unspecified mental disorder  





1.10  Evidence Gaps 
There is evidence from CYP with other conditions that physical and mental ill 
health are linked. Issues such as stress, changes in appearances and bullying 
are all likely to be encountered by CYP with cancer, and it therefore follows that 
they will also be at considerable risk of mental health problems. Despite this, 
there are many gaps in the current evidence base surrounding psychiatric late 
effects of CYP’s cancer. 
Although a number of studies have reported increased psychiatric and 
psychological morbidity in survivors of CYP’s cancers155,157,160–162,172, none 
include diagnoses from primary care, although there are studies looking at 
prescribing patterns156,165, which do include primary care data.  
Data from primary care on diagnoses, referrals and treatments would provide a 
much more robust estimate of the prevalence of psychiatric morbidity within 
survivors of CYP’s cancers, and potentially allowing identification of particular 
conditions which are more prevalent in this group. Using data linkage 
techniques, it may then be possible to identify particular patients groups who 
are at increased risk of mental health problems, based on age at diagnosis, 
cancer type and treatment modality. 
The majority of studies looking at mental health of CYP’s cancer survivors rely 
on self-reported data155,157,160–162,172. The evidence base would be greatly 
enhanced by the inclusion of clinician-diagnosed mental illness, particularly 
given the known difficulties with self-reporting of psychiatric symptoms158,159. 
1.11 Aims & Objectives 
This chapter has described the rationale for this project, and in particular the 
evidence gaps described in section 1.10 have guided the selection of aims and 
objectives. Section 1.9.2 gives details on how mental health disorders are 
classified, and explains which ones have been included in this work and why. 
This work aimed to investigate the prevalence and spectrum of mental health 
disorders in long-term survivors of children and young people’s cancers. The 
YSRCCYP was used to identify cancer survivors, whilst using datasets from 
NHS Digital and primary care to determine contacts with secondary and 
primary healthcare services respectively, relating to psychiatric disorder.  
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The objectives of this project were: 
1. To describe what is currently known about the mental health of CYP’s 
cancer survivors. 
2. To use data linked from secondary care to determine the prevalence 
of mental health disorders requiring secondary care input in CYP’s 
cancer survivors and compare this to the background population. 
3. To see whether any change in prevalence of mental health difficulty in 
CYP’s cancer survivors over time mirrors that seen in the background 
population. 
4. To attempt to identify groups who have particularly high prevalence of 
mental health disorder requiring secondary care input 
5. To use data linked from primary care to determine the prevalence of 
any diagnosed mental health disorder in childhood cancer survivors and 
compare this to the background population. 
6. To attempt to identify groups who have particularly high prevalence of 
specific mental health disorders, based on primary care records. 
7. To explore whether sub-fertility and fertility preservation impacted on 




Chapter 2 Systematic Review of the Literature  
2.1 Introduction 
The introduction to this area and rationale for study is explained in detail in 
Chapter 1: Introduction. Section 1.1.2: Epidemiology gives an overview of the 
epidemiology of cancer in children and young people, whilst Section 1.5: Late 
Effects of Childhood and Young Adult Cancer and Section 1.6: Physical Late 
Effects describe some of the long-term consequences of a cancer diagnosis 
and its treatment in this age group. Section 1.7: Late Effects on Mental Health 
gives some introduction to the topic of psychological and psychiatric late 
effects. In order to fully evaluate the existing literature and explore potential 
gaps which could be the target of this thesis, a systematic review was carried 
out. 
2.2 Methods 
In April 2017, a standard systematic review was performed of the PubMed, 
Embase/OVID, CINAHL and Web of Science databases using the following 
strategy: 
 
(child OR children OR childhood OR teen* OR adolescent* OR "young adult") 
AND (cancer OR leukaemia OR tumour OR tumor) 
AND survivor 
AND "mental health" or "mental illness" or "psychiatric" or "psychological" or 
"emotional" or "behavioural" or “behavioral” 
AND "late effects" or "long term" 
 
Each abstract was screened by 2 separate individuals to decide whether it met 
the criteria for inclusion. Where the 2 initial reviewers disagreed on whether or 
not to include the paper, a third individual reviewed the abstract separately. As 
well as the author of this thesis, 2 medical students, Emily Hughes and Kristian 
Dye, were involved in the screening, and were given authorship of the 
published work as described in the declarations at the beginning of the thesis. 
Most ineligible papers were able to be excluded at the abstract screening 
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stage, however there were some papers where the abstract included 
insufficient detail to determine exclusion and these therefore proceeded to full 
text review before exclusion. 
The reference lists of each included study were also reviewed to identify 
additional papers which may not have been picked up in the original search but 
which may have been relevant. 
2.2.1 Inclusion criteria 
Papers looking at the prevalence of mental health problems in long term 
survivors of CYP’s cancer were included. Papers focussing on patients who 
had undergone haematopoietic stem cell transplant (HSCT) for non-malignant 
conditions were also included, on the basis that these individuals would have 
been exposed to intensive chemotherapeutic agents in their conditioning 
regimes, and would therefore be at risk of similar LEs to cancer survivors.  
2.2.2 Exclusion criteria 
Papers focussing only on cognitive function were excluded, as this issue has 
already been relatively well described in the literature, and was therefore not a 
key focus of this work. Papers which included patients less than 5 years from 
diagnosis were excluded, as these individuals would not be classed as “long 
term” survivors. Papers which included adult patients and did not report 
separately on outcomes for CYPs were also excluded. Conference abstracts 
which did not provide sufficient information to ensure inclusion criteria were met 
were also excluded, as were papers where the full text was not available in 
English language. 
2.3 Results 
The initial search returned 1530 papers: 320 papers underwent full text review, 
and 64 were included in the final review. Three additional papers were 
identified from screening reference lists of included studies. Figure 2.1 

































Records identified through 
database searching  
Records after duplicates removed  
(n = 1530) 
Records screened  
(n = 1530) 
Records excluded  
(n = 1,210) 
Full-text articles excluded 
as included adult 
patients, those less than 5 
years from diagnosis or 
focussed solely on 
cognitive impairment 
Total studies included in 
qualitative synthesis  
(n = 67) 
Studies included in 
qualitative synthesis  
(n = 64) 
Full-text articles 
assessed for eligibility  
(n = 320) 
Additional studies 
identified from screening 
reference lists of 
included studies (n = 3) 
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Table 2.1 describes the 67 included studies and gives details of their findings. 
The country of the study and year of publication, study and control groups, 
outcomes and results, as well as strengths and limitations, are described. 
The qualitative synthesis suggested increased mental health problems in 
survivors of CYP’s cancers, with some papers finding that as many as half of 
survivors report a psychiatric diagnosis at some point since treatment and 
around a third report a current psychiatric diagnosis252. Difficulties were still 




Table 2.1 Summary of included studies in the final synthesis.  
Abbreviations: 15D, 15 Dimensional Health Related Quality of Life Instrument. ASPP, Assessment of Social Perspective-Taking 
Performance. ASR, Adult Self Report. AYA, adolescent and young adult. BFS, Behaviour and Feeling Survey. BPI, Behaviour 
Problems Inventory. BSI, Brief Symptom Inventory.BSI-18, Brief Symptom Inventory (18 question form). CBCL, Child Behaviour 
Checklist. CDI, Children’s Depression Inventory. CES-D, Centre for Epidemiological Studies – Depression Scale. CISS, Coping 
Inventory for Stressful Situations. DIA-X, Diagnostic Expert System for Mental Disorders, DSM-IV, Diagnostic and Statistical Manual of 
Mental Disorders Fourth Addition. FRI, Family Relationship Index. GvHD, Graft versus Host Disease. GSI, Global Severity Index. 
HADS, Hospital Anxiety and Depression Scale. IES, Impact of Event Scale. IES-R, Impact of Event Scale – Revised version. IES-R-J, 
Impact of Event Scale – Revised version – Japanese language version. IWS, International Worry Scale. MINI, Mini-International 
Neuropsychiatric Interview. MOS-SSS, Medical Outcomes Study – Social Support Survey. PDS, Post-Traumatic Diagnostic Scale. 
PTSD, Post-Traumatic Stress Disorder. RAND-36, 36 item form developed by the Research And Development Corporation. RB, 
retinoblastoma. SCL-90-R, Symptom Checklist (90 item form) – Revised version. SF-36, Short Form Survey (36 item form). SI-PTSD, 
Structured Interview for Post-Traumatic Stress Disorder. YSR, Youth Self Report.  
Citation Country and 
Year of Study 





Finland, 2015 13860 childhood and 
YA cancer survivors 





Mood disorders more common 
in childhood (HR 1.3; CI 1.1–
1.7) and YA (1.3; CI 1.1–1.5) 
cancer survivors than in 






disorders, were slightly more 
common in childhood (HR 1.3; 
1.0–1.7), and YA survivors 
(HR 1.2; 1.0–1.5) compared 
with siblings. 
Psychotic disorders slightly 
more common in childhood 
survivors (HR 1.4; 1.0–1.9) 












Ander et al255 Sweden, 
2016 
28 10-year survivors of 
adolescent cancer 
HADS scores 29% reported possible anxiety 













USA, 2014 50 childhood brain 
tumour survivors, 40 
siblings of brain 
tumour survivors, and 
40 solid tumour 








score and general 
adaptive 
composite score 
Brain tumour survivors scored 
lower than siblings (p < 0.01) 
and solid tumour survivors 
(p < 0.04) across all domains. 
There was no significant 
difference between solid 
tumour survivors and siblings. 
Global score average 96 for 
brain tumour survivors vs 107 






- Use of 
siblings as 
control group 





mean IQ still 
fell within the 
“average” 
range) 







56.2% report at least one 
psychiatric diagnosis since 
their cancer diagnosis, 
including 35.4% with an 
ongoing disorder. 
- Reliance on 
self-report 












48% of females had a 
negative score compared to 
31% of males (p<0.00001) 








Body image was poorer in 









USA, 2016 3,893 survivors of 
cancer diagnosed <21 
years of age 
BPI scores Treatment with ≥ 30 Gy CRT 
compared with treatment with 
< 30 Gy associated with 
greater odds of global 
symptoms (OR 3.2; 95% CI 
1.2 - 8.4) and internalizing 
symptoms (OR 1.7; CI 1.0 - 
2.8) 
Treatment with ≥ 300 mg/m2 
anthracyclines compared no 
anthracycline treatment was 
associated with increased risk 
of internalizing symptoms (OR 
1.9; CI 1.2 - 3.0) 




+ Inclusion of 
patients in the 
“young adult” 
category 








USA, 2013 4569 childhood cancer 
survivors 
BSI-18 scores Survivors with a mild-to-
moderate medical condition at 
baseline were more likely to 
have persistent symptoms of 
depression (OR=1.6; CI=1.2–
2.2), anxiety (OR=1.6; CI=1.1–
2.5) and somatisation 
(OR=1.8; CI=1.2–2.9). 
Survivors who perceived their 
physical health to be 
worsening over time were 
more likely to have persistent 
symptoms of depression 
(OR=2.9; CI=2.0–4.1), anxiety 
(OR=3.4; CI=2.3–5.4) and 
somatisation (OR=4.4; 
CI=2.8–6.8) and more likely to 
have increasing symptoms of 
depression (OR=3.3; CI=2.4–
4.5), anxiety (OR=3.0; CI=2.2–
















4.0) and somatisation 
(OR=5.3; CI=3.9–7.4). 
Survivors who reported higher 
levels of cancer-related pain 
also had higher rates of 
persisting symptoms of 
depression (OR=2.1; CI=1.4–
3.2) and somatisation 
(OR=3.3; CI=2.0–5.4) and 
higher rates of increasing 
somatisation (OR=2.4; 
CI=1.6–3.6).  
Change from being married to 
being single was associated 






Change to unemployed was 
associated with persistent 
somatic symptoms (OR=1.8, 
CI=1.2–2.8) 
Female survivors were more 





USA, 2013 10378 adult survivors 
of childhood cancer 







22% of survivors reported 
psychotropic medicine 
prescriptions at baseline, 
compared to 15% of controls 
(p<0.001). 31% of survivors 
reported new prescription of 
psychotropic medication 
during the study period, 
compared to 25% of controls 
(p<0.001). 
+ Very large 
sample size 
- Use of 
sibling 
controls 


















Survivors were significantly 
more likely than siblings to be 
prescribed 
hypnotics/anxiolytics/sedatives 
(OR 1.64, CI 1.17–2.28) but 
not antidepressants, 







USA, 2014 9128 childhood cancer 












Survivors were more 1.8-2 
times more likely to report 
suicidal ideation at baseline 
and at each follow-up. 
Survivors were 2.6 times more 
likely than siblings to report 
recurrent suicidal ideation. 
Even after adjusting for 
depression, survivors with 
poor physical health were 
more likely to report suicidal 
+ Very large 
sample size 














ideation than those in good 
health. 
6.4% of survivors died during 
the study period. 1.6% of 
deaths were due to suicide 
and 30% of those who 
completed suicide had 
previously reported suicidal 
ideation.  
Risk of all-cause mortality was 
greater in survivors with a 
history of suicidal ideation 
compared to those without 
(HR = 1.29, CI = 1.03-1.61). 
Survivors with a history of 
suicidal ideation had greater 







USA, 2005 443 black, 503 
Hispanic and 7,821 
non-Hispanic white 





Black survivors reported fewer 
mental health problems than 
white survivors (male OR 0.5; 
CI 0.3-0.8; female OR 0.6; CI 
0.4-0.9). 
All black survivors were less 
likely than white to report 
anxiety (male OR 0.4; CI 0.2-
0.9; female OR, 0.5; CI 0.2-
0.9) and adverse mental 
health in at least one domain 
(male OR 0.5; CI 0.3-0.8; 
female: OR 0.6; CI 0.4-0.9). 
Male black survivors were also 
less likely to report adverse 
global mental health (OR 0.4; 
CI 0.2-0.8) and depression 





- Relies on 
self-report 













Taiwan, 2009 98 survivors of 
childhood brain tumour 
or ALL 
Quality of life 
scores 
ALL survivors scored higher in 
all domains, p<0.001. Mean 
ranks; body image 62.95 for 
ALL vs 36.05 for brain 
tumours, psychological 
functioning 62.04 for ALL vs 
36.96 for brain tumours; 
intimate relationships 55.80 for 
ALL vs 43.20 for brain 
tumours; social functioning 












Cox et al262 USA, 2016 1189 childhood cancer 
survivors 
Self-reported 
unmet care needs 
25% of survivors reported no 
unmet care needs. Mostly 
commonly reported unmet 
needs were psycho-emotional 
(54 %), cancer-related 
information (51 %), 
care/support and health care 
system concerns (35%), 
+ Large 
sample size 
- Reliance on 
self-report 





reported coping needs (41%) 




USA, 2016 16,079 childhood 
cancer survivors and 
3085 siblings 
BSI-18 scores Compared with siblings, 
survivors were less likely to be 
asymptomatic (62% vs 74%, 
p<0.0001), more likely to have 
comorbid distress (11% vs 
5%, p<0.0001). Survivors of 
leukaemia (OR 1.34; CI 1.12-
1.61), CNS tumours (OR 1.30; 
CI 1.05-1.61) and sarcoma 
(OR 1.26; CI 1.01-1.57) had a 
greater risk of comorbid 
distress than survivors of other 
solid tumours.  




+ Very large 
cohort 
+ Inclusion of 
subgroup 
analysis 




Daniel et al264 USA, 2016 154 survivors of non-
CNS childhood cancer 
Time to fall 
asleep and 
duration of sleep 
No difference in time to sleep 
or duration of sleep between 
survivors and controls. 





and 170 age and sex 
matched controls 
BSI-18 scores Survivors with longer duration 
of sleep and greater reported 
fatigue also reported higher 








- Reliance on 
self-reporting 
of sleep times 
De Laage et 
al253 
France, 2016 348 long term 
survivors of childhood 
cancer compared to 





Survivors experienced a 
higher prevalence of anxiety 
and mood disorders compared 
to controls, even a long time 
after diagnosis. Prevalence 
ratios; major depressive 
disorder 2.08, dysthymia 2.52, 
panic disorder 1.48, 
generalised anxiety disorder 
1.49, agoraphobia 2.29 










Deyell et al265 Canada, 
2012 
2,389 survivors 
childhood and young 
adult (dx <25) cancer 
and 23,890 randomly 






Survivors more likely to have 
filled a prescription for 
antidepressant medication 
(OR 1.21; CI 1.09–1.35) than 
controls. Females, young 
adults and very long term (>20 
years) survivors had highest 
use of antidepressants. 











USA, 1999 40 long term survivors 
of childhood cancer 





- Lack of 
controls 
 
Fidler et al267 UK, 2015 10 488 survivors of 
childhood cancer 
(results compared with 
SF-36 scores in 
role emotional 
Females more likely to be 
limited in all three questions 
(Q1 OR 1.6 95% CI 1.4-1.8; 





















SF-36 scores in 
social functioning 
Q2 OR 1.5 95% CI 1.3-1.7; Q3 
OR 1.8 95% CI 1.6-2.0). 
Survivors of NHL (Q1 OR 1.4 
95% CI 1.1-1.9; Q2 OR 1.4 
95% CI 1.1-1.7; Q3 OR 1.6 
95% CI 1.2-2.1), CNS tumours 
(Q1 OR 1.6 95% CI 1.4-2.0; 
Q2 OR 1.5 95% CI 1.2-1.7; Q3 
OR 1.5 95% CI 1.2-1.8), and 
bone sarcoma (Q1 OR 1.7 
95% CI 1.2-2.4; Q2 OR 1.4 
95% CI 1.1-1.9; Q3 OR 1.5 
95% CI 1.1-2.1) more likely to 
be limited for all questions 
compared to survivors of 
leukaemia.. 
Females more likely to report 
dysfunction in both domains 
(Q1 OR 1.5 95% CI 1.3–1.7; 




























SF-36 scores in 
mental health 
Survivors of CNS tumours (Q1 
OR 1.6 95% CI 1.4–1.9; Q2 
OR 2.5 95% CI 2.1–2.9) and 
bone sarcomas (Q1 OR 2.0 
95% CI 1.5–2.7; Q2 OR 3.0 
95% CI 2.3–4.0) more likely to 
report dysfunction in both 
domains compared to 
leukaemia survivors. Survivors 
of soft tissue sarcomas more 
likely to report dysfunction 
when asked “Has your health 
limited your social activities?” 
compared to leukaemia 
survivors (OR 1.6 95% CI 1.2-
2.0) 
Survivors who were female 
(ORs 1.2-1.7) or who had 
never worked or were 
unemployed (ORs 1.3-2.6) 
53 
 
were significantly more likely 
to report dysfunction in all 5 
questions.  
Ford et al268 USA, 2015 470 retinoblastoma 
survivors and 2820 
siblings of childhood 
cancer survivors 
BSI-18 scores Survivors significantly less 
likely to report global 
symptoms (standardised T 
score 43.7 vs 46.7, p<0.01), 
depression (standardised T 
score 46.1 vs 47.1, p=0.02), 
somatic distress (standardised 
T score 45.2 vs 48.2, p<0.01) 
and anxiety (standardised T 
score 44.6 vs 46.8, p<0.01) 
compared with siblings. 
+ Large 
sample size 




- Use of 
sibling control 
group 












1602 survivors of 










No significant difference 
between survivors and 
siblings. However, of those 
with BSI-18 scores indicating 
distress, 34% of survivors 
accessed mental health 
services, compared to 20% of 
siblings (p<0.001) 
No significant difference 










Gunn et al 
(a)269 
Finland, 2015 740 childhood brain 
tumour survivors and 




Increased in survivors 
compared with siblings (HR 
1.8; CI 1.4–2.5). Significantly 
increased risk for 
schizophrenia/delusional 
disorders (HR 2.2; CI 1.1–4.1), 



















Finland, 2015 315 AYA brain tumour 





No statistically significant 
increase in survivors 





looks at AYAs 
- Sibling 
control group 






Gunn et al 
(c)271 
Finland, 2016 21 childhood brain 
tumour survivors 





Only 4.8% of respondents 
scored highly enough to 
indicate any level of 
depression. 











Survivors had worse scores in 
mobility (mean score 0.92 vs 
1.0), vision (mean score 0.93 
vs 0.98), hearing (mean score 
0.91 vs 0.99), eating (mean 
score 0.96 vs 1.0), speech 
(mean score 0.84 vs 0.99), 
usual activities (mean score 
0.82 vs 0.97), mental function 
(mean score 0.82 vs 0.93), 
and sexual activity (mean 
score 0.90 vs 0.96). 
+ Population 
controls 
- Very small 
sample size 
Harila et al272 Finland, 2010 63 childhood cancer 
survivors compared to  
RAND-36 scores Survivors scored significantly 
better than general population 
on the subscales of role 
limitations due to emotional 
problems (mean score 91 vs 











health (mean score 80 vs 74, 
p = 0.030) 
  
Hill et al  USA, 1998 110 survivors of 
childhood ALL (mean 
age 20.8 years) 
randomised to receive 
either 2400 centigray 















(MANCOVA 10.1 vs 7.9 p = 
0.001) in patients treated with 
cranial radiation compared to 
those who did not receive 
cranial irradiation. 
Significantly greater 
(MANCOVA 8.6 vs 6.7 p = 
0.049) in patients treated with 
cranial radiation compared to 
those who did not receive 
cranial irradiation. 
+ Use of 
validated 
questionnaire 






















18% of patients reported a 
diagnosis of depression (2% 
of these committed suicide 
during follow-up) 
Depression was more 
common in those who had 
HSCT transplant at 6-12 years 
(HR 2.29, CI 1.5–3.5, p = 
0.0002) or 12-18 years (HR 
3.63 CI 2.3–5.7, p<0.0001) 
+ Large 
sample size 























Female survivors had 
significantly lower scores for 
externalizing (delinquent 
behaviour, aggressive 
behaviour) than population 
averages (mean score 
11.37 ± 9.43 vs 14.35 ± 13.48, 
p = 0.003) 
+ Use of 
validated 
questionnaires 








12.5% had scores ranging 
from borderline to clinical in 
internalizing, externalising 
and/or total problems. 
Only one child had evidence 
of post-traumatic stress and 
the mean score was very low 






528 survivors of CNS 












More likely in survivors 
(30.1%) than controls (17%) 
 
 
More likely in survivors 
(30.1%) than controls (17%) 
 
 
+ Use of 
random 
controls 











More likely in survivors 
(22.2%) than controls (7.4%) 
Hudson et 
al275 
USA, 2015 6875 childhood cancer 
survivors and 2351 
siblings 
Reported adverse 
mental health (as 
per BSI-18) 
More likely in survivors than 
siblings, (PR 1.66; 95% CI 
1.52 to 1.80) 






















Japan, 2015 185 childhood cancer 
survivors 
IES-R-J scores 20.7% of survivors scored 
above the cut off for PTSD. 





Female survivors, those who 
were older at the time of 
diagnosis and those suffering 
from late effects were at 
higher risk of PTSD. Better 
family functioning was 
associated with decreased risk 
of PTSD (β = −.27, p=0.001) 
as was increased satisfaction 




- Lack of 
control group 









More prevalent in those who 
were socially withdrawn (OR 
1.5, 95% CI 1.1-2.1) or used 
stimulant drugs (OR 1.9, 95% 
CI 1.1-3.2) during 
adolescence 
More prevalent in those 
socially withdrawn in 


























adolescence (OR 1.7, 95% CI 
1.1-2.5) 
More prevalent in those with 
adolescent antisocial 
behaviour (OR 2.6, 95% CI 
1.6-4.2) 
Less prevalent in those using 
stimulant medication during 








- Lack of 
details on 
which groups 










USA, 2016 87 adult survivors of 
non-CNS malignancy 
diagnosed between 






No significant difference 
between survivors and 
controls in any domain, 































32% reported psychological 
problems, including feeling 
inferior or negative about 
themselves, useless and 
depressed. 
46% described physical 
sequalae which interfered with 
and caused negative feelings 
about their looks. 
- Very small 
sample 
- Relies on 
self-report 
 
Lesko et al279 USA, 1992 51 acute leukaemia 
survivors treated with 
chemotherapy alone 
and 22 treated with 
BSI scores Rates of distress were higher 
in both groups that the general 
population but this did not 









There was no difference 
between groups. 
- Very small 
sample size 
- Lack of non-
cancer-patient 
control group 

















(25.8%) and oppositional 
behaviour (20%) than the 
expected rate of 10% (all 
p<0.0001) 
Significantly higher 
frequencies of GAD (3.2% vs. 
1.1%), OCD (10.3% vs. 1-3%), 
Simple/Social Phobias (22.3% 
vs. 15.8%) and ODD (15.9% 











vs. 8.3%) than the general 
population (all p<0.05) 
Löf et al281 Sweden, 
2009 
51 stem cell transplant 
survivors and 152 
healthy controls 
HADS scores 35% of survivors reported 
problems with anxiety and 
depression, compared to 10% 
of controls. 14% had problems 
with both anxiety and 
depression, 16% with anxiety 







Lown et al282 USA, 2008 10 398 childhood 
cancer survivors, 3034 
siblings and 4774 
respondents from the 
National Alcohol 
Survey 





Risk factors for 
heavy drinking 
Less likely (OR = 0.9; CI 0.8–
1.0) in survivors 
 
Less likely (OR = 0.8; CI 0.7–
0.9) in survivors 
Among survivors, symptoms 
of depression, anxiety or 
somatization, fair/poor health, 
+ Large cohort 

















activity limitations and anxiety 
about cancer were associated 
with heavy drinking. 
Cognitively compromising 
treatment, brain tumours and 























7085 childhood cancer 




for mental health 
problems 
Excess risk for inpatient 
contact for mental disorders 
was 0·92 contacts per 1000 
person-years for male 
survivors of childhood cancer 








data on all 
67 
 
(CI 0·30–1·54) and 0·84 for 
females (0·24–1·46). 
Excess risk for in- and out-
patient contacts was 2·25 
contacts per 1000 person-
years for males (CI 1·45–3·04) 
and 1·26 for females (0·26–
2·26). 
- Use of 
sibling 
controls 









5452 survivors of 
childhood cancer and 




Survivors were at increased 
risk of being prescribed 
antidepressants (HR 1.4; CI 
1.3–1.5). Risk was higher for 
stem cell transplant recipients 
(HR 1.9; CI 1.2–3.1) and those 
with solid tumours in the 
extremities (HR, 1.8; CI 1.4–
2.3) 















No significant difference 
between groups 



















No significant difference 
between groups 
 
Higher scores (poorer 
functioning) for cancer 
survivors in domains of 
love/sex relationships (mean 
difference 0·87, CI 0·53-1·22), 
friendship (0·37, CI 0·07–
0·67), non-specific social 
contacts (0·40, CI 0·20–0·60), 






























353 childhood cancer 
survivors aged 18-30 
who were more than 7 
years from completion 
of treatment 
RAND-36 scores Survivors of brain tumors had 
a lower score on 
psychosexual development (β 
= –0.89, p < 0.05) than 
survivors of 
leukemia/lymphoma.  
Having been treated with 
radiotherapy was negatively 
related to Social development 
(β = –3.12, p <0.01) and to 
psychosexual development (β 
= –1.14 p < 0.05). 
Combination chemo- and 
radiotherapy was negatively 
associated with psychosexual 
development (β = -1.21, p < 
0.001). Longer treatment 









duration was negatively 
related to social development 





987 adult (>20) 
survivors of childhood 
cancer 
BSI scores 24.6% (CI 21.9-27.3%) of 
survivors scored highly on 2 or 
more domains or on the global 
severity index. Women 
(OR=1.88), only children 
(OR=2.09) and immigrants 
(OR=1.96) were more likely to 
report high distress than men, 
those with siblings, and those 
born in Switzerland. 






- Lack of 
control group 
 
Milam et al172 USA, 2015 193 long term 
survivors of childhood 
cancer 
Self-reported 
substance use in 
past 30 days 
Prevalence was 11% for 
tobacco, 25% for alcohol and 
14% marijuana. 16% of the 
cohort used at least 2 
substances. 
- Reliance on 
self-reporting 











USA, 2014 1863 long term (> 10 
years) childhood 
cancer survivors  
BSI-18 scores 15.1%. of survivors reported 
an elevated level of global 
emotional distress; 11.7% 
reported elevated levels of 
anxiety, 15.0% reported 
elevated levels of depression 
and 17.8% reported elevated 
levels of somatization. 
Survivors who completed 
education prior to college had 
more distress than those who 
completed college or post-
graduate education (OR 1.65; 
CI, 1.10–2.48). Survivors 
unable to work due to 
illness/disability had more 
distress than survivors who 
were either working or not 
working by choice e.g. 
students, retired (OR 1.83; CI 









1.01–3.34). Survivors without 
medical insurance had more 
distress than those with 
private medical insurance (OR 
1.60; CI 1.11–2.32). 
Ozono et 
al287 
Japan, 2010 88 survivors of 
childhood cancers, 87 
mothers and 72 fathers 
of survivors 
CDI scores Mean scores of 9.8 (SD 6.0), 
12.4 (SD 5.8) and 15.1 (SD 
7.7) were found from children 
from “supportive”, 
“intermediate” and “conflictive” 
families, respectively (p=0.02). 



























14% reported mood swings 
 
 
42% had clinically elevated 
scores on the total behaviour 
- Very small 
sample size 
- Tool used in 
patients up to 







problems scale, 50% on the 
internalizing behaviour 
problems scale, and 17% on 








USA, 2015 2589 survivors of 
adolescent and young 
adult cancer, 3603 
survivors of childhood 
cancer and 390 
siblings 
BSI-18 scores Survivors diagnosed as 
adolescents reported greater 
anxiety (OR 2.00; CI 1.17-
3.43), somatization (OR 2.36; 
CI 1.55-3.60) and depression 
(OR 1.55; CI 1.04-2.30), than 
siblings.  
+ Very large 
sample size 












1,049 childhood (dx < 
16 years) cancer 





Higher (OR = 1.7; CI 1.3–2.1) 
in survivors compared to 
background population 








More likely (OR = 2.9; CI 2.3–
3.8) in survivors 








Reported by 12.8% of 
survivors (more likely in 
survivors who were younger at 
diagnosis, those who had had 
cranial irradiation and those 
with symptoms of depression) 
+ Use of 
validated 
questionnaires 






USA, 2009 214 survivors of 
childhood HSCT plus 
an age and sex-
matched group of 
controls 
SCL-90-R scores Survivors were more likely to 
be depressed (p=0.03) than 
controls 






some way to 
survivors 













USA, 2015 482 childhood 
rhabdomyosarcoma 







Survivors had higher rates of 
depression (13.3% vs. 8.1%, 
p=0.020) and anxiety (7.9% 
vs. 4.4%, p=0.038) than 
siblings. 
Survivors reported poorer 
emotional functioning (19.2% 
vs. 13.5%, p=0.030) and 
greater role limitation due to 
emotional problems (21.3% 





USA, 2007 2,979 survivors and 
649 siblings of cancer 
survivors aged 12-17 
BPI scores Survivors were 1.5 times (CI 
1.1 - 2.1) more likely than 
siblings to have symptoms of 
depression/anxiety and 1.7 







times (1.3 - 2.2) more likely to 
have antisocial behaviours.  
- Use of 
sibling 
controls 
Seitz et al245 Germany, 
2010 
820 young adult 
survivors of childhood 













22.4% of survivors had 
clinically relevant scores 
compared to 14.0% of controls 
(ORs 1.77; CI 1.39–2.26). 
Posttraumatic stress was 
more likely in male (OR 3.92, 
CI 1.80–8.51) and female (OR 
3.83, CI 2.54–5.76) survivors 
than controls. 
24.3% survivors fulfilled the 
diagnostic criteria for at least 
one DSM-IV diagnosis 
including PTSD, depression 
and/or anxiety, compared to 
only 15.3% of controls (OR 
























USA, 2010 6542 childhood cancer 
survivors and 368 
sibling controls 
PTSD symptoms 9% of survivors reported 
symptoms of PTSD compared 
with 2% of siblings (OR 4.14; 
CI 2.08–8.25). PTSD was 
more likely in survivors treated 
with more intensive treatment 
(OR 1.36; CI 1.06–1.74) and 
those who received cranial 
radiotherapy before the age of 
4 (OR 2.05; CI 1.41–2.97). 










Sun et al295 USA, 2011 1065 long-term HCT 
survivors, plus a 
sibling control group 
BSI-18 scores 22% of survivors and 8% of 
siblings reported adverse 
psychological outcomes. Risk 
of distress was increased in 
survivors with active GvHD, 
self-reported poor physical 
















246 young adult 






9% reported concerns about 
disease recurrence or further 
malignancy. 
4.5% reported low self-
confidence. 
3.5% reported distressing 
memories. 
3% reported hospital anxiety. 
3% reported low mood. 
2% reported anxiety. 
2.5% reported other mood 
disturbance. 
15% reported difficulties as a 
result of altered body 
appearance e.g. scars, poor 
hair quality, prostheses 





- Lack of any 









28 survivors of 
childhood/adolescent 





and BFS scores 
Overall scores were not 
significantly different to 
reference sample groups, 
although the survivors scored 
more highly for positive social 
interactions (mean scores 
84.88 vs 69.8, p=0.003), lower 
for depression (mean scores 
7.39 vs 12.51, p=0.005) and 
more highly for intelligence 
(mean scores  3.41 vs 3.11, 
p=0.009) 






















628 childhood cancer 
survivors and 440 
healthy controls 
HADS scores No significant difference 
between survivors and 
controls overall, however 
survivors who had had cranial 
radiotherapy had a 
significantly higher HADS 
score than the control group 











6.6±5.3, p=0.05) or other 
survivors (p=0.01) 
 






survivors (compared to 
a reference sample) 













Young (<12y) and adolescent 
male RB survivors reported to 
have higher rates of 
internalising problems 
compared with reference 
group (young mean difference 
6.2, p = 0.037; adolescent 
mean difference 5.6, p = 
0.030). Young (<12y) and 
adolescent male RB survivors 
reported to have higher rates 
of somatic problems 
compared with reference 
group (young mean difference 
6.1, p=0.011; adolescent 
mean difference 3.6, 
p=0.047). Young female RB 
survivors reported to have 

































more somatic problems 
compared with reference 
group (mean difference 7.7, 
p=0.013). 
Adolescent female RB 
survivors reported fewer 
externalising problems (mean 
difference 3.8, p=0.045), 
especially rule-breaking (mean 
difference 1.8, p=0.034) and 
aggressive behaviour (mean 
difference 2.5, p=0.022), than 
the reference sample; they 
also reported fewer thought 
problems (mean difference 
2.4, p=0.004). 
Adult male RB survivors 
reported fewer thought 
problems (mean difference 
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1.3, p=0.047) than the 
reference group. Adult female 
RB survivors reported more 
somatic problems (mean 
difference 1.9, p=0.048) than 
the reference group, but fewer  
total problems (mean 
difference 3.3, p=0.025), 
particularly externalising 
problems (mean difference 
2.8, p=0.024), aggressive 
behaviour (mean difference 
1.3, p=0.038) and intrusive 
behaviour (mean difference 
2.2, p=0.000) 






survivors compared to 




Survivors were less likely to 
employ the emotion-oriented 
coping strategy than the 
reference cohort (mean scores 
27.57 vs 37-42 for adult 






















females, 25.06 vs 34-38 for 
adult males, 25.50 vs 48.38 
for adolescent females and 
28.40 vs 39.62 for adolescent 
males. All other strategies 
were used similarly. 
Adolescents who experienced 
reduced social support 
reported more total problems 
(β = -0.357). In adults, 
increased exposure to 
stressful life events (β = 0.24), 
more emotion-oriented coping 
(β = 0.534) and lower social 
support (β = -0.188) were 
associated with greater total 
problem scores. 
Adolescents with reduced 
social support (β = -0.447) and 
















acceptance (β = -0.396) 
reported higher internalizing 
problems. Adults with lower 
scores on disease acceptance 
experienced more internalizing 
problems (β = -0.156). 
Increased exposure to 
stressful life events (β = 
0.265), more emotion-oriented 
coping (β = 0.448) and lower 
social support (β = -0.309) 
were also associated with 









Depression was more 
prevalent in survivors with 
endocrine conditions (RR1.3, 
95% CI 1.1-1.6) and 
pulmonary conditions (RR 1.4, 














95% CI 1.1-1.7). Anxiety was 
more prevalent in survivors 
with cardiac conditions 
(RR=1.5, 95% CI 1.2-1.8) and 
pulmonary conditions (RR 1.6, 
95% CI 1.3-.2.0). 
Post-traumatic stress 
symptoms were more likely in 
patients with cardiac (RR 1.3, 
95% CI 1.2-1.5), endocrine 
(RR 1.3, 95% CI 1.2-1.5) and 
pulmonary conditions (RR 1.4, 


















17% of the study sample were 
identified as clinically 
distressed, compared to 10% 
of the general population. 
14% of cohort had scores 
indicative of clinically 









significant PTSD (26% of solid 
tumor survivors vs 11% of 
leukemia, Hodgkin lymphoma 










2,778 survivors of 
childhood or 
adolescent solid 
tumours and 2,925 
sibling controls 
BSI-18 scores Both survivors and siblings 
reported lower scores than 
population norms. 






- Use of 
sibling control 
group 
















Zebrack et al 
(b)303 
USA, 2004 1101 brain tumour 
survivors and 2817 
sibling controls 
BSI-18 scores 11% of survivors had scores 
indicating clinically significant 
distress, compared to 5% of 
siblings. 
+ Very large 
sample size 








Zebrack et al 
(c)304 
USA, 2002 4914 survivors of 
childhood 
haematological 
malignancy and 2446 
sibling controls 
BSI scores 5.4% of survivors reported 
symptomatic depression, 
compared with 3.4% of 
siblings. 12.7% of survivors 
reported somatic distress, 
compared with 8% of siblings.  
+ Very large 
sample size 











7147 survivors of CYP 
(<21yrs) cancer and 
388 siblings 
BSI-18 scores Survivors reported higher 
scores of global distress than 
siblings (mean scores 49.17 
vs 46.64), but both groups 
scored lower than population 
averages. 
+ Very large 
sample size 








Zevon et al306 USA, 1990 46 survivors of 
childhood ALL with a 








Those who received cranial 
irradiation had lower scores 
than those who received only 
intrathecal methotrexate 
(F=4.49, p<0.05). 
Significantly higher in female 





- Lack of non-
cancer-patient 
controls 





Zuzak et al307 Switzerland, 
2008 






33% reported behavioural 
problems 
+ Use of 
validated 
questionnaire 







2.3.1 Mental Health of CYP’s cancer Survivors 
A wide variety of problems were reported. These included difficulties with 
interpersonal relationships283, increased somatic 
distress/somatisation155,295,299,302–304, poor self-esteem247, depression and other 
mood disorders245,254,293,302,303,255,265,278,280,281,288,291,292, anxiety and other 
neurotic disorders255,292,293,295,303,304, antisocial behaviour277,293, 
PTSD244,266,276,292,301, schizophrenia and other psychotic disorders255,269, poor 
body image281, difficulties fulfilling expected roles due to emotional 
disturbance269, behavioural problems307, mood swings288, ODD277, drug and 
alcohol misuse172,289, suicidal ideation259,290 and unmet emotional and coping 
needs262.  
One large study of hospital contacts found survivors of CYP’s cancers were 
more likely to have both in- and out-patient assessment and treatment for 
mental health problems162. However, another study found that CYP’s cancer 
survivors were more likely to access healthcare for mental health problems 
than siblings with the same problems160. It is therefore difficult to know whether 
increased hospital contact truly represents an increase in prevalence, or merely 
an increased likelihood of seeking help. 
Two large studies investigated prescriptions amongst CYP’s cancer survivors. 
One found increased prescribing of antidepressants156 and another increased 
prescribing of psychotropic medication in general258 amongst CYP’s cancer 
survivors compared to the general population. Interestingly, the study reporting 
increased general psychotropic medication use did not note an increase in 
prescribing of antidepressant drugs258. Unfortunately, a reliance on self-
reported data in one study and a lack of information on indications for 
prescriptions in the other mean that it is difficult to infer whether these 
increases in prescriptions truly represent increased prevalence of mental ill 
health. Furthermore, the study looking at overall psychotropic prescribing 
included analgesics in their defined “psychotropic” medications. Given the 
prevalence of chronic pain in cancer survivors, this makes the results 




2.3.1.1 Risk Factors for Poor Mental Health in Survivors 
Literature was available not only on the mental health problems and difficulties 
faced by some CYP’s cancer survivors, but also on factors which appeared to 
be associated with increased risk of mental ill health. 
2.3.1.1.1 Treatment 
A number of studies reported on the effects of different treatment modalities, 
including chemotherapy, radiotherapy and surgery, on mental health outcomes. 
Cranial irradiation161,298,306,308, particularly at an early age244, treatment with 
high doses (≥ 300 mg/m2) of anthracyclines295 and more intense treatment 
generally244 were all associated with greater likelihood of mental ill health, 
including increased PTSD risk. These differences were noted in older studies, 
which were carried out when cranial irradiation was a routine part of ALL 
treatment, but also in more modern studies. However, only 2 of these 5 studies 
also looked at a non-cancer control groups. Additionally, patients who had 
undergone brain surgery also reported more adverse mental health 
outcomes275. 
Results of a small and somewhat dated study suggest that leukaemia survivors 
treated with BMT had no greater risk of distress than those treated with 
chemotherapy alone279. However, timing of BMT was important, with another, 
much larger, study finding depression risk higher in survivors who underwent 
transplant in their teenage years than those transplanted as younger 
children273.  
2.3.1.1.2 Pathology 
Multiple studies investigated results for survivors of different tumour types. 
Evidence from several robust, large-scale studies indicates that solid tumour 
survivors (including survivors of CNS tumours) appeared to have poorer mental 
health outcomes than survivors of haematological malignancy. Although some 
of these studies used scores from the HADS questionnaire, which is only 
validated in hospital inpatients and thus of limited applicability in an outpatient 
setting, similar results were found in large scale studies using validated 
questionnaires. Available evidence suggested that CNS tumour survivors had 
reduced social functioning256,267, increased psychological distress263 and poorer 
psychosexual development284 as well as globally poorer quality of life scores261 
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than survivors of other cancers. Amongst non-CNS tumour survivors, sarcoma 
survivors appeared to have particularly poor psychological outcomes261,284.  
2.3.1.1.3 Physical Health 
The impact of ongoing poor physical health on mental health was explored in a 
number of studies. Perhaps unsurprisingly, survivors with more marked 
disability, chronic ill health and physical sequalae of cancer treatment reported 
more adverse mental health outcomes. Lack of health insurance and inability to 
work due to disability were likely to have accounted for some of these effects. 
Issues with health insurance are less applicable to a UK population, but 
unemployment due to ill health is a global issue. Issues identified included 
problems with body image161,257,278, generally increased prevalence of distress 
and poor mental health157,286,288, increased risk of PTSD244 and increased risk 
of suicidal ideation259,290. Whilst many of these results came from studies 
looking solely at survivors of CNS tumours or sarcoma, the increased 
prevalence of physical ill health in survivors of these conditions means that this 
was probably a reasonable sample group. There were also some more specific 
findings noted, such as obesity being associated with higher risk of depression 
in patients treated with BMT273 and fatigue and sleep problems being 
associated with higher levels of anxiety, depression and somatisation264, 
although these were only looked at in single studies. 
2.3.1.1.4 Demographic Factors 
Different demographic factors were found to impact on risk of mental ill health 
in a number of studies. Female survivors appeared to have greater risk of 
mental health difficulties than males264,273,278,285,306. PTSD in particular was 
more common in female cancer survivors245.  
A large scale study covering a diverse ethnic population found that, after 
adjustment for socioeconomic status, black survivors were less likely to report 
adverse mental health than white or Hispanic survivors260, although no non-
cancer controls were used in this study. No studies were found which reported 
on South Asian ethnicity. This probably reflects the fact that the majority of 
studies came from North America, where black and Hispanic individuals are the 




Another large-scale study found that survivors without siblings were at higher 
risk of psychological distress than survivors with siblings, whilst immigrants 
were at higher risk of distress than those who had not immigrated285. 
Smaller studies of specific tumour survivors also found poor social support, 
reduced disease acceptance, exposure to other stressful life events and a more 
emotion-oriented coping strategy were associated with higher levels of 
distress287,300 and a larger study of whole families found reduced family 
functioning to be associated with increased risk of PTSD276. 
2.3.1.2 Alternative Viewpoints 
Not all studies reported increased mental health problems, with some 
suggesting psychiatric disorder258, work and educational attainment283, poor 
body image and displeasure with current status246 were no more common in 
CYP’s cancer survivors. Anxiety and depression256,277,278 and sleep problems264 
were no more prevalent in some cohorts of CYP’s cancer survivors than 
controls. Some studies of CYP’s cancer survivors found overall low levels of 
PTSD305, depression255,271 and other mental health problems296, however lack 
of a control group makes it difficult to know whether these results simply reflect 
a lower prevalence of these disorders in the population sampled. One study 
found no evidence of depression in their cohort255. However, one of these 
studies looked only at survivors of TYA cancer and excluded survivors of 
childhood cancers and these studies tended to be smaller than those which did 
find increased risk of mental health disorder256,277,278,283,296.  
There was also some discrepancy in risk factors, with one study suggesting 
mental health difficulties were less common amongst individuals who had 
received cranial radiotherapy306, although this was a very small and now dated 
study. 
2.3.1.2.1 Positive Mental Health Outcomes 
As well as reports of considerable difficulties, positive outcomes were also 
identified, with CYP’s cancer survivors less likely to drink alcohol heavily or in a 
risky fashion than the general population282, although this may reflect 
individuals following recommended lifestyle advice to minimise the risk of other 
late effects. Alternatively, the use of self-report may mean that these reported 
outcomes were not accurate, as individuals may not want to admit to behaving 
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in what is perceived to be an unhealthy way. Reduced risk of mental health 
problems272 and behavioural problems were found in several very small 
studies274,299 These findings were replicated in 2 larger scale studies268,305 
although use of sibling control groups limits the reliability of these findings, as 
siblings are known to suffer from their own mental health problems by virtue of 
being the sibling of someone with cancer309. It is only by comparing CYP’s 
cancer survivors with a population unaffected by cancer that the true impact of 
cancer can be measured. 
2.3.1.3 The Impact of Mental Health on Physical Health 
Several very large cohort studies reported on the links between poor mental 
health and later physical health. We found evidence of links between poor 
psychological functioning and later risky health behaviours277, such as 
increased heavy and risky drinking in survivors with depression and anxiety173. 
All-cause mortality was higher in survivors who had a history of suicidal 
ideation259. 
2.4 Discussion 
This systematic review highlights the wide variety of psychological, psychiatric 
and psychosocial difficulties which may be faced by long term survivors of 
CYP’s cancer. The high prevalence of these conditions means that all 
healthcare providers looking after these patients should be competent in 
identification of these problems.  
Some potential causative and associated factors were also noted. 
The increased risk of psychological distress seen in patients who had 
undergone cranial irradiation244,290,298,308 and any form of brain surgery275 may 
go some way to explaining why brain tumour survivors have greater mental 
health difficulties than survivors of other cancers. However, these patients also 
had lower average IQ256 and increased physical health275 problems which may 
also account for at least some of the differences seen.  
Higher risk of mental health problems in patients treated with anthracyclines161 
may be due to the severe LEs often seen in these patients, particularly 
cardiomyopathy and congestive cardiac failure310, and the association between 
chronic illness and poor mental health286. The anthracycline dose associated 
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with increased risk of cardiotoxicity (>300mg/m2) is the same as the dose 
associated with increased mental distress310, which adds further weight to this 
theory. 
Patients with sarcoma are often treated with high dose anthracyclines311,312, 
and it may be that the link between anthracycline treatment and increased 
distress is responsible for the increased mental health difficulties in sarcoma 
survivors. Additionally, these patients may have experienced disfiguring 
surgery which can cause marked distress313. 
The complex nature of cancer biology and treatment means that it is difficult to 
attribute psychiatric morbidity to a single cause. In the case of CNS tumours, 
for example, the currently available literature does not provide sufficient 
evidence on causation and it is not possible to determine how much morbidity 
is due to the direct effects of brain surgery and/or cranial radiotherapy and how 
much is due to residual disability. 
Some studies had seemingly conflicting findings, for example a study finding 
increased interpersonal difficulties but no difference in work or educational 
attainment283. There may be many reasons for this, but it is possible that, as a 
result of having to continue with education during treatment, survivors are used 
to persisting with work or study despite ongoing difficulties. However, whilst it is 
positive to find good function in patients despite their difficulties, reduction of 
distress remains an important goal. 
There were a number of limitations to the studies found. Many used siblings of 
survivors as a control group. Siblings will have similar genetics and upbringings 
to survivors and therefore allow good control for some confounding variables, 
however siblings have been shown to be at risk of considerable psychological 
distress themselves309. These studies therefore risk underestimating any 
increased prevalence of problems in survivors. Several of the studies finding no 
difference between prevalence of mental health problems in survivors versus 
controls used sibling controls and this may be the reason for the lack of 
difference found160,256,270. Some studies reporting low levels of mental health 
problems had no control group at all274,297, making interpretation of these 
results even more difficult. 
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Most of the data from included studies was obtained from self-reports and 
questionnaires rather than clinician-made diagnoses. Self-reporting of 
symptoms is known to have a low predictive value for psychiatric diagnoses 
such as depression158 and even well validated scores are less accurate in the 
presence of co-morbidity159.  
Reports of secondary care contacts are helpful, however these also risk 
seriously underestimating the prevalence of mental health problems, which are 
largely treated in a primary care setting163.  
Studies looking at antidepressant prescribing156,265 did not provide information 
on the indication for prescription. Various antidepressants, including tricyclics 
and selective serotonin reuptake inhibitors (SSRIs), have been used to treat 
neuropathic pain167. Pain is another commonly reported symptom in cancer 
survivors168 and therefore without data on indication for prescriptions of 
antidepressant medication, it is difficult to know how much increased 
prescribing is actually a result of increased prevalence of depression. 
Furthermore, antidepressant medications, in particular SSRIs, are also used for 
a number of psychiatric conditions, such as obsessive-compulsive disorder 
(OCD)169, generalised anxiety disorder (GAD)170 and bulimia nervosa171, so 
whilst increased prescribing does likely indicate higher rates of psychiatric 
illness in this cohort, it would be useful to know specifically which conditions 
were more prevalent. In the United Kingdom, first line therapy for mild to 
moderate depression is psychological therapy such as cognitive behavioural 
therapy166. It is therefore likely that looking at antidepressant prescribing alone 
would underestimate the prevalence of depression in our population. 
Additionally, other studies looking at prescriptions of psychotropic 
medications258 included analgesics. As increased rates of pain are seen in this 
population and therefore higher levels of analgesic prescribing would be 
expected cancer survivors168, these studies do not accurately help to ascertain 
prevalence of mental health problems. 
We found no studies reporting on primary-care-diagnosed mental health 
problems, despite the evidence that this is the commonest place for them to be 
diagnosed and managed163. Although the studies we found reporting on 
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prescribing data156,265 did include prescriptions from primary care, diagnoses 
were not ascertained in these cases.  
One study did report that cancer survivors were more likely to seek help for 
mental ill health than sibling controls160, and it is therefore possible that some of 
the studies reporting increased mental health contacts amongst CYP cancer 
survivors are in part explained by an increase in help-seeking. However, 
papers which actually reported on clinician-made diagnoses or mental health 
problems162,254,269,270, or prescriptions of psychotropic medications156,165,258,265 
accounted for a minority of included studies. It is unlikely that help-seeking 
would impact on self-reported or questionnaire-diagnosed problems, and thus 
increased help-seeking is not an adequate explanation for the overall increase 
in reported mental health problems amongst CYP cancer survivors.  
Many studies included mostly survivors of ALL; although this is reflective of 
survivorship patterns, it may be that because these patients are at lower risk of 
problems, issues seen in survivors of rarer malignancies, such as poor body 
image257, were not present at a statistically significant level. Even in studies 
where there were overall no difference in prevalence of problems, there were 
some sub-groups with increased risk of anxiety and depression298 and sleep 
problems264. 
The studies included in this review focussed mainly on survivors of childhood 
cancer. Of 67 included studies, only 5 either included only TYA survivors or 
reported results for TYA survivors separately to childhood 
survivors240,255,270,278,296. Many other studies chose their age range such that 
the majority of TYA would have been included (many included under 18s or 
under 21s), however these studies did not report separately on TYA outcomes. 
Additionally, we found no studies including young adults up to the age of 30.  
This highlights the striking lack of literature on TYA survivors, who have 
historically been excluded from many trials314.  
Although this review included 67 studies, only 2 were carried out within the 
United Kingdom. Over half of the studies (n=35) were from North America. 26 
were from mainland Europe, with 13 of these from Scandinavia, and the final 4 
were from East Asia. Differences in the way healthcare is accessed, funded 
and paid for may well impact of the prevalence of diagnosed mental health 
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problems and there is therefore a need for more local work to ascertain the true 
prevalence of these debilitating issues in our population. 
Whilst this systematic review identified a large number of papers, the broad 
definition of “mental health” means that there were likely some papers on 
specific conditions which were not identified. Further reviews considering 
specific mental health conditions may be useful in ascertaining the state of 
knowledge regarding particular diagnoses. Additionally, it was out with the 
scope of this review to look at intervention or treatment. A review of treatment 
options may enable the development of a clinical guideline which would assist 
clinicians caring for long term survivors of CYP cancer. 
2.5 Conclusion 
This systematic review has served to identify the wide range of mental health 
conditions experienced by survivors of CYP’s cancer.  It is difficult to tease out 
the exact incidence, prevalence and risk-factors for their development from the 
existing literature.  Given the potential for marked distress as a result of these 
conditions, further work is essential.  Comprehensive linkage of primary 
care/community health and hospital records may help to resolve this and 
support robust identification of those diagnosed with cancer at a young age 
who are at risk of developing late mental health morbidity. 
2.6 Repeat Literature Search 
The initial literature search for this review was carried out some time ago. 
Therefore, in January 2020, the search was repeated to identify any important 
papers which had been published in the period between the initial search and 
the preparation of this thesis. 
There were no papers published in the interim which altered the overall 
conclusions of the initial review, however, there were several papers published 
which further highlighted the need for more research in this area.  
A moderate-sized American study highlighted the increased healthcare service 
utilisation of childhood cancer survivors with PTSD315. A small French study 
found increased anxiety and depression amongst childhood cancer survivors, 
although unlike the other study included in this review172, they also found 
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increased risk of substance use316. They also reported lower risk of suicide316, 
which is also in contrast to other studies259,290. A large German study reported 
increased mental distress amongst childhood cancer survivors, including 
suicidality, and highlighted females, those with lower educational levels, those 
with low incomes and unemployed individuals as at highest risk317. A moderate-
sized Canadian study of ALL survivors found moderate prevalence of anxiety, 
depression and distress, which appeared higher in adolescent survivors than 
adult survivors, although the study lacked a control group318. A large study of 
neuroblastoma survivors found increased mental health difficulties, which were 
significantly more likely in those with chronic physical ill health, although this 
study was limited by the use of a sibling control group319. All of these studies 
were limited by self-report or questionnaire-based methodologies. 
A systematic review and meta-analysis looking specifically at mental health in 
survivors of adolescent and young adult cancer highlighted the increased risk 
of mental ill health in this group, particularly amongst female survivors and 
those individuals who were older (within the “young adult” group) at the time of 
diagnosis320. Importantly, this review only included 4 papers and they highlight 
the important point that literature focussing on young adults is lacking320. A 
literature review which also focussed on survivors of adolescent and young 
adult cancer highlighted PTSD as a particular problem faced by this group321. 
A large Canadian study found increased rates of mental health services use 
amongst CYP’s cancer survivors compared to the general population, with 
survivors of adolescent cancer at greatest risk322. Unlike other studies, this 
work used administrative data to determine rates of hospital and other 
healthcare provider visits for mental health care. The main limitation of this 
work is that although almost all individuals diagnosed with cancer under the 
age of 15 were included, only about half of those aged 15-18 at diagnosis were 
included, and the work did not include any individuals diagnosed over the age 
of 18322. 
These further studies highlight the likely increased risk of mental ill health 
amongst survivors of CYP’s cancer. A single population-based study which 
used routinely-collected data was identified322, however this was not based in 
the UK and thus similar work in a more local population remains necessary. 
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Chapter 3 Data Sources and Methods 
3.1 The Yorkshire Specialist Register of Cancer in Children 
and Young People 
The YSRCCYP is a regional, population-based register of cancer diagnoses 
and diagnoses of benign CNS tumours in children and young people in the 
North of England. The YSRCCYP covers the Yorkshire and the Humber 
Strategic Health Authority, which covers 15,000 square kilometres and has a 
population of 5 million67. The area covered by the YSRCCYP is show in figure 
3a. 
Figure 3a: Strategic Health Authorities in England, with Yorkshire and the 
Humber indicated by the arrow, in light blueb 
                                            





Since 1974, data have been collected on all cases of cancer and non-malignant 
CNS tumours diagnosed in children aged 15 years and under living in the 
former Yorkshire Regional Health Authority323. Additionally, data have been 
collected on young people aged 15-29 years at the time of cancer/CNS tumour 
diagnosis since 1990. The YSRCCYP contains detailed information regarding 
socio-demographic factors, diagnoses and treatments, as well as information 
on tumour type (by both ICCC and Birch classifications), survival and 
relapse323. A list of all fields recorded in the YSRCCYP is attached in Appendix 
A. The majority of primary notification data is obtained directly from hospital 
records as either electronic downloads or manual abstractions, however where 
additional data sources have been used, these are described below. Vital 
status is checked 2-yearly, with pro-formas sent to hospital or primary care 
doctors to request this information. Deaths are then checked with the National 
Cancer Registration and Analysis Service (NCRAS). 
3.1.1 Ethnicity 
Where ethnicity information was available from hospital records, this was used 
as the primary method of classification. However, this field was occasionally 
incomplete, with no ethnicity available in around 10% of cases324. Onomap 
software, which calculates probabilities of patients being from different ethnic 
backgrounds based on their name325, was therefore used to ascertain likely 
ethnicities for those where this information was not available from hospital 
records. Previous work on ethnicity using the YSRCCYP has shown very high 
levels of agreement between ethnic group classification from hospital records 
and those from Onomap324. In cases of discrepancies between ethnicity 
ascertained from hospital records and Onomap, the hospital records were 
assumed to be correct. Due to small numbers of individuals being from some 
ethnic groups, which makes meaningful analysis difficult, individuals were 
grouped into larger groups - White, South Asian or Other - for the purposes of 
analysis. The “South Asian” group consisted of those of Indian, Pakistani and 
Bangladeshi origins, the “White” group consisted of those of White British, 
White Irish and Other White Background and the “Other” group consisted of all 
other ethnicities, e.g. Black African, Black Caribbean, Other Asian, as well as 
mixed or unknown ethnicities. South Asian is the most common ethnic minority 
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in the UK, comprising just over 5% of the population in the 2011 National 
Census326. Use of Onomap reduced the number of records without a known 
ethnicity to 0.4%324. 
3.1.2 Deprivation  
Deprivation was calculated using the Townsend deprivation index associated 
with the postcode where the patient lived at the time of their cancer diagnosis. 
The Townsend index uses Census data captured on unemployment, home 
ownership, vehicle ownership and household overcrowding to calculate a 
deprivation score for each Census output area and then aggregated up to 
electoral ward level327. This information was taken from the most recent 
national Census in 2011. For the purposes of this analysis, we grouped 
electoral ward areas into fifths, from 1 (least deprived) to 5 (most deprived). 
The Townsend deprivation index has been used to assess deprivation on the 
YSRCCYP for many years, as it is a multi-modal assessment and takes into 
account factors other than household income327. It has also been available for 
longer than other measures, such as the Index of Multiple Deprivation, and is 
this more appropriate for a registry-based study going back to the 1970s. 
3.2 Office for National Statistics 
Mid-year estimates of the usual resident population for the 2011 census output 
areas within Yorkshire and the Humber were obtained from the Office for 
National Statistics (ONS)328. The number of individuals living in the Yorkshire 
and Humber region, which are estimated annually, were available for the years 
2002-2017328. This information is broken down by age group and sex.   
3.3 Hospital Episode Statistics 
Hospital episode statistics (HES) are “a database containing details of all 
admissions, A and E attendances and outpatient appointments at NHS 
hospitals in England”329. These data are routinely collected by NHS services 
and maintained by NHS Digital (formerly the Health and Social Care 
Information Service; HSCIC)329. The primary purpose of HES data is to allow 
appropriate activity-based payment to NHS service providers, however the data 
can be made available for research purposes329 and linked to cancer 
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registration data using personal identifiers such as NHS number. There have 
been concerns regarding the reliability of HES data, but steps over time have 
been to engage clinicians in the coding and collection of data, resulting in more 
reliable data from more recent years330,331. 
3.3.1 Mental Health Datasets 
The HES data of most interest for the purposes of this thesis was that 
pertaining to mental health. Between 2006 and August 2014, data were 
collected in a dataset known as the Mental Health Minimum Dataset (MHMDS), 
which included information on contacts with adult inpatient, outpatient, 
community and mental health services332. In September 2014, in the dataset 
was renamed the Mental Health and Learning Disabilities Dataset (MHLDDS), 
and was expanded to include contacts with learning disability services as well 
as the mental health services collected by the MHMDS333. In February 2016, 
the dataset was renamed the Mental Health Services Dataset (MHSDS), and 
was extended to include contacts with autism services and services specifically 
for children and young people334. The MHMDS and MHLDDS include contacts 
by children and young people to general adult services, but does not include 
information on contacts with mental health, learning disability or autism 
services specifically for children and young people, as these data were only 
collected following the creation of the MHSDS334. 
This thesis used data from the MHMDS and MHLDDS but not MHSDS, 
because linked HES data were only available up to 2015. The focus of this 
thesis was on whether or not an individual had any recorded contact on the 
MHMDS or MHLDDS, due to the other data fields being poorly filled in. For 
example, “year of first known psychiatric contact” was provided in less than 
30% of cases. 
A list of all fields available from the provided HES mental health datasets is 
attached in Appendix B. 
3.3.2 Hospital Admitted Patient Care Activity Dataset 
The HES Hospital Admitted Patient Care Activity dataset contains details of all 
patients admitted to hospital for any reason, including dates of admission, 
diagnoses and any surgical operations or procedures. This information has 
been collected since 1998335. Throughout this thesis, this dataset will be 
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referred to as the “inpatient dataset”. Data were available for use in this thesis 
from 1998-2015. This dataset was used to identify individuals who had a listed 
mental health diagnosis. For the purposes of this work, mental health 
diagnoses included were the following ICD-10 codes: 
 F10-F19: Mental and behavioural disorders due to psychoactive 
substance use 
 F20-F29: Schizophrenia, schizotypal and delusional disorders 
 F30-F39: Mood [affective] disorders 
 F40-F48: Neurotic, stress-related and somatoform disorders 
 F50: Eating disorders 
 F60-F63; F65; F68-F69: Disorders of adult personality and behaviour 
(specifically excluding F64: Gender identity disorders and F66: 
Psychological and behavioural disorders associated with sexual 
development and orientation) 
 F90-F93: Hyperkinetic disorders, conduct disorders, mixed disorders of 
conduct and emotions, and emotional disorders with onset specific to 
childhood 
 F99: Unspecified mental disorder 
For the purposes of this thesis, individuals were only considered to have had a 
mental health diagnosis on this dataset if this was recorded subsequent to their 
cancer diagnosis. 
3.3.3 Combined Indicator of Mental Ill Health 
Although not a specific HES dataset, the author then created a “combined 
indicator of mental ill health”. This consisted of individuals who had either a 
record on a mental health dataset (MHMDS or MHLDDS), a mental health 
diagnosis recorded on inpatient HES or both. 
Individuals who received specialist mental health care between 2006 and 2015 
will appear on the mental health dataset. Those who received specialist mental 
health care, but only on dates out-with this period, will not appear on the 
dataset. Individuals who had a hospital admission for a mental health disorder 
between 2006 and 2015 should appear on the mental health dataset and also 
have a mental health diagnosis on inpatient HES. Individuals who had a 
hospital admission for a mental health disorder before 2006, but since 1998, 
should have a mental health diagnosis recorded on inpatient HES. Individuals 
who accessed purely outpatient-based mental health services between 2006 
and 2015 will have a record on mental health HES, but will only have a mental 
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health diagnosis recorded on inpatient HES if they were admitted to hospital for 
another reason and their mental health condition was listed as a co-morbidity. 
Individuals who had a mental health condition which was only ever managed by 
their GP will not appear on mental health HES, but may have a mental health 
diagnosis recorded on inpatient HES if they were admitted to hospital for 
another reason between 1998 and 2015, and their mental health condition was 
listed as a co-morbidity. 
3.4 Leeds Teaching Hospitals NHS Trust Records 
Leeds Teaching Hospitals NHS Trust (LTHT) is a large hospital trust located in 
Yorkshire. It provides care to both the local population in Leeds, as well as 
specialist services to the wider Yorkshire region336.   
For patients treated within LTHT, medical records were able to be directly 
accessed to obtain information about clinic attendances and follow-up 
appointments. 
Electronic patient records on the PPM+ system (the system used by LTHT) 
contain details of clinic appointments, correspondence and investigations for 
the majority of clinical specialties, including oncology and haematology, for 
patients of all ages. Full electronic records were only accessible for those 
patients who had been treated in Leeds Teaching Hospitals NHS Trust.  
In order to comply with licensing regulations from the Human Fertilisation and 
Embryology Authority (HFEA), data regarding use of fertility services is still kept 
in paper records. 
3.5 Leeds Fertility 
Our local assisted conception unit, Leeds Fertility, were able to provide a list of 
all patients who had undergone semen cryopreservation since 2008. Their 
indication for banking was also recorded, which meant it was possible to 
identify all patients who had undergone semen cryopreservation because of a 
diagnosis of malignant disease. 
A retrospective case note review of the paper fertility service notes was carried 
out in order to identify the following characteristics: 
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- Age at banking 
- Paternity status at time of banking 
- Semen analysis at banking 
- Whether or not the patient had been followed up by fertility services after 
banking 
- Whether or not a post-treatment semen analysis had taken place and, if so, 
whether post-treatment semen analysis was normal. 
3.6 Methodology 
3.6.1 Cohort Selection 
Details of cancer diagnoses were obtained from the YSRCCYP. Eligible 
individuals were diagnosed with a malignancy or non-malignant brain tumour 
between 1974 and 2012, before their 30th birthday, within the Yorkshire and 
Humber region, and had survived a minimum of 5 years post diagnosis. Data 
were extracted from the YSRCCYP in June 2017. Data were available on 9609 
individuals, of whom 7253 (75.5%) had survived for at least 5 years following 
an initial cancer diagnosis. These 7253 individuals made up the cancer survivor 
cohort described in this thesis. Further details of this cohort, including their 
characteristics and how they differ from those individuals who did not become 5 
year survivors, are given in Chapter 4: Cohort Description. 
3.6.2 Data linkage 
NHS Digital were provided with a list of all patients on the YSRCCYP through a 
secure file transfer process (FTP) and returned details of contacts recorded on 
the MHMDS and MHLDDS between 2006 and 2015, as well as contacts on the 
inpatient dataset since 1998. Data linkage and extraction was performed by 
NHS Digital using the following identifiers from the YSRCCYP: NHS number, 
date of birth, sex and postcode. 
Any individual with a linked record on the MHMDS or MHLDDS was considered 
to have accessed specialist mental health services. 
The inpatient HES data were also searched for any admissions where a mental 
health condition was either the primary reason for admission or a listed co-
morbidity. The ICD diagnostic codes included as “mental health conditions” are 
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listed earlier in this chapter, under section 1.3.2 Hospital Admitted Patient Care 
Activity Dataset. Individuals who had an admission primarily for a mental health 
condition were also considered to have accessed specialist mental health 
services, whilst those individuals who had a mental health condition listed as a 
co-morbidity were considered to have a mental health diagnosis. 
3.6.3 Yorkshire Population Data 
NHS Digital also provided tabulations of the number of contacts recorded on 
the MHMDS and MHLDDS between 2006 and 2015 for individuals living in 
Yorkshire and The Humber. Although it was not possible to obtain individual-
level records, aggregated data tables were available, with number of contacts 
broken down by 5-year age group and sex.  
Inpatient HES data was also obtained for all individuals in Yorkshire and The 
Humber, and, like the inpatient HES data for the YSRCCYP population, were 
searched for admissions with a documented mental health condition as a 
reason for admission or a co-morbidity.  
The number of contacts on the MHMDS and MHLDDS were compared to the 
estimated population from the ONS in order to generate a rate of specialist 
mental health care access in the population of Yorkshire. 
Rates of documented mental health conditions on inpatient HES were also 
compared to the estimated population from the ONS in order to generate a rate 
of documented mental health conditions in the Yorkshire population. 
3.6.4 Fertility Data 
Data on semen cryopreservation, provided by Leeds Fertility, were linked to the 
survivor cohort from the YSRCCYP to identify patients who were both 5 year 
survivors of CYP’s cancer and who had undergone semen cryopreservation. 
Patients on the YSRCCYP who were male diagnosed with cancer in 2008 or 
later and who were 13 or older at the time of diagnosis were identified as 
controls. As there are multiple potential fertility services within the Yorkshire 
area, only patients who were likely to have stored semen at Leeds Fertility 
(those from Bradford, Wakefield, Airedale, Harrogate, Leeds, Halifax, 
Huddersfield and Harrogate) were included as controls. Data on cancer 
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diagnosis as well as their age at diagnosis and year of diagnosis, were 
ascertained directly from the YSRCCYP. 
3.7 Statistical Methods 
3.7.1 Standardised Incidence Ratios 
Standardised incidence ratios were calculated to compare the incidence of 
contacts with specialist mental health services (based only on the presence of 
a linked record on the MHMDS or MHLDDS) between 5 year survivors of 
CYP’s cancer with a record on the YSRCCYP and the Yorkshire population as 
a whole. This calculation was made using the “PHE tool for calculating common 
public health statistics and confidence intervals”, downloaded from the PHE 
Fingertips website337. 
3.7.2 Regression 
Logistic regression was performed to determine the odds ratio (and 95% 
confidence intervals) of having at least one contact with specialist mental health 
services (identified by the presence of a linked record on the MHMDS or 
MHLDDS, or a record on inpatient HES where a mental health diagnosis was 
the primary reason for admission), and of having at least one mental health co-
morbidity (identified by a record on inpatient HES where a mental health 
diagnosis was a listed co-morbidity) for different exposures, including disease-
related factors such as tumour type and stage at diagnosis, as well as 
demographic factors such as age at diagnosis, race and deprivation status. All 
statistical analyses were performed using Stata-15 software. 
3.7.3 Causal Inference Methods 
Causal inference methods were used to identify an appropriate minimal set of 
confounders for each risk factor of interest, with separate regression models 
run for each variable338. Causal inference methods and directed acyclic graphs 
(DAGs), were chosen as they provide a robust way of identifying confounding 
variables and causal pathways whilst reducing the risk of over adjustment339 
and increasing statistical efficiency340, and are thus preferable to other 
statistical methods341. Causal inference methodology has been shown to be 
effective in clinical research342. DAGs were created to define the theoretical 
causal relationships with mental ill health using DAGitty software343 (figure 3.1). 
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DAGs with each possible primary risk factor of interest are provided in 
Appendix C. 
 
Figure 3.1 A Directed acyclic Graph describing the causal relationship between 
risk of mental health hospitalisation and “age at diagnosis” highlighted as 




DAGitty software suggested the following minimal adjustment sets for each 
primary risk factor (exposure): 
 Age at diagnosis – deprivation, gender 
 Deprivation – ethnicity, gender 
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 Ethnicity – nil (ethnicity sufficient on its own) 
 Gender – nil (gender sufficient on its own) 
 Stage at diagnosis – age at diagnosis, deprivation, ethnicity, tumour 
group, year of diagnosis 
 Treatment at TYA unit – age at diagnosis, deprivation, gender, stage at 
diagnosis, tumour group, year of diagnosis 
 Tumour group – age at diagnosis, deprivation, ethnicity, gender, year of 
diagnosis 
 Year of diagnosis – nil (year sufficient on its own) 
A further DAG was created specifically to look at the relationship between 
semen cryopreservation and mental ill health. Gender was removed from the 
causal pathway, given that only males would be offered semen banking, and 
semen cryopreservation was added in. This DAG is shown in figure 3.2. 
Figure 3.2 A Directed Acyclic Graph describing the causal relationship 





DAGitty software suggested the following minimal adjustment set when looking 
at sperm banking as the primary risk factor: age at diagnosis, deprivation, 
ethnicity, stage at diagnosis, treatment type, tumour group, treatment at TYA 
unit, year of diagnosis. 
3.7.4 χ2 and Fisher’s Exact Tests 
In order to test the hypothesis that there was a difference between groups, 
such as total individuals on the YSRCCYP and 5 Year Survivors, χ2 was used 
to generate p values, with p<0.05 being regarded as statistically significant. 
Where smaller numbers were present, such as in the fertility work in chapter 6, 
Fisher’s exact test was used as an alternative. 
3.8 Ethical Approval 
The YSRCCYP has longstanding ethical approval from the Northern and 
Yorkshire Multi Centre Research Ethics Committee (reference MREC/0/1/3)67, 
and approval from the Health Research Authority Confidentiality Advisory 
Group (reference 1-07(b)/2014). These approvals allow identifiable cancer 
registration data to be used without the need for explicit patient consent, 
although all individuals have the opportunity to opt out of the registry. Approvals 
also allow the linkage of registry data to other healthcare data sources. 
Specific, additional ethical approval was not required for the work described in 




Chapter 4 Cohort Description 
4.1 Yorkshire Specialist Register of Cancer in Children and 
Young People 5-plus year survivors 
The YSRCCYP contained information on 7253 patients who had survived at 
least 5 years after a diagnosis of cancer and were aged under 30 years at 
diagnosis. Patients were diagnosed between 1974 and 2012; until 1990, all 
patients on the register were under 15 years old at diagnosis and since 1990 
patients have been included if they were diagnosed before their 30th birthday. 
The decision to include patients up to the age of 30 was taken to ensure all in 
the TYA age group were included, and to try to broaden this group to include 
older patients who may still be considered “young adults”. The inclusion of 
patients up to the age of 40, consistent with some definitions of “adolescents 
and young adults” was not considered feasible from an administrative point of 
view. Data recorded included sex, age at diagnosis and diagnosis, classified 
according to the ICCC. Data on Townsend deprivation score (based on 
postcode at time of diagnosis), ethnicity, year of diagnosis and duration of 
follow up was also recorded. At the time of data extraction, 7092 (97.8%) 
individuals were alive. See Chapter 3: Data Sources and Methods for full 
details. 
Of the 7253 5 year survivors, 59.8% (4335) were male. Median age at 
diagnosis was 15 years, interquartile range (IQR) 5-24 years. The most 
common malignant diagnoses were leukaemias (1458 cases, 20.1%), 
lymphomas (1421 cases, 19.6%) and central nervous system tumours (1279 
cases, 17.6%). Patients had been followed up for a mean of 16.2 years 
(median length of follow up 15 years, IQR 9-22 years). As described in the 
introduction, Section 1.1.3: Cancer Classification, some cancers are most 
common in different age groups. Therefore, median age at diagnosis for 
individuals with a diagnosis within each of the ICCC diagnostic groups is shown 





Table 4.1 Median age at cancer diagnosis in years for each International 
Classification of Childhood Cancer diagnostic group, with Central Nervous 
System tumours separated into high and low grade tumours. 
Diagnostic Group Median age at diagnosis (IQR), years 
Leukaemias 6 (3-14) 
Lymphomas 20 (13-25) 
CNS Tumours 11 (5-20) 
Neuroblastoma 1 (0-4) 
Retinoblastoma 1 (0-2) 
Renal 3 (1-7) 
Hepatic 1 (3-18.5) 
Bone 14 (11-20) 
Soft Tissue 14 (5-24) 
Germ Cell 24 (19-27) 
Other Epithelial 24 (19-27.5) 
Other 23 (12-29) 
All Diagnostic Groups 15 (5-24) 
 
Characteristics of eligible patients on the register are summarised in table 4.2. 
The criteria for being an “eligible” patient is described in Chapter 3: Data 
Sources and Methods, Section 3.1: The Yorkshire Specialist Register of 
Cancer in Children and Young People. Note that period of diagnosis is 
categorised in 5 year brackets, aside from the earliest period (1974-1979; 6 
years) and the latest period (2010-2012; 3 years). This was to enable the 
periods before and after 1990, when patients aged 15-29 years at diagnosis 
started to be included on the register, to be clearly identifiable, whilst breaking 
down the majority of years of diagnosis into equal groups. All patients 
diagnosed before 1990 were under 15 at the time of diagnosis. This change in 
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recording also means that the majority of patients with longer follow up periods 
would have been diagnosed before their 15th birthday.  
Table 4.2 Baseline characteristics of eligible patients and 5 year survivors 
identified from the Yorkshire Specialist Register of Cancer in Children and 
Young People 
Characteristic Eligible registry 
patients 
5 year survivors χ2 statistic (p 
value)c 
Gender 
Male 5618 (58.5%) 4335 (59.8%) 2.9  
(0.0866) Female 3991 (41.5%) 2918 (40.2%) 
Age group at diagnosis  
0-4 2226 (23.2%) 1631 (22.5%) 38.7 
(<0.001)* 5-9 1294 (13.5%) 916 (12.6%) 
10-14 1030 (10.7%) 1002 (13.8%) 
15-19 1233 (12.8%) 883 (12.2%) 
20-24 1565 (16.3%) 1178 (16.2%) 
25-29 2261 (23.5%) 1643 (22.7%) 
Tumour Group (International Classification of Childhood Cancer25) 
Leukaemia 1943 (20.2%) 1458 (20.1%) 143 
(<0.001)* Lymphoma 1734 (18.1%) 1421 (19.6%) 
CNS 1765 (18.4%) 1279 (17.6%) 
Neuroblastoma 350 (3.6%) 229 (3.2%) 
Retinoblastoma 150 (1.6%) 124 (1.7%) 
Renal 314 (3.3%) 254 (3.5%) 
                                            
c * denotes statistical significance 
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Hepatic 84 (0.9%) 44 (0.6%) 
Bone 435 (4.5%) 301 (4.1%) 
Soft Tissue 579 (6.0%) 437 (6.0%) 
Germ Cell 1307 (13.6%) 1144 (15.8%) 
Other Epithelial 752 (7.8%) 548 (7.6%) 
Other 196 (2.0%) 14 (0.2%) 
Year of Diagnosis 
1974-1979 529 (5.5%) 403 (5.6%) 567 
(<0.001)* 1980-1984 400 (4.2%) 327 (4.5%) 
1985-1989 443 (4.6%) 386 (5.3%) 
1990-1994 1153 (12.0%) 1039 (14.3%) 
1995-1999 1284 (13.4%) 1179 (16.3%) 
2000-2004 1643 (17.1%) 1505 (20.8%) 
2005-2009 1754 (18.3%) 1641 (22.6%) 
2010-2012 2403 (25.0%) 773 (10.7%) 
Deprivation fifth (based on Townsend score of postcode at diagnosis) 
1 (least deprived) 1812 (18.9%) 1344 (18.5%) 1.2 
(0.885) 2 1767 (18.4%) 1351 (18.6%) 
3 1730 (18.7%) 1345 (18.5%) 
4 1792 (18.7%) 1357 (18.7%) 
5 (most deprived) 2488 (26.0%) 1856 (25.6%) 
Ethnic Group 
White 8180 (85.1%) 6474 (89.3%) 118 
(<0.001)* South Asian 666 (6.9%) 453 (6.3%) 
Other 417 (4.3%) 242 (3.3%) 
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Unknown 346 (3.6%) 84 (1.2%) 
Duration of Follow Up 
<10 years 3110 (32.3%) 2113 (29.1%) 91.2 
(<0.001)* 10-19 years 3297 (34.3%) 2774 (38.2%) 
20-29 years 2022 (21.0%) 1587 (21.9%) 
30-39 years 817 (8.5%) 669 (9.2%) 
40+ years 363 (3.8%) 130 (1.8%) 
Vital Status as of June 2017 
Alive 8541 (88.9%) 7092 (97.8%) 484 
(<0.001)* Dead 1068 (11.1%) 161 (2.2%) 
 
Individuals who survived at least 5 years were very similar in gender and 
deprivation status to all individuals on the register. A greater proportion of 
individuals who had survived at least 5 years were of White ethnicity. This is in 
keeping with studies which report a survival advantage for White individuals 
over those from ethnic minorities344, particularly in those with ALL345, despite 
there being a higher risk of childhood cancer in ethnic minority populations346. 
This may be in part due to increased socio-economic deprivation amongst 
individuals from non-White groups347. There were differences in tumour types 
and age at diagnosis between individuals who had survived 5 years and all 
individuals on the register, which is unsurprising given the differences in 
prognosis between tumour types, and their peak onset at different ages. 
NCSI risk levels101 were available for patients who were currently under the 
long-term follow up service in LTHT. 1509 (20.8%) patients had an NCSI level 
recorded in the LTHT database who had also been identified as 5 year 
survivors from the YSRCCYP. These are summarised in table 4.3. Further 
details on the NCSI levels, their history, and how they are assigned, are 
described in the introduction, Section 1.5.1: Risk of Late Effects. 
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Table 4.3 Available National Cancer Survivorship Initiative levels for patients 
included in analysis  
National Cancer Survivorship Initiative Level 5 year survivors 
1 68 (4%) 
2 1056 (66%) 
3 476 (30%) 
 
Of patients who had an NCSI level allocated, the majority (66%) were level 2, 
with just under one third allocated level 3. Only a very small number were level 
1. Compared to other studies, the number of individuals with NCSI level 1 was 
very low348. This is likely to reflect the fact that, in line with national 
recommendations99, many patients with NCSI level 1 are not followed up in 
clinic and thus information regarding their NCSI level was not available on our 
database of patients receiving active follow up. 
There were some differences between those patients who had an allocated 
NCSI level and those who didn’t. Patients without an assigned NCSI level were 
more likely to be older at the time of diagnosis (47.2% diagnosed after age 19 
vs 7.4% of patients with an assigned NCSI level). Far more patients without an 
assigned NCSI had a diagnosis of germ cell tumour (17.7% vs 8.5%), which 
may be due to the fact that these patients often receive less intensive 
treatment, sometimes being treated with surgery only, and thus referral to long 
term follow up may not be necessary99. Patients who had an assigned NCSI 
level appeared to have been diagnosed earlier (39.6% diagnosed before 1990, 
compared to 9.0% of patients without an assigned NCSI level). This may reflect 
the fact that older treatments were often more toxic and that both cancer and 
survival were rarer at this time21,22 meaning a higher percentage of patients 
were followed up. Additionally, some of the patients diagnosed more recently 
would still be under standard oncology follow up, as referral to long term follow 
up only takes place 5 years after the cessation of treatment. These differences 
are summarised in table 4.4. 
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Table 4.4 Characteristics of 5 year survivors with and without an allocated 
National Cancer Survivorship Initiative level. 
Characteristic NCSI level assigned 
No of patients 
No NCSI level 
assigned 
No of patients 
 
χ2 statistic (p 
value)d 
Gender 
Male 874 (57.9%) 3461 (60.3%) 2.71 
0.100 Female 635 (42.1%) 2283 (39.7%) 
Age group at diagnosis 
0-4 515 (34.1%) 1116 (19.4%) 962 
(<0.001)* 5-9 345 (22.9%) 571 (9.9%) 
10-14 386 (25.6%) 616 (10.7%) 
15-19 152 (10.1%) 731 (12.7%) 
20-24 68 (4.5%) 1110 (19.3%) 
25-29 43 (2.8%) 1600 (19.4%) 
Tumour Group (International Classification of Childhood Cancer25) 
Leukaemia 514 (34.1%) 944 (16.4%) 407 
(<0.001)* Lymphoma 244 (16.2%) 1177 (20.5%) 
CNS 238 (15.8%) 1041 (18.1%) 
Neuroblastoma 65 (4.3%) 164 (2.9%) 
Retinoblastoma 21 (1.4%) 103 (1.8%) 
Renal 81 (5.4%) 173 (3.0%) 
Hepatic 9 (0.6%) 35 (0.6%) 
Bone 88 (5.8%) 213 (3.7%) 
                                            
d *denotes statistical significance 
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Soft Tissue 100 (6.6%) 337 (5.9%) 
Germ Cell 129 (8.5%) 1015 (17.7%) 
Other Epithelial 20 (1.3%) 528 (9.2%) 
Other 0  14 (0.2%) 
Year of Diagnosis 
1974-1979 232 (15.4%) 171 (3.0%) 958 
(<0.001)* 1980-1984 168 (11.1%) 159 (2.8%) 
1985-1989 198 (13.1%) 188 (3.3%) 
1990-1994 208 (13.8%) 831 (14.5%) 
1995-1999 232 (15.4%) 947 (16.5%) 
2000-2004 246 (16.3%) 1259 (21.9%) 
2005-2009 184 (12.2%) 1457 (25.4%) 
2010-2012 41 (2.7%) 732 (12.7%) 
Deprivation fifth (based on Townsend score of postcode at diagnosis) 
1 298 (19.8%) 1046 (18.2%) 12.8 
(0.01)* 2 315 (20.9%) 1036 (18.0%) 
3 262 (17.4%) 1083 (18.9%) 
4 250 (16.6%) 1107 (19.3%) 
5 384 (25.5%) 1472 (25.6%) 
Ethnic Group 
White 1360 (90.1%) 5114 (89.0%) 27 
(<0.001)* South Asian 114 (7.6%) 339 (5.9%) 
Other  30 (2.0%) 212 (3.7%) 
Unknown 5 (0.3%) 79 (1.4%) 
Duration of Follow Up 
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<10 years 180 (11.9%) 1913 (33.3%) 789 
(<0.001)* 10-19 years 477 (31.6%) 2297 (40.0%) 
20-29 years 417 (27.6%) 1170 (20.4%) 
30-39 years 362 (24.0%) 307 (5.3%) 
40+ years 73 (4.8%) 57 (1.0%) 
Vital Status as of June 2017 
Alive 1495 (99.1%) 5597 (97.4%) 14.7 
(<0.001)* Dead 14 (0.9%) 147 (2.6%) 
4.2 Yorkshire Population 
The Yorkshire population was used as a comparison group throughout this 
thesis. Their baselines characteristics are summarised in table 4.5, obtained 
from the 2011 census data349 and Mendeley data350,351. As at March 2011, 
Yorkshire had a population of 5.3 million people. Just over half (50.8%) were 
female. The median age at this time within Yorkshire was 39 years. The 
population were largely white (88.8%), with South Asians being a notable 
minority (6.0%). Slightly more individuals live in the most deprived areas than 
other areas (21.5% in quintile 5 compared to just over 19% in quintile 1-4). The 
data which were available regarding gender, age, ethnicity and deprivation 
distributions in Yorkshire are described in Table 4.5.  
Table 4.5 Characteristics of the Yorkshire Population, based on the 2011 
census 
Characteristic Yorkshire Population 
Gender 
Male 2598078 (49.2%) 
Female 2685655 (50.8%) 
Age Group 
0-4 328447 (6.2%) 
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5-9 297475 (5.6%) 
10-14 306096 (5.8%) 
15-19 348645 (6.6%) 
20-24 382679 (7.2%) 
25-29 347304 (6.6%) 
30-34 321328 (6.1%) 
35 and over 2951759 (55.9%) 
Ethnicity 
White 4691956 (88.8%) 
South Asian 317568 (6.0%) 
Other 274209 (5.2%) 
Deprivation Fifth 
1 1030528 (19.5%) 
2 1049472 (19.8%) 
3 1046435 (19.8%) 
4 1023789 (19.4%) 
5 1137988 (21.5%) 
 
4.3 Comparisons Between the Yorkshire Specialist Register of 
Cancer in Children and Young People Cohort and the 
Yorkshire Population 
The Yorkshire population as a whole consisted of almost equal numbers of 
males and females, whilst there were many more males in the YSRCCYP 5 
year survivor cohort. This likely reflects the fact that cancer in children, who 
have been included on the register for a much longer time period than TYAs, is 
more common in males14. The ethnic composition of the YSRCCYP 5 year 
survivor cohort was very similar to that of the Yorkshire population as a whole. 
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There were a greater proportion of individuals from the most deprived fifth on 
the YSRCCYP compared to Yorkshire as a whole. This is in keeping with 
previous literature, which suggests an increased risk of cancer in the most 
deprived groups352, although this is not a consistent finding353. Some cancers 
affecting the young adult population, including breast354 and colorectal355 
cancers, are also more common in more deprived populations, probably due to 
increased rates of smoking and obesity, and this may also account for some of 
the variation seen with deprivation.   
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Chapter 5 Mental Health Services Use and Co-Morbidity in 5 
Year plus Survivors of Childhood and Young Adult Cancer  
As described in the methods section, data linkage techniques allowed us to 
determine patients in our cohort of cancer survivors who had had at least one 
recorded episode on the MHMDS or MHLDDS, indicating contact with 
specialist mental health services, in the period 2006-2015. We were also able 
to determine patients who had had at least one recorded mental health 
diagnosis (either as the reason for admission or a documented co-morbidity) 
from inpatient HES records for the period 1998-2015. 
This chapter describes which patients experienced a mental health episode, 
and whether any particular groups appeared at greater risk of having these 
records. 
5.1 Characteristics of Childhood and Young Adult Cancer 
Survivors with Mental Health Services Contacts 
In total, 777 (10.7%) survivors had at least one recorded episode on the 
MHMDS or MHLDDS, indicating contact with specialist mental health services 
in the period 2006-2015.  
Characteristics of patients who had a recorded episode on the MHMDS and/or 
MHLDDS are summarised in table 5.1a. Data on ethnicity were available for 
763 of the 777 patients. All other variables (age at diagnosis, cancer type, year 
of diagnosis, deprivation score) were available for all 777 patients. Median age 
at diagnosis in these patients was 19 years (interquartile range 10-25 years). 
Just over half were male. Most commonly seen diagnoses were germ cell 
tumours in males and non-CNS solid tumours in females. The majority of 
patients were White British.  Age at diagnosis, diagnostic group, period of 
diagnosis, deprivation quintile and ethnic group for patients with a recorded 
episode on the MHMDS and/or MHLDDS are also shown in figures 5.1a-5.1e, 
respectively. A higher proportion of individuals diagnosed with cancer in the 
TYA period (15-29) had a recorded episode on the MHMDS and/or MHLDDS 
than those diagnosed in childhood (0-14). A higher proportion of females 
appeared to have a recorded episode on the MHMDS and/or MHLDDS than 
males, aside from in those aged 5-14 at diagnosis, where a higher proportion of 
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males had a recorded episode on the MHMDS and/or MHLDDS. A higher 
proportion of individuals with CNS tumours, lymphomas and germ cell tumours 
had a recorded episode on the MHMDS and/or MHLDDS than of individuals 
with leukaemias and non-CNS solid tumours.   A higher proportion of 
individuals from the most deprived fifth of areas had a recorded episode on the 
MHMDS and/or MHLDDS than individuals from less deprived areas. A higher 
proportion of White British individuals had a recorded episode on the MHMDS 
and/or MHLDDS than individuals of other ethnicities. A higher proportion of 
individuals diagnosed with cancer between 2005 and 2009 had a recorded 
episode on the MHMDS and/or MHLDDS than individuals diagnosed in other 
periods.  Section 5.6: Groups at Increased Risk of Mental Health Services Use 
and Co-Morbidity uses logistic regression to determine which of these 
differences are statistically significant.
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Table 5.1a Characteristics of 5 year childhood and young adult cancer survivors who had a recorded specialist mental health contacte  
Variable Number with a recorded episode on MHMDS 
and/or MHLDDS  (total individuals on registry) 
Proportion of each group with a recorded 
episode on MHMDS and/or MHLDDS 
Male Female Male Female 
Age Group at diagnosis (years) 0-4 49 (901) 60 (723) 5.4% 8.3% 
5-9 50 (526) 27 (390) 9.5% 6.9% 
10-14 58 (562) 39 (440) 10.3% 8.9% 
15-19 63 (519) 62 (364) 12.1% 17.0% 
20-24 95 (758) 64 (420) 12.5% 15.2% 
25-29 126 (1026) 84 (581) 12.3% 14.5% 
Diagnostic group Leukaemia 62 (833) 54 (621) 7.4% 8.7% 
Lymphoma 95 (857) 71 (563) 11.1% 12.6% 
                                            
e CNS = Central Nervous System; non-CNS solid = all solid tumours out with the central nervous system, including lymphomas but 
excluding germ cell tumours 
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CNS 85 (692) 76 (587) 12.3% 12.9% 
Germ cell 128 (1005) 13 (138) 12.7% 9.4% 
Non-CNS 
solid 
71 (942) 122 (1004) 7.5% 12.1% 
Period of diagnosis 1974-1979 18 (230) 11 (173) 7.8% 6.4% 
1980-1984 14 (181) 17 (146) 7.7% 11.6% 
1985-1989 18 (212) 29 (174) 8.5% 16.7% 
1990-1994 64 (622) 52 (417) 10.3% 12.5% 
1995-1999 80 (718) 49 (461) 11.1% 10.6% 
2000-2004 94 (911) 69 (594) 10.3% 11.6% 
2005-2009 123 (989) 84 (652) 12.4% 12.9% 
2010-2012 30 (472) 25 (301) 6.4% 8.3% 
Deprivation category (based on 
Townsend deprivation index) 
1 (least 
deprived) 58 (785) 
57 (559) 7.4% 10.2% 
2 76 (824) 61 (527) 9.2% 11.6% 
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3 76 (810) 59 (535) 9.4% 11.0% 
4 86 (828) 63 (529) 10.4% 11.9% 
5 (most 
deprived) 145 (1088) 
96 (768) 13.3% 12.5% 
Ethnicity White British 394 (3798) 299 (2566) 10.4% 11.7% 
South Asian 26 (291) 21 (198) 8.9% 10.6% 





Figure 5.1a Age at diagnosis for all 5+ year survivors on the Yorkshire 
Specialist Register of Cancer in Children and Young People with a 
recorded episode on the Mental Health Services Data Set and/or the 
Mental Health and Learning Disability Data Set 
 
 
Figure 5.1b Diagnostic group for all 5+ year survivors on the Yorkshire 
Specialist Register of Cancer in Children and Young People with a 
recorded episode on the Mental Health Services Data Set and/or the 
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Figure 5.1c Period of diagnosis for all 5+ year survivors on the Yorkshire 
Specialist Register of Cancer in Children and Young People with a 
recorded episode on the Mental Health Services Data Set and/or the 




Figure 5.1d Deprivation quintile for all 5+ year survivors on the Yorkshire 
Specialist Register of Cancer in Children and Young People with a 
recorded episode on the Mental Health Services Data Set and/or the 
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Figure 5.1e Ethnic group for all 5+ year survivors on the Yorkshire Specialist 
Register of Cancer in Children and Young People with a recorded episode on 
the Mental Health Services Data Set and/or the Mental Health and Learning 




5.2 Characteristics of Childhood and Young Adult Cancer 
Survivors with A Recorded Mental Health Diagnosis on 
Inpatient Hospital Episode Statistics 
In total, 905 (12.5%) survivors had a recorded mental health diagnosis, either 
as the primary reason for admission or as a listed co-morbidity in the period 
1998-2015.  
Characteristics of patients who had had a recorded mental health diagnosis are 
summarised in table 5.1b. Data on all variables (age at diagnosis, cancer type, 
year of diagnosis, deprivation score, ethnicity) were available for all 905 
patients. Mean age at diagnosis in these patients was 19 years (interquartile 
range 10-25 years). Just over half were male. The most common diagnoses 
were germ cell tumours and lymphomas in males and non-CNS solid tumours 
females. The majority of patients were White British. Age at diagnosis, 
diagnostic group, period of diagnosis, deprivation quintile and ethnic group are 
also shown in figures 5.2a-5.2e, respectively. A higher proportion of individuals 
diagnosed with cancer in the TYA period (15-29) had a recorded mental health 
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proportion of females had a recorded mental health diagnosis on inpatient HES 
than males, aside from amongst individuals with germ cell tumours, where a 
slightly higher proportion of males had a recorded mental health diagnosis on 
inpatient HES. A higher proportion of individuals with lymphomas and germ cell 
tumours had a recorded mental health diagnosis on inpatient HES than other 
tumour types.  The proportion of individuals with a recorded mental health 
diagnosis on inpatient HES increased as deprivation fifth increased (i.e. as the 
population got more deprived). The proportion of White British and South Asian 
individuals with a recorded mental health diagnosis on inpatient HES was 
similar. A higher proportion of individuals diagnosed between 2000 and 2009 
had a recorded mental health diagnosis on inpatient HES than those diagnosed 
in other time periods. Further statistical analysis to explore whether these 
differences are significant has been carried out and is described in section 5.6: 




Table 5.1b Characteristics of 5 year childhood and young adult cancer survivors who had a recorded mental health diagnosis on the 
inpatient Hospital Episode Statistics dataset 
Variable Number with recorded mental health 
diagnosis (total individuals on registry) 
Proportion of each group with a 
recorded mental health diagnosis 
Male Female Male Female 
Age Group at diagnosis 0-4 58 (901) 63 (723) 6.4% 8.7% 
5-9 42 (526) 50 (390) 8.0% 12.8% 
10-14 59 (562) 52 (440) 10.5% 11.8% 
15-19 78 (519) 67 (364) 15.2% 18.4% 
20-24 108 (758) 80 (420) 14.2% 19.0% 
25-29 151 (1026) 97 (581) 14.7% 16.7% 
ICCC diagnostic group Leukaemia 68 (833) 73 (621) 8.2% 11.8% 
Lymphoma 116 (857) 97 (563) 13.5% 17.2% 
CNS 81 (692) 75 (587) 11.7% 12.8% 





87 (942) 145 (1004) 9.2% 14.4% 
Period of diagnosis 1974-1979 17 (230) 14 (173) 7.4% 8.1% 
1980-1984 14 (181) 18 (146) 7.7% 12.3% 
1985-1989 20 (212) 24 (174) 9.4% 13.8% 
1990-1994 64 (622) 52 (417) 10.3% 12.5% 
1995-1999 80 (718) 73 (461) 11.1% 15.8% 
2000-2004 122 (911) 101 (594) 13.4% 17.0% 
2005-2009 132 (989) 101 (652) 13.3% 15.5% 
2010-2012 47 (472) 26 (301) 10.0% 8.6% 
Deprivation category (based on 
Townsend deprivation index) 
1 73 (785) 50 (559) 9.3% 8.9% 
2 84 (824) 61 (527) 10.2% 11.6% 
3 80 (810) 72 (535) 9.9% 13.5% 
4 94 (828) 98 (529) 11.4% 18.5% 




British 452 (3798) 370 (2566) 
11.9% 14.4% 
South Asian 35 (291) 26 (198) 12.0% 13.1% 
Other 9 (159) 13 (118) 5.7% 11.0% 
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Figure 5.2a Age at diagnosis for all 5+ year survivors on the Yorkshire 
Specialist Register of Cancer in Children and Young People with a 
recorded mental health diagnosis on the Inpatient Hospital Episode 
Statistics Data Set  
 
 
Figure 5.2b Diagnostic group for all 5+ year survivors on the Yorkshire 
Specialist Register of Cancer in Children and Young People with a 
recorded mental health diagnosis on the Inpatient Hospital Episode 
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Figure 5.2c Period of diagnosis for all 5+ year survivors on the Yorkshire 
Specialist Register of Cancer in Children and Young People with a 
recorded mental health diagnosis on the Inpatient Hospital Episode 




Figure 5.2d Deprivation quintile for all 5+ year survivors on the Yorkshire 
Specialist Register of Cancer in Children and Young People with a 
recorded mental health diagnosis on the Inpatient Hospital Episode 
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Figure 5.2e Ethnic group for all 5+ year survivors on the Yorkshire Specialist 
Register of Cancer in Children and Young People with a recorded mental 




5.3 Combined Indicators of Mental Ill Health 
Some individuals with a record on the MHMDS and/or MHLDDS also had a 
recorded mental health diagnosis on inpatient HES. 
Figure 5.3 shows the number of individuals with a recorded contact with 
specialist mental health services, a recorded mental health diagnosis on 
inpatient HES or both.  Of the 777 individuals with a record of specialist mental 
health services use, 365 also had a recorded mental health diagnosis on 
inpatient HES and 412 only had an MHMDS or MHLDDS record. 540 
individuals only had a recorded mental health diagnosis on inpatient HES.  
In total, 1317 (18.2%) individuals had at least one indicator of mental ill health. 
The characteristics of these individuals are shown in table 5.1c. Ethnicity data 
were available for 1303 (98.9%) of these individuals. Data on sex, age at 
diagnosis, diagnostic group, period of diagnosis and deprivation (Townsend 
deprivation index) were available for all individuals. Age at diagnosis, 
diagnostic group, period of diagnosis, deprivation quintile and ethnic group are 
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A higher proportion of individuals diagnosed in the TYA period (15-29) had at 
least one indicator of mental ill health than those diagnosed as children. A 
higher proportion of individuals with lymphomas, CNS tumours and germ cell 
tumours had at least one indicator of mental ill health than those with 
leukaemias or non-CNS solid tumours. A higher proportion of individuals 
diagnosed with cancer in 2005-2009 had at least one indicator of mental ill 
health than those diagnosed in other periods. A higher proportion of individuals 
from more deprived fifths (4 and 5) had at least one indicator of mental ill health 
that those from less deprived fifths. A higher proportion of White British 
individuals had at least one indicator of mental ill health than other ethnic 
groups. Section 5.6: Groups at Increased Risk of Mental Health Services Use 
and Co-Morbidity uses logistic regression to determine which of these 
differences are statistically significant. 
Figure 5.3 Venn diagram showing the numbers of individuals with a recorded 
mental health contact on Mental Health Services Data Set or Mental 
Health and Learning Disabilities Data Set, a recorded mental health 






Table 5.1c Characteristics of 5 year childhood and young adult cancer survivors who had either a recorded mental health contact on 
the Mental Health Services Data Set or the Mental Health and Learning Disabilities Data Set, a recorded mental health diagnosis 
on the inpatient hospital episode statistics dataset, or both. 
Variable Number with recorded mental health contact, 
diagnosis or both  (total individuals on registry) 
Proportion of each group with recorded 
mental health contact, diagnosis or both 
Male Female Male Female 
Age Group at diagnosis 0-4 91 (901)  96 (723) 10.1% 13.3% 
5-9 76 (526) 60 (390) 14.4% 15.4% 
10-14 93 (562) 75 (440) 16.5% 17.0% 
15-19 112 (519) 96 (364) 21.6% 26.4% 
20-24 159 (758) 110 (420) 21.0% 26.2% 
25-29 209 (1026) 140 (581) 20.4% 24.1% 
ICCC diagnostic group Leukaemia 110 (833) 99 (621) 13.2% 15.9% 
Lymphoma 167 (857) 131 (563) 19.5% 23.3% 
CNS 126 (692) 120 (587) 18.6% 20.4% 





133 (942) 201 (1004) 14.1% 20.0% 
Period of diagnosis 1974-1979 27 (230) 20 (173) 11.7% 11.6% 
1980-1984 22 (181) 25 (146) 12.2% 17.1% 
1985-1989 30 (212) 43 (174) 14.2% 24.7% 
1990-1994 102 (622) 80 (417) 16.4% 19.2% 
1995-1999 124 (718) 97 (461) 17.3% 21.0% 
2000-2004 169 (911) 129 (594) 18.6% 21.7% 
2005-2009 202 (989) 145 (652) 20.4% 22.2% 
2010-2012 64 (472) 38 (301) 13.6% 12.6% 
Deprivation category (based on 
Townsend deprivation index) 
1 112 (785) 82 (559) 14.3% 14.7% 
2 130 (824) 98 (527) 15.8% 18.6% 
3 125 (810) 98 (535) 15.4% 18.3% 
4 139 (828) 129 (529) 16.8% 24.4% 




British 667 (3798) 518 (2566) 
17.6% 20.2% 
South Asian 50 (291) 36 (198) 17.2% 18.2% 
Other 14 (159) 18 (118) 8.8% 15.3% 
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Figure 5.4a Age at diagnosis for all 5+ year survivors on the Yorkshire 
Specialist Register of Cancer in Children and Young People, and those 




Figure 5.4b Diagnostic group for all 5+ year survivors on the Yorkshire 
Specialist Register of Cancer in Children and Young People, and those 
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Figure 5.4c Period of diagnosis for all 5+ year survivors on the Yorkshire 
Specialist Register of Cancer in Children and Young People, and those 




Figure 5.4d Deprivation quintile for all 5+ year survivors on the Yorkshire 
Specialist Register of Cancer in Children and Young People, and those 
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Figure 5.4e Ethnic group for all 5+ year survivors on the Yorkshire Specialist 
Register of Cancer in Children and Young People, and those with at least 




5.4 Comparison between Mental Health Services Use amongst 
Individuals on the Yorkshire Specialist Register of Cancer 
in Children and Young People and the Yorkshire 
Population as a Whole 
HES data on mental health contacts were available for each financial year from 
2006-07 to 2015-16, although the data for 2015-16 were only available for half 
of the financial year; this was because of the way data were recorded changed 
half way through this year, as described in the Methods chapter. Individual-
level data were obtained for all individuals on the YSRCCYP. Aggregated data, 
giving the number of individuals who had an MHMDS or MHLDDS record (i.e. 
the number of individuals who had accessed specialist mental health care 
services) in each year, were also obtained for the population of Yorkshire. 
Tables showing full details of the population of Yorkshire, the number of 
individuals with a mental health care service contact, the cohort characteristics 
on the YSRCCYP (the total number of individuals on the YSRCCYP who were 





















Total 5+ year survivors With any documented mental health issue
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mental health care service contact for each financial year are provided in 
Appendix D: Mental Health Contacts Per Financial Year 2006-07 to 2015-16.  
In the financial year 2006-07, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a record on the MHMDS 
in the groups male 5 to 9, male 10 to 14, male 15 to 19, female 10 to 14, 
female 15 to 19, female 20 to 24, female 25 to 29, female 30 to 34, female 35 
to 39, female 40 to 44 and female 45 to 49. There were higher proportions of 
individuals from the Yorkshire population than from the YSRCCYP with a 
records on the MHMDS in the groups male 20 to 24, male 25 to 29, male 30 to 
34, male 35 to 39, male 40 to 44, male 45 to 49 and female 5 to 9. 
In the financial year 2007-08, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a record on the MHMDS 
in the groups male 5 to 9, male 10 to 14, male 15 to 19, male 20 to 24, male 25 
to 29, male 30 to 34, male 35 to 39, female 10 to 14, female 15 to 19, female 
20 to 24, female 25 to 29, female 30 to 34, female 35 to 39 and female 40 to 
44. There were higher proportions of individuals from the Yorkshire population 
than from the YSRCCYP with a records on the MHMDS in the groups male 40 
to 44, male 45 to 49, female 5 to 9 and female 45 to 49. 
In the financial year 2008-09, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a record on the MHMDS 
in the groups male 5 to 9, male 10 to 14, male 15 to 19, male 20 to 24, male 30 
to 34, male 40 to 44, female 5 to 9, female 10 to 14, female 15 to 19, female 20 
to 24, female 25 to 29, female 30 to 34 and female 40 to 44. There were higher 
proportions of individuals from the Yorkshire population than from the 
YSRCCYP with a records on the MHMDS in the groups male 25 to 29, male 35 
to 39, male 45 to 49, female 35 to 39 and female 45 to 49. 
In the financial year 2009-10, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a record on the MHMDS 
in the groups male 5 to 9, male 10 to 14, male 15 to 19, male 20 to 24, female 
5 to 9, female 10 to 14, female 15 to 19, female 20 to 24, female 25 to 29, 
female 30 to 34 and female 45 to 49. There were higher proportions of 
individuals from the Yorkshire population than from the YSRCCYP with a 
records on the MHMDS in the groups male 25 to 29, male 30 to 34, male 35 to 
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39, male 40 to 44, male 45 to 49, male 50 to 54, female 35 to 39 female 40 to 
44 and female 50 to 54. 
In the financial year 2010-11, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a record on the MHMDS 
in the groups male 5 to 9, male 10 to 14, male 15 to 19, male 20 to 24, male 40 
to 44, male 45 to 49, female 5 to 9, female 10 to 14, female 20 to 24, female 25 
to 29, female 30 to 34 and female 45 to 49. There were higher proportions of 
individuals from the Yorkshire population than from the YSRCCYP with a 
records on the MHMDS in the groups male 25 to 29, male 30 to 34, male 35 to 
39, male 50 to 54, female 15 to 19, female 35 to 39 female 40 to 44 and female 
50 to 54. 
In the financial year 2011-12, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a record on the MHMDS 
in the groups male 10 to 14, male 15 to 19, male 45 to 49, male 50 to 54, 
female 5 to 9, female 15 to 19, female 20 to 24, female 25 to 29, and female 50 
to 54. There were higher proportions of individuals from the Yorkshire 
population than from the YSRCCYP with a records on the MHMDS in the 
groups male 5 to 9, male 20 to 24, male 25 to 29, male 30 to 34, male 35 to 39, 
male 40 to 44, female 10 to 14, female 30 to 34, female 35 to 39, female 40 to 
44 and female 45 to 49. 
In the financial year 2012-13, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a record on the MHMDS 
in the groups male 10 to 14, male 15 to 19, male 20 to 24, male 50 to 54, 
female 5 to 9, female 20 to 24, female 25 to 29, and female 50 to 54. There 
were higher proportions of individuals from the Yorkshire population than from 
the YSRCCYP with a records on the MHMDS in the groups male 5 to 9, male 
25 to 29, male 30 to 34, male 35 to 39, male 40 to 44, male 45 to 49, female 10 
to 14, female 15 to 19, female 30 to 34, female 35 to 39, female 40 to 44 and 
female 45 to 49. 
In the financial year 2013-14, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a record on the MHMDS 
in the groups male 10 to 14, male 15 to 19, male 20 to 24, male 45 to 49, 
female 20 to 24 and female 25 to 29. There were higher proportions of 
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individuals from the Yorkshire population than from the YSRCCYP with a 
records on the MHMDS in the groups male 5 to 9, male 25 to 29, male 30 to 
34, male 35 to 39, male 40 to 44, male 50 to 54, female 5 to 9, female 10 to 14, 
female 15 to 19, female 30 to 34, female 35 to 39, female 40 to 44, female 45 
to 49 and female 50 to 54. 
In the financial year 2014-15, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a record on the MHMDS 
or MHLDDS in the groups male 5 to 9, male 10 to 14, male 15 to 19, male 20 to 
24, male 25 to 29, female 25 to 29 and female 50 to 54. There were higher 
proportions of individuals from the Yorkshire population than from the 
YSRCCYP with a records on the MHMDS or MHLDDS in the groups male 30 to 
34, male 35 to 39, male 40 to 44, male 45 to 49, male 50 to 54, male 55 to 59, 
female 5 to 9, female 10 to 14, female 15 to 19, female 20 to 24, female 30 to 
34, female 35 to 39, female 40 to 44, female 45 to 49 and female 55 to 59. 
In the partial financial year 2015-16, there were higher proportions of 
individuals from the YSRCCYP than from the Yorkshire population with a 
record on the MHLDDS in the groups male 10 to 14, male 45 to 49 and female 
10 to 14. There were higher proportions of individuals from the Yorkshire 
population than from the YSRCCYP with a records on the MHLDDS in the 
groups male 5 to 9, male 15 to 19, male 20 to 24, male 25 to 29, male 30 to 34, 
male 35 to 39, male 40 to 44, male 50 to 54, male 55 to 59, female 5 to 9, 
female 15 to 19, female 20 to 24, female 25 to 29, female 30 to 34, female 35 
to 39, female 40 to 44, female 45 to 49, female 50 to 54 and female 55 to 59. 
In order to compare the rates of specialist mental health service access 
between the Yorkshire population and the YSRCCYP, standardised incidence 
ratios were calculated. These are shown in Table 5.2, and presented as a 
forest plot in figure 5.5. In order to make valid calculations, and to avoid under-
estimating the use of mental health services in the Yorkshire population, all 
small number suppressed values were assumed to be 4. This was because the 
calculation couldn’t be performed without a number being inserted, and the 
maximum possible number of contacts which could be reported as suppressed 
was 4. It would have been possible to assume that these suppressed values 
were 1, 2 or 3 instead, but by choosing 4, this ensures that the Yorkshire 
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population contacts are not being over estimated. This was the case on 3 




Table 5.2 Standardised incidence ratios for mental health services use in the 
Yorkshire Specialist Register of Cancer in Children and Young People 








95% Confidence Intervals 
2006-07 139 55.1 252.2 212.1 297.8 
2007-08 236 77.0 306.4 268.6 348.1 
2008-09 197 86.7 227.3 196.7 261.4 
2009-10 158 87.4 180.7 153.7 211.2 
2010-11 173 90.3 191.6 164.1 222.4 
2011-12 179 113.9 157.2 135.0 182.0 
2012-13 200 115.0 173.9 150.6 199.7 
2013-14 185 120.4 153.7 132.3 177.5 
2014-15 194 140.2 138.4 119.6 159.3 
2015-16  76 217.8 34.9 27.5 43.7 
Total 
(excluding 
2015-16) 1,661 874.1 190.0 181.0 199.4 
Total 
(including 
2015-16) 1,737 1000.0 173.7 165.6 182.1 
 
 
                                            
f Expected contacts were calculated by taking the number of contacts seen in 




Figure 5.4 Forest plot showing standardised incidence ratios for mental health services use in the Yorkshire Specialist Register of 
Cancer in Children and Young People population compared to the Yorkshire population.g. 
 
 
                                            
g Plot made using DistillerSR Forest Plot Generator from Evidence Partners399 
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There was a significantly greater rate of mental health services use amongst 
the YSRCCYP population than the Yorkshire population for all years except 
2015-16, which was initially left out of the calculation as data from this year was 
incomplete. When the all years are considered together, there remained a 
significantly greater rate of mental health services use in the YSRCCYP 
population. Adding in the 2015-16 data only marginally impacted on the overall 
values seen.  
Reasons for this increased rate of mental health services use amongst the 
YSRCCYP population are considered in section 7.4.1 Discussion, Strengths 
and Limitations of the Mental Health Work. As stated in the methods section, 
the way data were recorded on the data sets changed part way through the 
financial year 2015-16, and data were only available for part of the year. 
Inaccurate recording as a result may explain the anomalous findings for this 
year compared to other time periods. 
5.5 Comparison between Mental Health Co-Morbidity amongst 
Individuals on the Yorkshire Specialist Register of Cancer 
in Children and Young People and the Yorkshire 
Population 
Inpatient HES data were available for each financial year from 1997-98 to 
2016-27. Individual-level data were obtained for all individuals on the 
YSRCCYP and for the population of Yorkshire. Mental health diagnoses were 
identified from the “diagnosis” field within inpatient HES (see Chapter 3: Data 
Sources and Methods, Section 3.3.2 Hospital Admitted Patient Care Activity 
Dataset for list of ICD-10 codes classed as “mental health diagnoses” for the 
purposes of this work). Data were available for individuals under 45 years old 
from 1997-98 to 2008-09, for individuals up to 49 years old from 2009-10 to 
2010-11 and for individuals up to 59 years old from 2011-12 to 2016-17.  
Tables showing the population of Yorkshire, the number of individuals with a 
documented mental health diagnosis on inpatient HES, the population on the 
YSRCCYP (the total number of individuals on the YSRCCYP who were still 
alive that year) and the number of individuals on the YSRCCYP with a mental 
health diagnosis on inpatient HES for each financial year are provided in 
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Appendix E: Mental Health Co-Morbidity Per Financial Year 1997-98 to 2016-
17.   
In the financial year 1997-98, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 10 to 14, male 30 to 34, 
and female 20 to 24. There were higher proportions of individuals from the 
Yorkshire population than from the YSRCCYP with a recorded mental health 
diagnosis on inpatient HES in the groups male 5 to 9, male 15 to 19, male 20 to 
24, male 25 to 29, male 35 to 39, male 40 to 44, female 5 to 9, female 10 to 14, 
female 15 to 19, female 25 to 29, female 30 to 34, female 35 to 39 and female 
40 to 44. 
In the financial year 1998-99, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 30 to 34 and male 35 to 
39. There were higher proportions of individuals from the Yorkshire population 
than from the YSRCCYP with a recorded mental health diagnosis on inpatient 
HES in the groups male 5 to 9, male 10 to 14, male 15 to 19, male 20 to 24, 
male 25 to 29, male 40 to 44, female 5 to 9, female 10 to 14, female 15 to 19, 
female 20 to 24, female 25 to 29, female 30 to 34, female 35 to 39 and female 
40 to 44. 
In the financial year 1999-2000, there were higher proportions of individuals 
from the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the group male 10 to 14 only. There were 
higher proportions of individuals from the Yorkshire population than from the 
YSRCCYP with a recorded mental health diagnosis on inpatient HES in the 
groups male 5 to 9, male 15 to 19, male 20 to 24, male 25 to 29, male 30 to 34, 
male 35 to 39, male 40 to 44, female 5 to 9, female 10 to 14, female 15 to 19, 
female 20 to 24, female 25 to 29, female 30 to 34, female 35 to 39 and female 
40 to 44. 
In the financial year 2000-01, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 35 to 39 and female 15 to 
19 only. There were higher proportions of individuals from the Yorkshire 
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population than from the YSRCCYP with a recorded mental health diagnosis on 
inpatient HES in the groups male 5 to 9, male 10 to 14, male 15 to 19, male 20 
to 24, male 25 to 29, male 30 to 34, male 40 to 44, female 5 to 9, female 10 to 
14, female 20 to 24, female 25 to 29, female 30 to 34, female 35 to 39 and 
female 40 to 44. 
In the financial year 2001-02, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 10 to 14, male 20 to 24, 
female 15 to 19 and female 20 to 24. There were higher proportions of 
individuals from the Yorkshire population than from the YSRCCYP with a 
recorded mental health diagnosis on inpatient HES in the groups male 5 to 9, 
male 15 to 19, male 25 to 29, male 30 to 34, male 35 to 39, male 40 to 44, 
female 5 to 9, female 10 to 14, female 25 to 29, female 30 to 34, female 35 to 
39 and female 40 to 44. 
In the financial year 2002-03, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 10 to 14, male 40 to 44 
and female 15 to 19. There were higher proportions of individuals from the 
Yorkshire population than from the YSRCCYP with a recorded mental health 
diagnosis on inpatient HES in the groups male 5 to 9, male 15 to 19, male 20 to 
24, male 25 to 29, male 30 to 34, male 35 to 39, female 5 to 9, female 10 to 14, 
female 20 to 24, female 25 to 29, female 30 to 34, female 35 to 39 and female 
40 to 44. 
In the financial year 2003-04, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 5 to 9, male 10 to 14, 
female 10 to 14, female 20 to 24 and female 40 to 44. There were higher 
proportions of individuals from the Yorkshire population than from the 
YSRCCYP with a recorded mental health diagnosis on inpatient HES in the 
groups male 15 to 19, male 20 to 24, male 25 to 29, male 30 to 34, male 35 to 
39, male 40 to 44, female 5 to 9, female 15 to 19, female 25 to 29, female 30 to 
34 and female 35 to 39. 
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In the financial year 2004-05, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 10 to 14 and female 15 to 
19 only. There were higher proportions of individuals from the Yorkshire 
population than from the YSRCCYP with a recorded mental health diagnosis on 
inpatient HES in the groups male 5 to 9, male 15 to 19, male 20 to 24, male 25 
to 29, male 30 to 34, male 35 to 39, male 40 to 44, female 5 to 9, female 10 to 
14, female 20 to 24, female 25 to 29, female 30 to 34, female 35 to 39 and 
female 40 to 44. 
In the financial year 2005-06, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 5 to 9, male 10 to 14, 
female 10 to 14, female 15 to 19 and female 25 to 29. There were higher 
proportions of individuals from the Yorkshire population than from the 
YSRCCYP with a recorded mental health diagnosis on inpatient HES in the 
groups male 15 to 19, male 20 to 24, male 25 to 29, male 30 to 34, male 35 to 
39, male 40 to 44, female 5 to 9, female 20 to 24, female 30 to 34, female 35 to 
39 and female 40 to 44. 
In the financial year 2006-07, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 10 to 14, male 15 to 19, 
female 15 to 19, female 30 to 34 and female 40 to 44. There were higher 
proportions of individuals from the Yorkshire population than from the 
YSRCCYP with a recorded mental health diagnosis on inpatient HES in the 
groups male 5 to 9, male 20 to 24, male 25 to 29, male 30 to 34, male 35 to 39, 
male 40 to 44, female 5 to 9, female 10 to 14, female 20 to 24, female 25 to 29 
and female 35 to 39. 
In the financial year 2007-08, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups female 15 to 19 and female 30 
to 34 only. There were higher proportions of individuals from the Yorkshire 
population than from the YSRCCYP with a recorded mental health diagnosis on 
inpatient HES in the groups male 5 to 9, male 10 to 14, male 15 to 19, male 20 
to 24, male 25 to 29, male 30 to 34, male 35 to 39, male 40 to 44, female 5 to 
155 
 
9, female 10 to 14, female 20 to 24, female 25 to 29, female 35 to 39 and 
female 40 to 44. 
In the financial year 2008-09, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 5 to 9, male 10 to 14, 
male 15 to 19, female 5 to 9, female 15 to 19 and female 20 to 24. There were 
higher proportions of individuals from the Yorkshire population than from the 
YSRCCYP with a recorded mental health diagnosis on inpatient HES in the 
groups male 20 to 24, male 25 to 29, male 30 to 34, male 35 to 39, male 40 to 
44, female 10 to 14, female 25 to 29, female 30 to 34, female 35 to 39 and 
female 40 to 44. 
In the financial year 2009-10, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 5 to 9, male 10 to 14, 
male 15 to 19, male 45 to 49, female 10 to 14, female 15 to 19, female 25 to 29 
and female 30 to 34. There were higher proportions of individuals from the 
Yorkshire population than from the YSRCCYP with a recorded mental health 
diagnosis on inpatient HES in the groups male 20 to 24, male 25 to 29, male 30 
to 34, male 35 to 39, male 40 to 44, female 5 to 9, female 20 to 24, female 35 
to 39, female 40 to 44 and female 45 to 49. 
In the financial year 2010-11, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 5 to 9, male 10 to 14, 
male 15 to 19, male 20 to 24, female 10 to 14 and female 20 to 24. There were 
higher proportions of individuals from the Yorkshire population than from the 
YSRCCYP with a recorded mental health diagnosis on inpatient HES in the 
groups male 25 to 29, male 30 to 34, male 35 to 39, male 40 to 44, male 45 to 
49, female 5 to 9, female 15 to 19, female 25 to 29, female 30 to 34, female 35 
to 39, female 40 to 44 and female 45 to 49. 
In the financial year 2011-12, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 5 to 9 and male 10 to 14 
only. There were higher proportions of individuals from the Yorkshire population 
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than from the YSRCCYP with a recorded mental health diagnosis on inpatient 
HES in the groups male 15 to 19, male 20 to 24, male 25 to 29, male 30 to 34, 
male 35 to 39, male 40 to 44, male 45 to 49, male 50 to 54 female 5 to 9, 
female 10 to 14, female 15 to 19, female 20 to 24, female 25 to 29, female 30 
to 34, female 35 to 39, female 40 to 44, female 45 to 49 and female 50 to 54. 
In the financial year 2012-13, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 5 to 9, male 10 to 14, 
male 15 to 19, male 20 to 24, female 5 to 9 and female 15 to 19. There were 
higher proportions of individuals from the Yorkshire population than from the 
YSRCCYP with a recorded mental health diagnosis on inpatient HES in the 
groups male 25 to 29, male 30 to 34, male 35 to 39, male 40 to 44, male 45 to 
49, male 50 to 54, female 10 to 14, female 20 to 24, female 25 to 29, female 30 
to 34, female 35 to 39, female 40 to 44, female 45 to 49 and female 50 to 54. 
In the financial year 2013-14, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 5 to 9, male 15 to 19, 
female 5 to 9 and female 10 to 14. There were higher proportions of individuals 
from the Yorkshire population than from the YSRCCYP with a recorded mental 
health diagnosis on inpatient HES in the groups male 10 to 14, male 20 to 24, 
male 25 to 29, male 30 to 34, male 35 to 39, male 40 to 44, male 45 to 49, 
male 50 to 54, female 15 to 19, female 20 to 24, female 25 to 29, female 30 to 
34, female 35 to 39, female 40 to 44, female 45 to 49, female 50 to 54  and 
female 55 to 59. 
In the financial year 2014-15, there were higher proportions of individuals from 
the YSRCCYP than from the Yorkshire population with a recorded mental 
health diagnosis on inpatient HES in the groups male 5 to 9, male 10 to 14, and 
female 10 to 14. There were higher proportions of individuals from the 
Yorkshire population than from the YSRCCYP with a recorded mental health 
diagnosis on inpatient HES in the groups male 15 to 19, male 20 to 24, male 25 
to 29, male 30 to 34, male 35 to 39, male 40 to 44, male 45 to 49, male 50 to 
54, male 55 to 59, female 5 to 9, female 15 to 19, female 20 to 24, female 25 to 
29, female 30 to 34, female 35 to 39, female 40 to 44, female 45 to 49, female 
50 to 54 and female 55 to 59. 
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In the financial year 2015-16, there were no groups with higher proportions of 
individuals from the YSRCCYP than from the Yorkshire population with a 
recorded mental health diagnosis on inpatient. There were higher proportions 
of individuals from the Yorkshire population than from the YSRCCYP with a 
recorded mental health diagnosis on inpatient HES all groups. 
In the partial financial year 2016-17, there were no groups with higher 
proportions of individuals from the YSRCCYP than from the Yorkshire 
population with a recorded mental health diagnosis on inpatient. There were 
higher proportions of individuals from the Yorkshire population than from the 
YSRCCYP with a recorded mental health diagnosis on inpatient HES all 
groups. 
In order to compare the rates of mental health diagnoses (as recorded on 
inpatient HES) between the Yorkshire population and the YSRCCYP, 
standardised incidence ratios were calculated. These are shown in Table 5.3, 






Table 5.3 Standardised incidence ratios for mental health diagnoses Yorkshire 
Specialist Register of Cancer in Children and Young People population 
compared to the Yorkshire population. Expected contacts were calculated by 
taking the number of contacts seen in the Yorkshire population and multiplying 
these by the population on the Yorkshire Specialist Register of Cancer in 








95% Confidence Intervals 
1997-98 9 12 75 34 142 
1998-99 15 18 83 46 136 
1999-2000 11 20 56 28 100 
2000-01 17 22 79 46 126 
2001-02 26 17 149 97 218 
2002-03 13 24 54 29 93 
2003-04 21 25 83 51 127 
2004-05 17 26 64 37 103 
2005-06 24 28 86 55 129 
2006-07 24 28 85 54 127 
2007-08 22 29 75 47 114 
2008-09 35 32 109 76 151 
2009-10 40 37 107 77 146 
2010-11 58 48 122 93 158 
2011-12 133 103 129 108 153 
2012-13 119 122 98 81 117 
2013-14 119 135 88 73 106 
2014-15 111 144 77 64 93 
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2015-16 92 148 62 50 76 




Figure 5.5 Forest plot showing standardised incidence ratios for mental health diagnoses on inpatient Hospital Episode Statistics in the 
Yorkshire Specialist Register of Cancer in Children and Young People population compared to the Yorkshire population.h  
                                            
h Plot made using DistillerSR Forest Plot Generator from Evidence Partners399. 
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There was no significant difference between rates of mental health 
diagnoses on inpatient HES between the Yorkshire population and the 
YSRCCYP. For the years 2002-03, 2014-15 and 2015-16 there was a 
significantly lower rate of mental health diagnoses amongst individuals on 
the YSRCCYP compared to the Yorkshire population, and for the year 2011-
12, there was a significantly higher rate of mental health diagnoses amongst 
individuals on the YSRCCYP compared to the Yorkshire population. When 
data on all years were combined, there was no significant difference in rates 
of mental health diagnoses in individuals on the YSRCCYP compared to the 
Yorkshire population. 
Reasons for the lack of difference between rates of recorded mental health 
diagnoses on inpatient HES are discussed in section 7.4.1 Discussion, 
Strengths and Limitations of the Mental Health Work 
5.6 Groups at Increased Risk of Mental Health Services Use 
and Co-Morbidity 
The results demonstrate an increased rate of mental health services use 
amongst individuals on the YSRCCYP compared to the wider Yorkshire 
population. There did not appear to be increased mental health co-morbidity 
documented on inpatient HES amongst individuals on the YSRCCYP 
compared to the wider Yorkshire population. Logistic regression was used to 
determine whether there were certain groups within the YSRCCYP who 
were at particular increased risk of mental health services use, mental health 
co-morbidity recorded on inpatient HES or both. The adjustments made are 
based on casual inference models and the DAGs described in Chapter 3: 
Data Sources and Methods. 
5.6.1 Hypotheses 
It was hypothesised that: 
 Individuals diagnosed aged 13-24 would be at increased risk of 
inclusion on the MHMDS/MHLDDS or having a recorded mental 
health diagnosis on inpatient HES. 
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 Individuals from a more deprived background would be at increased 
risk of inclusion on the MHMDS/MHLDDS or having a recorded 
mental health diagnosis on inpatient HES. 
 Individuals from a South Asian background would be at decreased 
risk of inclusion on the MHMDS/MHLDDS or having a recorded 
mental health diagnosis on inpatient HES. 
 Females would be at increased risk of inclusion on the 
MHMDS/MHLDDS or having a recorded mental health diagnosis on 
inpatient HES. 
 Individuals with more advanced, higher stage disease, or higher 
grade CNS tumours, would be at increased risk of inclusion on the 
MHMDS/MHLDDS or having a recorded mental health diagnosis on 
inpatient HES. 
 Individuals treated at a specialist TYA unit would be at decreased risk 
of inclusion on the MHMDS/MHLDDS or having a recorded mental 
health diagnosis on inpatient HES. 
 Individuals treated with radiotherapy, or combined chemo- and 
radiotherapy, would be at decreased risk of inclusion on the 
MHMDS/MHLDDS or having a recorded mental health diagnosis on 
inpatient HES, compared to those treated with chemotherapy alone or 
neither chemo- nor radiotherapy. 
 Individuals with NCSI level 3 would be at increased risk of inclusion 
on the MHMDS/MHLDDS or having a recorded mental health 
diagnosis on inpatient HES compared to individuals with NCSI level 1 
or 2. 
 Individuals with CNS tumours would be at increased risk of inclusion 
on the MHMDS/MHLDDS or having a recorded mental health 
diagnosis on inpatient HES compared to individuals with other tumour 
types. 
 Individuals diagnosed longer ago would be at increased risk of 
inclusion on the MHMDS/MHLDDS or having a recorded mental 
health diagnosis on inpatient HES. 
5.6.2 Age at diagnosis 
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Age at diagnosis was explored as a potential risk factor. As discussed in the 
introduction, those diagnosed at 13-24 years old are a particular group of 
interest, and thus this group was compared to those older and younger at 
diagnosis. The risk of mental health services use and mental health 
diagnosis was compared between individuals aged 13-24 and those older or 
younger at the time of diagnosis. Table 5.6a shows the number of individuals 
in each age group, as well as the odds ratio of mental health services use for 
those aged 13-24 and 25-29 at diagnosis, compared to those aged 12 and 
under. The odds ratio of mental health services use for those aged 25-29 
compared to those aged 13-24 at diagnosis is also shown. Table 5.6b shows 
the odds ratio of having a recorded mental health diagnosis on inpatient 
HES. Table 5.6c shows the odds ratio of having either a recorded mental 
health services contact, a recorded mental health diagnosis or both. 
Table 5.6a Odds ratios of mental health services use for individuals 














0-12 3073 229 Reference 
13-24 2537 338 1.93 1.61 2.30 
25-29 1643 210 1.83 1.50 2.23 
 
  
                                            
i adjusted for deprivation (Townsend deprivation index) and sex 
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Table 5.6b Odds ratios of mental health diagnoses on inpatient Hospital 
Episode Statistics for individuals diagnosed with cancer at different 
agesj 












0-12 3073 273 Reference 
13-24 2537 384 1.86 1.57 2.19 
25-29 1643 248 1.84 1.53 2.22 
 
Table 5.6c Odds ratios of mental health services use, mental health 
diagnoses on inpatient Hospital Episode Statistics, or both for 
individuals diagnosed with cancer at different agesk  












0-12 3073 403 Reference 
13-24 2537 565 1.92 1.67 2.21 
25-29 1643 349 1.80 1.54 2.11 
 
Individuals aged 13-24 and 25-29 at diagnosis were significantly more likely 
than individuals aged 12 and under at diagnosis to have a recorded mental 
health services contact or mental health diagnosis on inpatient HES. There 
was no significant difference in likelihood of mental health services contact 
between those aged 13-24 and those aged 25-29 at diagnosis. 
                                            
j adjusted for deprivation (Townsend deprivation index) and sex 
k adjusted for deprivation (Townsend deprivation index) and sex 




It was hypothesised that being from a more deprived background would be 
associated with increased mental health services use, due to the social and 
financial difficulties these individuals face leading to a suspected increased 
incidence of mental health difficulties. Logistic regression was performed 
using both raw Townsend deprivation index and deprivation fifths, as using 
the raw index scores gives more detailed information, but breaking the 
cohort into fifths allowed exploration of a trend which may not be linear. The 
odds ratio of mental health services use is shown in table 6.7a, whilst odds 
ratio of mental health diagnosis on inpatient HES is shown in table 6.7b. 
Table 6.7c shows the odds ratio of having either a recorded mental health 
services contact, a recorded mental health diagnosis or both. 
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Table 5.7a Odds ratios of mental health services use for individuals in each 
deprivation quintile and for individuals from areas with increasingly 
























1856 241 Reference 
4 1357 149 0.78 0.63 0.98 
3 1345 135 0.68 0.54 0.86 
2 1351 137 0.70 0.55 0.88 
1 (least 
deprived) 





per 1 point 
increase in 
deprivation) 




                                            
l adjusted for ethnicity and sex 
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Table 5.7b Odds ratios of mental health diagnoses on inpatient Hospital 
Episode Statistics for individuals in each deprivation quintile and for 


























1856 293 Reference 
4 1357 198 0.88 0.72 1.07 
3 1345 152 0.67 0.55 0.83 
2 1351 145 0.63 0.51 0.79 
1 (least 
deprived) 
1344 123 0.53 0.42 0.66 
Townsend 
deprivation 
index (per 1 
point increase 
in deprivation) 
n/a 1.06 1.04 1.08 
 
  
                                            
m adjusted for ethnicity and sex 
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Table 5.7c Odds ratios of mental health diagnoses on inpatient Hospital 
Episode Statistics, recorded mental health contacts or both for 
individuals in each deprivation quintile and for individuals from areas 






















1856 404 Reference 
4 1357 268 0.89 0.75 1.05 
3 1345 223 0.71 0.59 0.85 
2 1351 228 0.72 0.61 0.87 
1 (least 
deprived) 
1344 194 0.60 0.50 0.73 
Townsend 
deprivation 
index (per 1 
point increase 
in deprivation) 
n/a 1.05 1.03 1.07 
 
Individuals from less deprived areas were significantly less likely than those 
in the most deprived group to have had recorded mental health services use 
or recorded mental health diagnosis on inpatient HES. There was a small 
but significant increase in risk of mental health services use and risk of 
mental health diagnosis for each one point increase in Townsend deprivation 
                                            
n adjusted for ethnicity and sex 
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index. Similar results were seen when both indicators of mental ill health 
were combined.  
5.6.4 Ethnicity 
Ethnicity was also explored as a potential factor which would affect likelihood 
of mental health services use. It was hypothesised that individuals from a 
South Asian background would be less likely to have mental health services 
contacts than White British individuals, due to cultural stigma surrounding 
mental illness356,357. The odds ratios of mental health services use are 
shown in table 5.8a, risks of mental health diagnosis on inpatient HES are 
shown in table 5.8b and risks of either mental health services use, mental 
health diagnosis or both are shown in table 5.8c. 
 
Table 5.8a Odds ratios of mental health services use for individuals in 




















6364 693 Reference 
South Asian 489 47 0.87 0.64 1.19 
Other 277 23 0.74 0.48 1.14 
 
  
                                            
o no additional model adjustment required 
- 170 - 
 
Table 5.8b Odds ratios of mental health diagnoses on inpatient Hospital 























6364 822 Reference 
South Asian 489 61 0.96 0.73 1.27 
Other 277 22 0.58 0.37 0.90 
 
Table 5.8c Odds ratios of mental health services use and/or mental health 
diagnoses on inpatient Hospital Episode Statistics for individuals in 


















6364 1185 Reference 
South Asian 489 86 0.93 0.73 1.19 
Other 277 32 0.57 0.39 0.83 
                                            
p no additional model adjustment required 
q no additional model adjustment required 
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There was no statistically significant difference between risks of mental 
health services use between different ethnic groups, although a slightly 
lower risk of mental health services use was seen in South Asian and other 
ethnicities compared to White British. A significant reduction in likelihood of 
mental health diagnosis on inpatient HES was seen in the “other” ethnic 
group compared to White British individuals. When both indicators of mental 
ill health were combined, the “other” group had significantly reduced risk of 
mental ill health compared to the White British group.  
 
5.6.5 Sex 
Multiple studies have found that women are more likely to receive treatment 
for mental health difficulties than men358–360 and it was hypothesised that this 
would also be true within our cohort of cancer survivors. Odds ratio of mental 
health services use is shown in table 5.9a and of mental health diagnosis on 
inpatient HES is shown in table 5.9b. Odds ratio of either mental health 
services use, mental health diagnosis or both is show in table 5.9c. 
Table 5.9a Odds ratio of mental health services use for females compared 
to malesr 















Male 4335 441 Reference 
Female 2918 336 1.15 0.99 1.34 
 
                                            
r no additional model adjustment required 
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Table 5.9b Odds ratio of mental health diagnosis on inpatient Hospital 
Episode Statistics for females compared to maless 


















Male 4335 496 Reference 
Female 2918 409 1.26 1.10 1.45 
 
Table 5.9c Odds ratio of mental health services use, mental health 
diagnosis on inpatient Hospital Episode Statistics or both for females 
compared to malest 













Male 4335 740 Reference 
Female 2918 577 1.20 1.07 1.35 
 
Female survivors were at a slightly increased risk of mental health services 
use compared to males, although the difference between males and females 
was not statistically significant. However, females were significantly more 
                                            
s no additional model adjustment required 
t no additional model adjustment required 
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likely to have a mental health diagnosis on inpatient HES. When both 
indicators of mental ill health were combined, females were at a significant 
higher risk than males of recorded mental ill health.  
5.6.6 Stage at Diagnosis 
It was hypothesised that individuals with higher, more advanced stage 
disease at diagnosis would be at greater risk of mental health services use. 
For individuals with non-CNS solid tumours, regression was performed to 
determine whether stage at diagnosis was associated with increased risk of 
mental health services use. For those with CNS tumours, where stage does 
not always apply, grade of tumour was investigated. For patients with 
leukaemia, white cell count at diagnosis (below or greater than 50) was 
explored. These results are shown in table 5.10a. Odds ratio of mental 
health diagnosis on inpatient HES is shown in table 5.10b. Odds ratio of one 
or both indicators of mental ill health is shown in table 5.10c. 
Data on stage were only available for 1494 (33.1%) of the cohort with non-
CNS solid tumours. Data on grade was available for all but 2 individuals with 
CNS tumours; the 2 individuals without available grade had morphology 
coded as “neoplasm of uncertain behaviour”, meaning it could not be. Data 
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Table 5.10a Odds ratio of mental health services use for individuals with 
different stage or grade of disease at diagnosisu 

















1 616 75 Reference 
2 500 58 0.99 0.67 1.46 
3 175 14 0.77 0.41 1.42 
4 205 22 1.19 0.70 2.02 
















Low (I-II) 1980 256 Reference 
High (III-IV) 882 78 0.63 0.43 0.92 

















                                            
u adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
ethnicity, tumour type and year of diagnosis 
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<50 1024 87 Reference 
≥50 226 12 0.64 0.34 1.22 
 
Table 5.10b Odds ratio of mental health diagnoses on inpatient Hospital 
Episode Statistics for individuals with different stage or grade of 




















1 616 92 Reference 
2 500 73 0.97 0.69 1.38 
3 175 23 0.95 0.57 1.57 


















Low (I-II) 1980 277 Reference 













                                            
v adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
ethnicity, tumour type and year of diagnosis 








<50 1024 99 Reference 
≥50 226 22 1.00 0.60 1.67 
 
Table 5.10c Odds ratio of mental health services use, mental health 
diagnoses on inpatient Hospital Episode Statistics or both for 



















1 616 124 Reference 
2 500 101 1.02 0.75 1.38 
3 175 33 1.05 0.68 1.62 

















Low (I-II) 1980 410 Reference 
High (III-IV) 882 134 0.65 0.47 0.90 
                                            
w adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
ethnicity, tumour type and year of diagnosis 



















<50 1024 154 Reference 
≥50 226 28 0.84 0.53 1.31 
 
There was no significant difference in risk of mental health services use for 
any stage of tumour or high vs low white cell count at presentation. There 
did appear to be a reduced risk of mental health services use in those with 
stage 3 tumours (compared to stage 1 tumours), and in those with high 
grade CNS tumours (compared to low grade CNS tumours). 
There was no significant difference in risk of mental health diagnosis on 
inpatient HES for any stage or grade of tumour or high vs low white cell 
count at presentation. 
When both indicators of mental ill health (recorded mental health services 
contact and recorded mental health diagnosis on inpatient HES) were 
combined, those with high grade CNS tumours were at significantly reduced 
risk of recorded mental ill health compared to individuals with low grade 
tumours. Amongst individuals with a diagnosis of leukaemia or non-CNS 
solid tumours, white cell count at presentation and stage, respectively, had 
no impact on risk of recorded mental ill health. 
Reasons for the increased risk of mental ill health amongst those with low 
grade CNS tumours are considered in the discussion, sections 7.2 Clinical 
Implications and 7.4.1 Discussion, Strengths and Limitations of the Mental 
Health Work. 
5.6.7 Treatment at a Specialist Teenage Unit 
As previously stated in section 1.3.2: Principal treatment centres for 
Teenagers and Young Adults, many 13-24 year olds are given the option of 
being treated in a specialist unit just for TYA patients. Given the positive 
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feedback these units have received, and the evidence that they result in 
improved outcomes361, it was hypothesised that individuals treated on a 
specialist TYA unit would have reduced risk of mental health services use. 
As per the national guidance discussed in the thesis introduction, nearly all 
patients aged under 18 are treated in specialist units; this analysis was 
performed for patients aged 13-24, but also repeated just including those 
aged 18-24 at diagnosis. Given the lack of variation in place of treatment 
(specialist vs non-specialist units) for patients aged 13-17, this analysis was 
not felt to be worthwhile for this group specifically. Results are shown in 
Table 5.11a. Table 5.11b shows the results of similar calculations for the risk 
of mental health diagnoses on inpatient HES. Table 5.11c shows the results 
of the same logistic regression looking at either recorded mental health 
services use, recorded mental health diagnosis on inpatient HES, or both. 
Table 5.11a Odds ratio of mental health services use for individuals treated 

















No 759 86 Reference 

















No 547 63 Reference 
Yes 168 39 2.06 1.29 3.30 
                                            
x adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
sex, stage at diagnosis, treatment type (radiotherapy vs chemotherapy 
vs both vs neither), tumour type and year of diagnosis 
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Table 5.11b Odds ratio of mental health diagnosis on inpatient Hospital 
Episode Statistics for individuals treated on specialist TYA units 





















No 759 113 Reference 





















No 547 84 Reference 
Yes 168 42 1.54 0.99 2.40 
 
  
                                            
y adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
sex, stage at diagnosis, treatment type (radiotherapy vs chemotherapy 
vs both vs neither), tumour type and year of diagnosis 
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Table 5.11c Odds ratio of mental health services use, recorded mental 
health diagnosis on inpatient Hospital Episode Statistics or both for 
individuals treated on specialist TYA units compared to those treated 


















No 759 164 Reference 


















No 547 120 Reference 
Yes 168 62 1.78 1.20 2.64 
 
There appeared to be an increased risk of mental health services use in 
patients treated on specialist TYA units. There also appeared to be an 
increased risk of mental health diagnosis on inpatient HES. When both 
indicators of mental ill health were combined, there appeared to be a greater 
risk of recorded mental health difficulties amongst individuals treated on 
specialist TYA units, and this association was stronger when only 18-24 year 
olds were considered. However, there was a lot of missing data in this field, 
i.e. it was unknown whether patients were treated in TYA units or not. Of 
                                            
z adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
sex, stage at diagnosis, treatment type (radiotherapy vs chemotherapy 
vs both vs neither), tumour type and year of diagnosis 
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2537 patients who were diagnosed between the ages of 13 and 24, data on 
place of treatment (TYA unit or otherwise) was missing for 1453. 583 of 
these were aged 13-17 at diagnosis, and 870 were aged 18-24. The analysis 
was therefore repeated for patients who were probably treated on a TYA 
unit; it was assumed that if a patient was treated in a centre with a specialist 
unit open at the time of their diagnosis, they received treatment there. The 
results of this analysis for mental health services use are shown in table 
5.12a and for mental health diagnosis on inpatient HES are shown in table 
5.12b. The results for combined indicators of mental ill health are shown in 
table 5.12c. 
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Table 5.12a Odds ratio of mental health services use for individuals 
probably treated on specialist TYA units compared to those probably 




















No 2045 256 Reference 




















No 1364 172 Reference 
Yes 221 48 1.76 1.16 2.66 
 
                                            
aa adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
sex, stage at diagnosis, treatment type (radiotherapy vs chemotherapy 
vs both vs neither), tumour type and year of diagnosis 
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Table 5.12b Odds ratio of mental health diagnosis on inpatient Hospital 
Episode Statistics for individuals probably treated on specialist TYA 





















No 2045 300 Reference 





















No 1364 212 Reference 
Yes 221 48 1.19 0.80 1.78 
 
  
                                            
bb adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
sex, stage at diagnosis, treatment type (radiotherapy vs chemotherapy 
vs both vs neither), tumour type and year of diagnosis 
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Table 5.12c Odds ratio of mental health services use, mental health 
diagnosis on inpatient Hospital Episode Statistics or both for individuals 
probably treated on specialist TYA units compared to those probably 



















No 2045 440 Reference 



















No 1364 302 Reference 
Yes 221 73 1.41 0.99 2.00 
 
After including all patients who were likely to have been treated in specialist 
TYA units, there remained an increased risk of mental health services use 
amongst individuals aged 18-24 treated in specialist units, compared to 
those treated on standard units. A similar pattern was seen when all 
individuals aged 13-24 were included in the analysis, although this result did 
not achieve statistical significance. Risk of mental health diagnosis on 
inpatient HES did not appear to differ between individuals probably treated in 
specialist TYA units and those not treated on such units. When both 
indicators of mental ill health were combined, there was no difference in risk 
                                            
cc adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
sex, stage at diagnosis, treatment type (radiotherapy vs chemotherapy 
vs both vs neither), tumour type and year of diagnosis 
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of recorded mental ill health for 13-24 year olds probably treated on TYA 
units, although an increase in risk of recorded mental ill health for those 
aged 18-24 probably treated on specialist TYA units was suggested, 
although this did not achieve statistical significance. Reasons for the 
increased risk of specialist mental health services use in individuals treated 
on specialist TYA units are explored in section 7.4.1 Discussion, Strengths 
and Limitations of the Mental Health Work. 
5.6.8 Treatment Type 
It was hypothesised that different treatment types may impact likelihood of 
mental health service use. Logistic regression was used to determine 
whether having received chemotherapy, radiotherapy or both was 
associated with increased likelihood of mental health service use, or 
increased likelihood of mental health diagnosis on inpatient HES. It was also 
hypothesised that having undergone cranial irradiation would be a particular 
risk factor for the development of mental ill health. Individuals who had 
undergone radiotherapy and who had underlying diagnoses of either CNS 
tumours or leukaemias, were assumed to have undergone cranial irradiation. 
Risk of recorded mental health difficulties for those who had undergone 
cranial irradiation compared to those who hadn’t was also explored. These 
results are shown in tables 5.13a and 5.13b, respectively. Table 5.13c 
shows the results for this regression looking at either mental health services 
use, mental health diagnosis on inpatient HES or both. 
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Table 5.13a Odds ratio of mental health services use for individuals treated 
with radiotherapy, combined chemo- and radiotherapy, and neither 
chemo- nor radiotherapy compared to those treated with chemotherapy 
only, and for individuals who had undergone cranial irradiation 
compared to those who hadn’tdd 
















3634 364 Reference 
Radiotherapy 
only 
297 30 0.77 0.51 1.15 
Chemotherapy 
& radiotherapy 





2175 284 1.18 0.99 1.41 
















6589 722 Reference 
                                            
dd adjusted for age at diagnosis, stage at diagnosis, tumour type and 
year of diagnosis 
 




664 55 0.81 0.60 1.09 
 
Table 5.13b Odds ratio of mental health diagnosis on inpatient Hospital 
Episode Statistics for individuals treated with radiotherapy, combined 
chemo- and radiotherapy, and neither chemo- nor radiotherapy 
compared to those treated with chemotherapy only, and for individuals 
who had undergone cranial irradiation compared to those who hadn’tee 


















3634 459 Reference 
Radiotherapy 
only 
297 43 0.92 0.65 1.30 
Chemotherapy 
& radiotherapy 





2175 298 0.96 0.81 1.14 












                                            
ee adjusted for age at diagnosis, stage at diagnosis, tumour type and year of 
diagnosis 








6589 848 Reference 
Cranial 
irradiation 
664 57 0.74 0.55 0.99 
 
Table 5.13c Odds ratio of mental health services use, mental health 
diagnosis on inpatient Hospital Episode Statistics or both for individuals 
treated with radiotherapy, combined chemo- and radiotherapy, and 
neither chemo- nor radiotherapy compared to those treated with 
chemotherapy only, and for individuals who had undergone cranial 
irradiation compared to those who hadn’t ff 















3634 654 Reference 
Radiotherapy 
only 
297 59 0.88 0.65 1.20 
Chemotherapy 
& radiotherapy 





2175 443 1.03 0.89 1.19 
                                            
ff adjusted for age at diagnosis, stage at diagnosis, tumour type and year of 
diagnosis 
- 189 - 
 















6589 1229 Reference 
Cranial 
irradiation 
664 88 0.75 0.59 0.96 
 
Treatment with radiotherapy or combined chemotherapy and radiotherapy 
were not associated with increased risk of mental health services use 
compared with treatment with chemotherapy alone. However, treatment with 
neither chemotherapy nor radiotherapy was associated with increased risk of 
mental health services use compared with treatment with chemotherapy, 
although this result did not achieve statistical significance. Cranial irradiation 
was associated with a decreased risk of mental health services use, 
although this was not statistically significant. Treatment with combined 
chemo- and radiotherapy was associated with a significantly reduced risk of 
mental health diagnosis on inpatient HES compared to chemotherapy alone. 
There was no apparent difference in risk of mental health diagnosis on 
inpatient HES for patients treated with radiotherapy or neither chemo- nor 
radiotherapy. Individuals treated with cranial irradiation were significantly 
less likely to have a mental health diagnosis recorded on inpatient HES than 
individuals who hadn’t received cranial irradiation. 
When both indicators of mental ill health were combined, individuals who 
had received both chemo- and radiotherapy were at significantly decreased 
risk of recorded mental ill health compared to those who had only received 
chemotherapy. Individuals who had been treated with cranial irradiation were 
at significantly decreased risk of recorded mental ill health compared to 
those who had not received cranial irradiation. 
It was not immediately clear why individuals who had not received either 
chemotherapy or radiotherapy would be at increased risk of mental health 
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services use or risk of mental health diagnosis on inpatient HES. It was 
hypothesised that many of the individuals who had not received either 
chemotherapy or radiotherapy had had low grade CNS tumours which were 
treated with surgical resection alone. These individuals may have significant 
residual disability, placing them at high risk of mental health difficulties. In 
order to test this hypothesis, the regression looking at treatment type was 
performed separately for individuals with CNS tumours and other diagnoses. 
The results of these regressions are shown in tables 5.13d, 5.13e and 5.13f. 
 
Table 5.13d Odds ratio of mental health services use for individuals treated 
with chemotherapy, radiotherapy and combined chemo- and 
radiotherapy, compared to those treated with and neither chemo- nor 
radiotherapy, for individuals with CNS tumours; and odds ratio of 
mental health services use for individuals treated with radiotherapy, 
combined chemo- and radiotherapy, and neither chemo- nor 
radiotherapy compared to those treated with chemotherapy only, for 
individuals with other diagnoses gg 


















635 102 Reference 
Chemotherapy 
only 
271 27 0.67 0.41 1.08 
                                            
gg adjusted for age at diagnosis, stage at diagnosis, tumour type and 
year of diagnosis 
 




83 7 0.46 0.20 1.05 
Chemotherapy 
& radiotherapy 
290 25 0.54 0.32 0.91 





1540 182 0.98 0.79 1.21 
Chemotherapy 
only 
3363 337 Reference 
Radiotherapy 
only 
214 23 0.78 0.49 1.24 
Chemotherapy 
& radiotherapy 
857 74 0.85 0.65 1.12 
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Table 5.13e Odds ratio of mental health diagnosis on inpatient Hospital 
Episode Statistics for individuals treated with chemotherapy, 
radiotherapy and combined chemo- and radiotherapy, compared to 
those treated with and neither chemo- nor radiotherapy, for individuals 
with CNS tumours; and odds ratio of mental health services use for 
individuals treated with radiotherapy, combined chemo- and 
radiotherapy, and neither chemo- nor radiotherapy compared to those 
treated with chemotherapy only, for individuals with other diagnoses hh 





















635 94 Reference 
Chemotherapy 
only 
271 30 0.97 0.60 1.57 
Radiotherapy 
only 
83 10 0.75 0.37 1.54 
Chemotherapy 
& radiotherapy 
290 22 0.66 0.38 1.14 
Diagnoses other than CNS tumours 
Neither 
chemotherapy 
1540 204 0.87 0.71 1.06 
                                            
hh adjusted for age at diagnosis, stage at diagnosis, tumour type and 
year of diagnosis 
 






3363 429 Reference 
Radiotherapy 
only 
214 33 0.93 0.63 1.39 
Chemotherapy 
& radiotherapy 
857 83 0.75 0.58 0.97 
 
Table 5.13f Odds ratio of mental health services use, mental health 
diagnosis on inpatient Hospital Episode Statistics, or both for 
individuals treated with chemotherapy, radiotherapy and combined 
chemo- and radiotherapy, compared to those treated with and neither 
chemo- nor radiotherapy, for individuals with CNS tumours; and odds 
ratio of mental health services use for individuals treated with 
radiotherapy, combined chemo- and radiotherapy, and neither chemo- 
nor radiotherapy compared to those treated with chemotherapy only, for 
individuals with other diagnoses ii 



















635 156 Reference 
                                            
ii adjusted for age at diagnosis, stage at diagnosis, tumour type and 
year of diagnosis 
 




271 42 0.72 0.48 1.07 
Radiotherapy 
only 
83 14 0.61 0.33 1.14 
Chemotherapy 
& radiotherapy 
290 34 0.54 0.34 0.84 





1540 287 0.85 0.71 1.00 
Chemotherapy 
only 
3363 612 Reference 
Radiotherapy 
only 
214 45 0.89 0.62 1.26 
Chemotherapy 
& radiotherapy 
857 127 0.79 0.64 0.99 
Amongst individuals with CNS tumours, those treated with both chemo- and 
radiotherapy had significantly lower risk of mental health services use than 
those treated with neither chemo- nor radiotherapy. Amongst individuals with 
other diagnoses, no particular treatment type appeared to be associated with 
increased risk of mental health services use. 
Individuals with diagnoses other than CNS tumours treated with both chemo- 
and radiotherapy had significantly lower risk of mental health diagnoses on 
inpatient HES than those treated with chemotherapy alone. Individuals with 
CNS tumours did not appear to be at any particular risk of mental health 
diagnoses on inpatient HES based upon treatment type.  
When both indicators of mental ill health were combined, individuals who 
had received both chemo- and radiotherapy were at significantly decreased 
risk of recorded mental ill health in both the CNS and non-CNS groups. The 
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increased risk of recorded mental ill health in individuals treated with neither 
chemotherapy nor radiotherapy was no longer seen when CNS tumours and 
other diagnoses were looked at separately. 
 
5.6.9 National Cancer Survivor Initiative Levels 
Whilst it was possible to compare the risks of mental health service use 
between patients who had received different treatment modalities, this did 
not take into account the intensity of these treatments. However, NCSI levels 
are based on treatment intensity and are thus a proxy marker for intensity of 
treatment. Logistic regression was carried out to determine the likelihood of 
having a contact with specialist mental health services, a documented 
mental health co-morbidity, or both, depending on NCSI level. It was 
hypothesised that individuals allocated NCSI level 3, who had undergone the 
most intensive treatment, would be at greatest risk of mental health services 
use and mental health co-morbidity. Odds ratio of specialist mental health 
services use, of recorded mental health diagnosis on inpatient HES, and 
both, are shown in tables 5.14a, 5.14b and 5.14c, respectively. 
Table 5.14a Odds ratio of specialist mental health services use for 


















1 64 7 1.21 0.52-2.80 
2 1018 77 Reference 
3 427 64 1.84 1.26-2.70 
                                            
jj adjusted for age at diagnosis, stage at diagnosis, tumour type and year of 
diagnosis 
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Table 5.14b Odds ratio of recorded mental health diagnoses on inpatient 
Hospital Episode Statistics for individuals allocated different National 




















1 64 7 1.36 0.59-3.14 
2 1018 76 Reference 
3 427 69 2.31 1.59-3.36 
Table 5.14c Odds ratio of specialist mental health services use, recorded 
mental health diagnoses on inpatient Hospital Episode Statistics, or 




















1 64 10 1.18 0.58-2.42 
2 1018 120 Reference 
3 427 109 2.39 1.74-3.25 
 
Individuals allocated an NCSI level of 3 appeared to be at twice the risk of 
mental ill health than those allocated a level of 2. Those allocated a level of 
                                            
kk adjusted for age at diagnosis, stage at diagnosis, tumour type and year of 
diagnosis 
ll adjusted for age at diagnosis, stage at diagnosis, tumour type and year of 
diagnosis 
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1 appeared to be at a slight increased risk of mental ill health than those 
allocated a level of 2, although this difference was not statistically significant. 
It was hypothesised that a number of the individuals allocated NCSI level 3 
would be survivors of high-grade CNS tumours, and that those individuals 
may have different risks of mental health difficulties. Therefore, the 
regression looking at NCSI was performed separately for individuals with 
CNS tumours and other diagnoses. The results of these regressions are 
shown in tables 5.14d, 5.14e and 5.14f. 
Table 5.14d Odds ratio of specialist mental health services use for 
individuals allocated different National Cancer Survivor Initiative Levels, 



















1 4 0 No cases on MH register 
2 120 3 Reference 
3 114 24 4.00 0.78-20.45 
Diagnoses other than CNS tumours 
1 60 7 1.23 0.51-2.95 
2 898 74 Reference 
3 313 40 1.51 0.99-2.31 
 
  
                                            
mm adjusted for age at diagnosis, stage at diagnosis, tumour type and year of 
diagnosis 
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Table 5.14e Odds ratio of mental health diagnoses on inpatient Hospital 
Episode Statistics for individuals allocated different National Cancer 






















1 4 0 No cases on MH register 
2 120 1 Reference 
3 114 19 24.10 2.02-287.72 
Diagnoses other than CNS tumours 
1 60 7 1.10 0.47-2.63 
2 898 75 Reference 
3 313 50 1.88 1.26-2.80 
 
  
                                            
nn adjusted for age at diagnosis, stage at diagnosis, tumour type and year of 
diagnosis 
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Table 5.14f Odds ratio of recorded specialist mental health services use, 
mental health diagnoses on inpatient Hospital Episode Statistics, or 
both, for individuals allocated different National Cancer Survivor 





















1 4 0 No cases on MH register 
2 120 4 Reference 
3 114 33 4.62 1.10-19.35 
Diagnoses other than CNS tumours 
1 60 10 1.11 0.53-2.33 
2 898 116 Reference 
3 313 76 2.00 1.43-2.81 
 
Due to smaller numbers, it was not possible to draw conclusions about the 
risks of mental ill health for individuals who had had a diagnosis of CNS 
tumour and were allocated NCSI level 1. However, the risk of recorded 
mental ill health, and particularly recorded mental health conditions on 
inpatient HES, was significantly greater amongst CNS tumour survivors 
allocated NCSI level 3 than level 2. 
Amongst individuals with diagnoses other than CNS tumours, those with 
NCSI level 3 were twice as likely to have recorded mental ill health as those 
with NCSI level 2. Individuals with NCSI level 1 appeared slightly more likely 
                                            
oo adjusted for age at diagnosis, stage at diagnosis, tumour type and year of 
diagnosis 
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than those with level 2 to have recorded mental ill health, however this result 
was not statistically significant. 
  
5.6.10 Tumour Type 
As different tumour types have different treatments, prognoses and risks of 
late effects, it was hypothesised that different tumour types would be 
associated with different risks of mental health service use. Due to 
comparatively small numbers of individuals with diagnoses of 
neuroblastoma, retinoblastoma, renal tumours, liver tumours, bone tumours, 
soft tissue sarcomas, other epithelial tumours and miscellaneous tumours, 
these diagnoses were all grouped together as “non-CNS, non-germ cell solid 
tumours”. This was based on the ICCC criteria, however the largest groups 
of leukaemia, lymphoma, CNS tumours and germ cell tumours were the 
same in both Birch and ICCC criteria. Due to hypothesised differences 
between survivors of high and low grade CNS tumours, these were 
considered separately. Data on tumour type were available for all 
individuals, although of 1279 individuals with CNS tumours, grade was 
missing for 2. The results of the logistic regression on tumour type are show 
in table 5.15a. The regression was repeated looking at Odds ratio of mental 
health diagnosis on inpatient HES and these results are shown in table 
5.15b. Finally, the regression was carried out a third time for combined risks 
of mental health service use, mental health diagnosis on inpatient HES, or 
both, and these results are presented in table 5.15c.  
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Table 5.15a Odds ratio of mental health services use for individuals with 
diagnoses of leukaemia, lymphoma, CNS tumour and germ cell tumour 
compared to non-CNS, non-germ cell tumours. CNS tumours are 
divided into low (grades 1-2) and high (grades 3-4) grade tumourspp 












germ cell solid 
tumour 
1946 193 Reference 
Leukaemia 1454 116 0.91 0.71 1.17 
Lymphoma 1420 166 1.08 0.86 1.36 
Low grade CNS 
tumour 
863 123 1.54 1.20 1.97 
High grade 
CNS tumour 
425 38 0.98 0.68 1.42 
Germ cell 
tumour 
1143 141 1.13 0.88 1.46 
 
  
                                            
pp adjusted for age at diagnosis, deprivation (Townsend deprivation 
index), ethnicity, sex and year of diagnosis 
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Table 5.15b Odds ratio of mental health diagnosis on inpatient Hospital 
Episode Statistics for individuals with diagnoses of leukaemia, 
lymphoma, CNS tumour and germ cell tumour compared to non-CNS, 
non-germ cell tumours. CNS tumours are divided into low (grades 1-2) 
















germ cell solid 
tumour 
1946 232 Reference 
Leukaemia 1454 141 0.91 0.73 1.14 
Lymphoma 1420 213 1.15 0.94 1.42 
Low grade 
CNS tumour 
863 112 1.11 0.87 1.42 
High grade 
CNS tumour 
425 44 0.92 0.65 1.30 
Germ cell 
tumour 
1143 163 1.11 0.88 1.40 
 
  
                                            
qq adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
ethnicity, sex and year of diagnosis 
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Table 5.15c Odds ratio of recorded mental health services use, mental 
health diagnosis on inpatient Hospital Episode Statistics or both for 
individuals with diagnoses of leukaemia, lymphoma, CNS tumour and 
germ cell tumour compared to non-CNS, non-germ cell tumours. CNS 
tumours are divided into low (grades 1-2) and high (grades 3-4) grade 
tumoursrr 














germ cell solid 
tumour 
1946 334 Reference 
Leukaemia 1454 209 0.93 0.77 1.13 
Lymphoma 1420 298 1.14 0.95 1.36 
Low grade CNS 
tumour 
863 185 1.33 1.08 1.63 
High grade 
CNS tumour 
425 61 0.88 0.65 1.19 
Germ cell 
tumour 
1143 230 1.07 0.87 1.32 
 
Only low grade CNS tumours were associated with a significantly increased 
risk of mental health services use compared to non-CNS non-germ cell solid 
tumours (RR 1.33, 95% CI 1.08-1.63). High grade CNS tumours appeared to 
have a lower risk of mental health services use compared to non-CNS non-
germ cell solid tumours. No tumour group was associated with a notably 
increased risk of mental health diagnosis on inpatient HES.  
                                            
rr adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
ethnicity, sex and year of diagnosis 
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When both indicators of mental ill health were considered, those with low 
grade CNS tumours appeared to be at an increased risk of recorded mental 
ill health compared to non-CNS non-germ cell solid tumours. No other 
diagnostic group appeared to be at increased risk of recorded mental ill 
health, although high grade CNS tumours appeared to be associated with a 
decreased risk of recorded mental ill health. 
Given that the ICCC and Birch classifications were specifically designed for 
particular age groups, the analysis was run separately for children (0-14) 
using the ICCC and for TYA (15-29) using the Birch system. Tables 5.15d, 
5.15e and 5.15f show the results for children based on the ICCC and tables 
5.15g, 5.15h and 5.15i show the results for TYA based on the Birch system. 
Table 5.15d Odds ratio of mental health services use for individuals with 
different diagnoses, compared to those with leukaemia, for individuals 
aged 0-14 at diagnosis. CNS tumours are divided into low (grades 1-2) 
and high (grades 3-4) grade tumoursss 













Leukaemia 1104 75 Reference 
Lymphoma 437 36 1.10 0.72 1.70 
Low grade CNS 
tumour 
532 65 1.79 1.25 2.56 
High grade CNS 
tumour 
295 25 1.27 0.79 2.04 
Neuroblastoma 215 12 0.88 0.47 1.67 
Retinoblastoma 124 9 1.26 0.60 2.62 
                                            
ss adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
ethnicity, sex and year of diagnosis 
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Renal tumour 209 15 1.15 0.64 2.06 
Liver tumour 32 0 No cases on MH register 
Bone tumour 157 13 1.07 0.57 2.02 
Soft tissue sarcoma 238 20 1.24 0.74 2.09 
Germ cell tumour 138 11 1.18 0.61 2.29 
Miscellaneous/other 66 2 0.41 0.10 1.72 
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Table 5.15e Odds ratio of recorded mental health diagnoses on inpatient 
Hospital Episode Statistics for individuals with different diagnoses, 
compared to those with leukaemia, for individuals aged 0-14 at 
diagnosis. CNS tumours are divided into low (grades 1-2) and high 
(grades 3-4) grade tumourstt 















Leukaemia 1104 86 Reference 
Lymphoma 437 53 1.53 1.05 2.24 
Low grade CNS 
tumour 
532 57 1.32 0.92 1.89 
High grade CNS 
tumour 
295 23 0.99 0.61 1.60 
Neuroblastoma 215 12 0.75 0.40 1.41 
Retinoblastoma 124 9 1.08 0.52 2.23 
Renal tumour 209 24 1.62 0.99 2.63 
Liver tumour 32 1 0.39 0.05 2.92 
Bone tumour 157 21 1.64 0.96 2.78 
Soft tissue sarcoma 238 21 1.11 0.67 1.83 
Germ cell tumour 138 15 1.35 0.76 2.43 
Miscellaneous/other 66 2 0.34 0.08 1.41 
 
  
                                            
tt adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
ethnicity, sex and year of diagnosis 
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Table 5.15f Odds ratio of recorded mental ill health for individuals with 
different diagnoses, compared to those with leukaemia, for individuals 
aged 0-14 at diagnosis. CNS tumours are divided into low (grades 1-2) 
and high (grades 3-4) grade tumoursuu 















Leukaemia 1104 136 Reference 
Lymphoma 437 72 1.27 0.92 1.76 
Low grade CNS 
tumour 
532 95 1.43 1.07 1.92 
High grade CNS 
tumour 
295 36 0.98 0.66 1.45 
Neuroblastoma 215 20 0.79 0.48 1.31 
Retinoblastoma 124 15 1.16 0.65 2.08 
Renal tumour 209 29 1.23 0.80 1.91 
Liver tumour 32 1 0.25 0.03 1.83 
Bone tumour 157 29 1.41 0.89 2.23 
Soft tissue sarcoma 238 34 1.15 0.76 1.73 
Germ cell tumour 138 21 1.23 0.74 2.03 
Miscellaneous/other 66 3 0.31 0.10 1.01 
 
  
                                            
uu adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
ethnicity, sex and year of diagnosis 
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Table 5.15g Odds ratio of mental health services use for individuals with 
different diagnoses, compared to those with leukaemia, for individuals 
aged 15-29 at diagnosis. CNS tumours are divided into low (grades 1-
2) and high (grades 3-4) grade tumoursvv 













Leukaemia 349 41 0.76 0.51 1.13 
Lymphoma 973 128 0.88 0.66 1.18 
Low grade CNS 
tumour 
330 58 1.22 0.85 1.75 
High grade CNS 
tumour 
130 13 0.64 0.35 1.19 
Bone tumour 163 20 0.82 0.48 1.37 
Soft tissue sarcoma 177 25 1.00 0.62 1.62 
Germ cell tumour 989 127 Reference 
Melanoma/skin 
cancer 
18 1 0.32 0.04 2.49 
Carcinoma 537 73 0.85 0.59 1.21 
Miscellaneous/other 38 8 1.59 0.70 3.61 
 
  
                                            
vv adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
ethnicity, sex and year of diagnosis 
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Table 5.15h Odds ratio of recorded mental health diagnoses on inpatient 
Hospital Episode Statistics for individuals with different diagnoses, 
compared to those with leukaemia, for individuals aged 15-29 at 
diagnosis. CNS tumours are divided into low (grades 1-2) and high 
(grades 3-4) grade tumoursww 















Leukaemia 349 55 0.92 0.64 1.31 
Lymphoma 973 159 1.00 0.77 1.30 
Low grade CNS 
tumour 
330 55 1.00 0.70 1.43 
High grade CNS 
tumour 
130 21 0.95 0.57 1.58 
Bone tumour 163 23 0.82 0.50 1.34 
Soft tissue sarcoma 177 28 0.98 0.62 1.55 
Germ cell tumour 989 144 Reference 
Melanoma/skin 
cancer 
18 3 0.95 0.27 3.41 
Carcinoma 537 85 0.96 0.70 1.34 
Miscellaneous/other 38 8 1.35 0.59 3.08 
 
  
                                            
ww adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
ethnicity, sex and year of diagnosis 
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Table 5.15i Odds ratio of mental health services use, recorded mental 
health diagnosis on inpatient Hospital Episode Statistics or both, for 
individuals with different diagnoses, compared to those with leukaemia, 
for individuals aged 15-29 at diagnosis. CNS tumours are divided into 
low (grades 1-2) and high (grades 3-4) grade tumoursxx 















Leukaemia 349 73 0.85 0.62 1.17 
Lymphoma 973 223 0.99 0.79 1.25 
Low grade CNS 
tumour 
330 90 1.23 0.90 1.67 
High grade CNS 
tumour 
130 25 0.77 0.48 1.24 
Bone tumour 163 33 0.83 0.54 1.28 
Soft tissue sarcoma 177 43 1.13 0.76 1.68 
Germ cell tumour 989 204 Reference 
Melanoma/skin 
cancer 
18 3 0.63 0.18 2.23 
Carcinoma 537 120 0.93 0.69 1.24 
Miscellaneous/other 38 12 1.57 0.76 3.24 
 
Amongst individuals diagnosed under the age of 15, those with a low grade 
brain tumour were associated with over twice the risk of specialist mental 
health services use compared to those diagnosed with leukaemia. Amongst 
                                            
xx adjusted for age at diagnosis, deprivation (Townsend deprivation index), 
ethnicity, sex and year of diagnosis 
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those diagnosed during the TYA period, an increased risk of specialist 
mental health services use was also seen for those with low grade brain 
tumours when compared to germ cell tumours. No other diagnoses were 
associated with a clinically significantly different risk of specialist mental 
health services use. 
When considering risk of recorded mental health diagnosis on inpatient 
HES, amongst those diagnosed aged 0-14, renal tumours were the only 
diagnostic group associated with increased risk of mental health diagnosis 
compared to leukaemias. There was no difference in risk of having a 
recorded mental health diagnosis on inpatient HES between different 
diagnostic groups for those diagnosed aged 15-29. 
When both indicators of mental ill health were considered together, low 
grade CNS tumours were associated with an increased risk of recorded 
mental ill health compared to leukaemias amongst those diagnosed under 
the age of 15. Amongst those diagnosed in the TYA period, no particular 
diagnostic group was associated with a marked increased risk of recorded 
mental ill health when compared to germ cell tumours, although low grade 
CNS tumours tended toward significance with a lower confidence interval 
approaching 1 (RR 1.23; 95% CI 0.96-1.67). 
 
5.6.11 Year of Diagnosis 
Given that treatments have changed over the years, and also that, as more 
time post-diagnosis elapses, people’s perceptions and thoughts regarding 
their cancer may change, it was hypothesised that year of diagnosis would 
potentially impact risk of mental health services use and risk of mental health 
diagnosis on inpatient HES. The results of the regression analysis for year of 
diagnosis are shown in tables 5.16a, 5.16b and 5.16c according to age 
group at diagnosis. 
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Table 5.16a Odds ratio of mental health services use for individuals 
diagnosed in different periods, compared to those diagnosed between 
2005 and 2009, for children (0-14), teenagers and young adults (15-29) 

















403 29 2.01 1.14 3.56 
1980-
1984 
326 31 2.72 1.55 4.92 
1985-
1989 
386 47 3.59 2.13 6.07 
1990-
1994 
449 53 3.47 2.08 5.79 
1995-
1999 
468 43 2.62 1.54 4.45 
2000-
2004 
607 51 2.38 1.42 3.97 
2005-
2009 
592 22 Reference 
2010-
2012 
318 7 0.58 0.25 1.38 
Teenagers and young adults (15-29) 
1990-
1994 
590 63 0.68 0.50 0.93 
                                            
yy no additional model adjustment required 




711 86 0.79 0.59 1.04 
2000-
2004 
898 112 0.82 0.63 1.06 
2005-
2009 
1049 156 Reference 
2010-
2012 
455 77 1.17 0.87 1.57 
All individuals (0-29) 
1990-
1994 
1039 116 1.03 0.81 1.32 
1995-
1999 
1179 129 1.01 0.79 1.28 
2000-
2004 
1505 163 1.00 0.80 1.25 
2005-
2009 
1641 178 Reference 
2010-
2012 
773 84 1.00 0.76 1.32 
 
Table 5.16b Odds ratio of mental health diagnosis on inpatient Hospital 
Episode Statistics for individuals diagnosed in different periods, 
compared to those diagnosed between 2005 and 2009, for children (0-













                                            
zz no additional model adjustment required 









403 31 1.56 0.93 2.63 
1980-
1984 
326 32 2.04 1.22 3.42 
1985-
1989 
386 44 2.41 1.49 3.91 
1990-
1994 
449 49 2.29 1.43 3.68 
1995-
1999 
468 54 2.44 1.54 3.89 
2000-
2004 
607 60 2.05 1.31 3.23 
2005-
2009 
704 30 Reference 
2010-
2012 
206 24 1.53 0.88 2.66 
Teenagers and young adults (15-29) 
1990-
1994 
590 67 0.70 0.52 0.95 
1995-
1999 
711 99 0.89 0.68 1.16 
2000-
2004 
898 163 1.21 0.96 1.54 




1049 162 Reference 
2010-
2012 
455 90 1.35 1.02 1.80 
All individuals (0-29) 
1990-
1994 
1039 116 0.95 0.74 1.21 
1995-
1999 
1179 153 1.13 0.90 1.41 
2000-
2004 
1505 223 1.31 1.07 1.61 
2005-
2009 
1641 192 Reference 
2010-
2012 
773 114 1.31 1.02 1.68 
 
Table 5.16c Odds ratio of mental health services use, mental health 
diagnosis on inpatient Hospital Episode Statistics or both for individuals 
diagnosed in different periods, compared to those diagnosed between 










Odds ratio of 
Recorded 





                                            
aaa no additional model adjustment required 




403 47 1.64 1.07 2.53 
1980-
1984 
326 47 2.10 1.36 3.24 
1985-
1989 
386 73 2.90 1.95 4.33 
1990-
1994 
449 78 2.62 1.77 3.88 
1995-
1999 
468 81 2.61 1.77 3.85 
2000-
2004 
607 93 2.25 1.54 3.29 
2005-
2009 
592 44 Reference 
2010-
2012 
318 28 1.20 0.73 1.97 
Teenagers and young adults (15-29) 
1990-
1994 
590 104 0.70 0.54 0.90 
1995-
1999 
711 140 0.80 0.63 1.01 
2000-
2004 
898 205 0.97 0.78 1.19 
2005-
2009 
1049 246 Reference 
2010-
2012 
455 131 1.32 1.03 1.69 
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All individuals (0-29) 
1990-
1994 
1039 182 0.99 0.81 1.21 
1995-
1999 
1179 221 1.07 0.89 1.30 
2000-
2004 
1505 298 1.15 0.96 1.38 
2005-
2009 
1641 290 Reference 
2010-
2012 
773 159 1.21 0.97 1.50 
 
The risk of mental health services contact for those diagnosed under the age 
of 15 was higher in those individuals diagnosed before 2005, and appeared 
slightly lower in those diagnosed after 2009. A similar pattern was seen for 
risk of mental health diagnosis on inpatient HES, with this being increased 
for all time periods of diagnosis aside from 1974-1979. In those who were 
aged 15-29 at diagnosis, there was a lower risk of mental health services 
contact for those diagnosed before 2005, although this was only statistically 
significant for the year group 1990-1994 (RR 0.70; 95% CI 0.54-0.90). Risk 
of mental health diagnosis on inpatient HES appeared lower for those 
diagnosed in 1990-1994 and 1995-1999 but slightly higher for those 
diagnosed in 2000-2004 and 2010-2012. When all age groups were 
combined, only those diagnosed in the period 1974-1979 were at lower risk 
than those diagnosed in 2005-2009. The only clear difference in risk of 
mental health diagnosis on inpatient HES was for those diagnosed in 2000-
2004 and 2010-2012, who appeared at higher risk than those diagnosed in 
2005-2009. 
When both indicators of mental ill health were considered together, taking all 
children and young people together as one group, there was a reduced risk 
of recorded mental health contact in those diagnosed in 1974-1979, but no 
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other period. However, when children diagnosed aged 14 or under were 
considered separately, they had greater risk of recorded mental ill health if 
they were diagnosed before 2005, with this risk appearing greatest for those 
diagnosed in 1985-1989. Young people aged 15 and over at diagnosis had 
increased risk of recorded mental ill health if they were diagnosed after 
2009.  
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Chapter 6 The Impact of Fertility Preservation on Mental 
Health 
6.1 Introduction 
As described in the introduction to this thesis, subfertility is a common LE of 
CYP’s cancer112, and one which is associated strongly with poor mental 
health142. Subfertility can be a considerable cause of distress and is 
associated with difficulties with romantic relationships as well as the direct 
impact on the likelihood of having children. Subfertility amongst cancer 
survivors may have a causative link to mental health disorders142. 
In male cancer patients, cryopreservation of semen samples prior to 
beginning anti-cancer therapy is the only reliable fertility preservation 
strategy available, however this has been shown to be feasible even in 
young pubertal patients362. For pre-pubertal patients, there are no proven 
fertility preservation strategies, although with advances in technology it may 
become possible in the future to preserve testicular tissue for this 
purpose363.  
Subfertility can be extremely distressing and the link between subfertility and 
mental ill health is well documented364. There have been suggestions that 
mental health professionals have a role to play in the management of 
subfertility365. Within the UK, it is a requirement that any licensed centre 
providing assisted reproductive therapies employs a trained counsellor, but 
more expert roles are not required366.  
There have been small studies assessing the impact of fertility preservation 
on mental distress in cancer patients, but these have almost exclusively 
focussed on females367. One small study suggested that fertility preservation 
was beneficial in reducing distress related to subfertility, but only 9 males 
were included368. 
This work aimed to determine: 
 the rate of semen cryopreservation amongst male patients with a 
record on the YSRCCYP 
 the percentage of male patients with normal vs subfertility following 
cancer treatment 
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 whether having undergone fertility preservation impacted risk of 
inclusion on the MHMDS or recorded mental health diagnosis on 
inpatient HES 
 whether subfertility impacted risk of inclusion on the 
MHMDS/MHLDDS or recorded mental health diagnosis on inpatient 
HES 
6.1.1 Hypotheses 
It was hypothesised that  
 having undergone semen cryopreservation would be associated with 
reduced risk of inclusion on the MHMDS/MHLDDS or recorded mental 
health diagnosis on inpatient HES 
 subfertility following cancer treatment would be associated with increased 
risk of inclusion on the MHMDS/MHLDDS or recorded mental health 
diagnosis on inpatient HES. 
6.2 Methods 
As described in the methods section, a list of patients who had undergone 
semen cryopreservation for a diagnosis of malignant disease was obtained 
from our local fertility service and a retrospective case note review was 
carried out. 
We had details of all patients who had banked semen since 2008. This 
included patients of all age groups and for a variety of indications, not just a 
cancer diagnosis.  
In order to be included in this analysis, patients had to have a co-existing 
record on the YSRCCYP, meaning they were storing semen due to a 
diagnosis of cancer, and their cancer diagnosis was made at the age of 29 
years or younger. 
Data were extracted from paper fertility clinic notes by 2 individuals, who 
worked together to create an electronic form containing all relevant 
information. Data were gathered on the patient’s age at banking, indication 
for banking (i.e. their underlying diagnosis), paternity status at banking, the 
number of ampoules of semen banked and semen analysis at the time of 
banking. Information was also recorded regarding whether a patient had 
ever returned to the fertility clinic, whether they had undergone any assisted 
reproductive techniques and, if so, the outcome of these techniques.  
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Electronic patient records on the PPM+ system (the system used by LTHT) 
contain details of clinic appointments, correspondence and investigations for 
the majority of clinical specialties, including oncology and haematology for 
patients of all ages. Full electronic records were only accessible for those 
patients who had been treated in Leeds Teaching Hospitals NHS Trust. In 
this cohort, this was 30.8% of the patients initially identified, and 75.5% of 
those who had banked semen. Review of the PPM+ records allowed the 
malignant diagnosis recorded in the fertility notes and the YSRCCYP to be 
verified. Data were also gathered regarding whether patients had continued 
to be seen in the haematology or oncology clinic. 
Data on semen cryopreservation was linked to the working extract from the 
YSRCCYP to identify patients who were both 5 year survivors of CYP’s 
cancer and who had undergone semen cryopreservation. 
Patients on the YSRCCYP who were male diagnosed with cancer in 2008 or 
later and who were 13 or older at the time of diagnosis, but who had not 
undergone semen cryopreservation, were identified as controls. As there are 
multiple potential fertility services within the Yorkshire areas, only patients 
who were likely to have stored semen at Leeds Fertility (those from 
Bradford, Wakefield, Airedale, Harrogate, Leeds, Halifax, Huddersfield and 
Harrogate) were included as controls. Data on which cancer diagnoses 
patients had, as well as their age at diagnosis and year of diagnosis, were 
ascertained directly from the YSRCCYP and used to verify the data collected 
from the fertility records. 
As described in the methods chapter, the MHMDS and MHLDDS, as well as 
the inpatient dataset, were used to identify patients who had used specialist 
mental health services, and the inpatient dataset was used to identify 
patients with mental health diagnoses. 
6.3 Results 
A total of 363 patients on the working YSRCCYP extract were males 
diagnosed with cancer in 2008 or later who were 13 or older at diagnosis 
and who were from regions likely to bank semen at Leeds Fertility.  
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722 fertility records were provided Leeds Fertility. From these, we identified 
151 patients who had a record on the YSRCCYP and who had survived 
more than 5 years post diagnosis. The consort diagram shown in figure 6.1 
gives the reasons for excluding other records.  
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Figure 6.1 Consort diagram showing patients who had banked semen for 
cryopreservation prior to cancer treatment and who had a record on the 
YSRCCYP 
 
722 records of patients who 
banked sperm at Leeds 
Fertility between 2009 and 
2017 
401 records of patients 
aged under 30 at time of 
sperm banking (83 aged 18 
or under) 
370 records of patients who 
banked sperm because of a 
diagnosis of malignant 
disease 
151 patients who were on 
YSRCCYP and who had 
survived >5 years post 
diagnosis (up to 2017) 
78 patients had a post 
treatment semen analysis 
carried out 
321 records excluded as 
patients >29 at time of 
banking 
31 records excluded as 
patients banked for non-
malignant diagnosis 
214 records excluded as 
patients <5 years post 
diagnosis 
5 patients had 2 records as 
banked twice 
73 patients did not have a 
recorded post treatment 
semen analysis 
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This meant there were data available on 151 patients who had banked 
semen and 212 controls, and that 41.6% of the eligible population (i.e. 151 
out of an eligible 363) had undergone semen cryopreservation. 
Characteristics of those eligible to bank sperm, those who did and those who 
didn’t have a sample stored are summarised in Tables 6.1a-6.1d. 
Table 6.1a Age at diagnosis of malignancy of patients who did and didn’t 
undergo semen cryopreservationbbb 




χ2 Statistic (p 
value)ccc 
Age group at diagnosis 
13-17 82 25 (30.5%) 57 (69.5%) 5.09 
(0.02)* 18-29 279  124 (44.4%) 155 (55.6%) 
Total 361 149 (41.3%) 212 (58.7%) 
 
                                            
bbb There were also 2 patients aged 3 and 11, respectively, at the time 
of initial cancer diagnosis who banked after a diagnosis of relapse or 
second malignancy. 
 
ccc *denotes statistical significance 
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Table 6.1b Characteristics of patients who did and didn’t undergo semen 
cryopreservation who were aged between 13 and 17 at the time of diagnosis 
of malignancy 







Tumour Group  
Leukaemia 21 7 (33.3%) 14 (66.7%) 0.10 
Lymphoma 19 8 (42.1%) 11 (57.9%) 
CNS 19 1 (5.3%) 18 (94.7%) 
Germ Cell 8 3 (37.5%) 5 (62.5%) 
Non CNS solid 15 6 (40%) 9 (60%) 
Deprivation fifth 
1 22 12 (54.5%) 10 (45.5%) 0.07 
2 13 3 (23.1%) 10 (76.9%) 
3 12 1 (8.3%)  11 (91.7%) 
4 19 7 (36.8%) 12 (63.2%) 
5 16 7 (43.8%) 9 (56.3%) 
Ethnic Group 
White 69 21 (30.4%) 48 (69.6%) 0.593 
South Asian 7 3 (42.9%) 4 (57.1%) 
Other 6 1 (16.7%) 5 (83.3%) 
 
  
                                            
ddd *denotes statistical significance 
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Table 6.1c Characteristics of patients who did and didn’t undergo semen 
cryopreservation who were aged between 18 and 29 at the time of 
diagnosis of malignancy 







Tumour Group  
Leukaemia 15 4 (26.7%) 11 (73.3%) <0.001* 
Lymphoma 70 44 (62.9%) 26 (37.1%) 
CNS 27 1 (3.7%) 26 (96.3%) 
Germ Cell 117 57 (48.7%) 60 (51.3%) 
Non CNS solid 50 18 (36%) 32 (64%) 
Deprivation fifth 
1 38 16 (42.1%) 22 (57.9%) 0.02* 
2 52 31 (59.6%) 21 (40.4%) 
3 39 11 (28.2%) 28 (71.8%) 
4 64 31 (48.4%) 33 (51.6%) 
5 87 31 (35.6%) 56 (64.4%) 
Ethnic Group 
White 185 79 (42.7%) 106 (57.3%) 0.265 
South Asian 34 11 (32.4%) 23 (67.6%) 
Other 14 8 (57.1%) 6 (42.9%) 
 
  
                                            
eee *denotes statistical significance 
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Table 6.1d Characteristics of patients who did and didn’t undergo semen 
cryopreservation (all ages) 







Tumour Group  
Leukaemia 37 12 (32.4%) 25 (67.6%) <0.001* 
Lymphoma 90 53 (58.9%) 37 (41.1%) 
CNS 46 2 (4.3%) 44 (95.7%) 
Germ Cell 125 60 (48%) 65 (52%) 
Non CNS solid 65 24 (36.9%) 41 (63.1%) 
Deprivation fifth 
1 61 29 (47.5%) 32 (52.5%) 0.01* 
2 65  34 (52.3%) 31 (47.7%) 
3 51  12 (23.5%) 39 (76.5%) 
4 83 38 (45.8%) 45 (54.2%) 
5 103 38 (36.9%) 65 (63.1%) 
Ethnic Group 
White 255  101 (39.6%) 154 (60.4%) 0.776 
South Asian 42  15 (35.7%) 27 (64.3%) 
Other 20 9 (45%) 11 (55%) 
 
The mean age at diagnosis was 22.2 years for all patients. The commonest 
malignant diagnoses were germ cell tumours (34.4%; 39.7% of patients who 
had banked semen vs 30.7% of patients who hadn’t banked semen) and 
                                            
fff *denotes statistical significance 
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lymphoma (24.8%; 35.1% of patients who had banked semen vs 17.5% of 
patients who hadn’t banked semen).  
In patients aged 13-17 at diagnosis, diagnoses were more evenly 
distributed, with leukaemias accounting for 25.6% and lymphomas and CNS 
tumours each accounting for 23.2% of eligible patients. However, when 
looking specifically at patients aged 13-17 at diagnosis who had undergone 
semen cryopreservation, lymphomas accounted for 32% of patients and 
leukaemias accounted for 28% of patients. CNS tumours accounted for only 
4% of 13-17 year olds who had banked semen, but 31.6% of 13-17 year olds 
who hadn’t banked semen. 
In older patients aged 18-29 at diagnosis, 41.9% of eligible patients had a 
diagnosis of germ cell tumour and 25.1% had a diagnosis of lymphoma. 46% 
of patients in this age group who had banked semen had germ cell tumours 
and 35.5% had lymphomas. Amongst 18-29 year olds who hadn’t banked 
semen, 38% had germ cell tumours and 20.6% had non-CNS solid tumours. 
17 (11.3%) of those individuals who banked sperm had already fathered a 
child prior to undergoing fertility preservation. 
83 (55.0%) of those who had banked semen prior to cancer treatment were 
seen again in the fertility service. 8 (9.6%) of those who were seen again in 
the fertility service had fathered a child since banking semen. 7 (8.4% of 
those who were seen again and 4.6% of those who originally banked) 
individuals underwent fertility treatment. In 2 cases, there was documented 
concomitant female factor infertility which influenced the treatment strategy 
used. Neither of these couples achieved a pregnancy. Of the remaining 5 
individuals, all achieved a pregnancy. 
78 (51.7%) of those who had banked semen prior to cancer treatment had 
had a post treatment sample analysed. 26 (33.3%) of those with a post 
treatment sample had a normal semen analysis. 
114 (75.5%) of those who had stored semen were treated at LTHT. 50 
(43.9%) of those treated in LTHT were under active follow up in the oncology 
late effects clinic.  
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The reasons for the differences in banking and follow-up patterns are 
explored in section 7.5: Discussion, Strengths and Limitations of the Fertility 
Preservation Work. 
6.3.1 Mental Health and Fertility 
It was hypothesised that having banked sperm, having a normal (fertile) post 
treatment semen sample and continued follow up in the 
haematology/oncology clinic would all be associated with decreased risk of 
mental ill health. Table 6.2a shows the risks of specialist mental health 
services contacts for individuals who had banked sperm (vs those who 
hadn’t), those who had been seen again in fertility clinic (vs those who 
hadn’t), those who had a fertile post-treatment sample (vs those who had a 
sub-fertile post treatment sample) and those who were under active 
oncology or haematology follow up (vs those who weren’t). The risks of 
having mental health diagnoses recorded on inpatient HES for individuals 
who had banked sperm (vs those who hadn’t), those who had been seen 
again in fertility clinic (vs those who hadn’t), those who had a fertile post-
treatment sample (vs those who had a sub-fertile post treatment sample) 
and those who were under active oncology or haematology follow up (vs 
those who weren’t) are shown in table 6.2b The risk of any indicator of 
mental ill health (i.e. either a recorded contact with specialist mental health 
services and/or a recorded mental health diagnosis on inpatient HES) for 
individuals who had banked sperm (vs those who hadn’t), those who had 
been seen again in fertility clinic (vs those who hadn’t), those who had a 
fertile post-treatment sample (vs those who had a sub-fertile post treatment 
sample) and those who were under active oncology or haematology follow 
up (vs those who weren’t) are shown in table 6.2c. 
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Table 6.2a Odds ratios of specialist mental health services contacts for 
individuals who had and hadn’t banked semen, had and hadn’t been 
followed up by fertility services, had and hadn’t had a fertile post-
treatment semen analysis and were or weren’t under active 
haematology or oncology follow upggg 
 Number of 
Individuals 







No 212 Reference  
Yes 151 0.54 0.26 1.16 
Seen Again in Fertility Clinic 
Yes 83 Reference   
No 68 1.78 0.42 7.49 
Normal (Fertile) Post-Treatment Semen Analysis 
No 52 Reference  
Yes 26 0.06 0.00 1.71 
Under Active Haematology or Oncology Follow Up 
No 64 Reference   
Yes 50 0.76 0.10 5.68 
 
  
                                            
ggg Adjusted for age at diagnosis, deprivation, ethnicity, stage at diagnosis, 
treatment type, tumour group, treatment at TYA unit, year of diagnosis 
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Table 6.2b Odds ratios of mental health diagnoses recorded on inpatient 
HES for individuals who had and hadn’t banked semen, had and hadn’t 
been followed up by fertility services, had and hadn’t had a fertile post-
treatment semen analysis and were or weren’t under active 
haematology or oncology follow uphhh 
 Number of 
Individuals 







No 212 Reference  
Yes 151 0.91 0.49 1.67 
Seen Again in Fertility Clinic 
Yes 83 Reference   
No 68 0.68 0.24 1.93 
Normal (Fertile) Post-Treatment Semen Analysis 
No 52 Reference  
Yes 26 0.55 0.13 2.29 
Under Active Haematology or Oncology Follow Up 
No 64 Reference   
Yes 50 0.23 0.55 0.97 
 
  
                                            
hhh Adjusted for age at diagnosis, deprivation, ethnicity, stage at diagnosis, 
treatment type, tumour group, treatment at TYA unit, year of diagnosis 
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Table 6.2c Odds ratios of specialist mental health services contact and/or 
mental health diagnoses recorded on inpatient HES for individuals who 
had and hadn’t banked semen, had and hadn’t been followed up by 
fertility services, had and hadn’t had a fertile post-treatment semen 
analysis and were or weren’t under active haematology or oncology 
follow upiii 
 Number of 
Individuals 









No 212 Reference  
Yes 151 0.82 0.47 1.42 
Seen Again in Fertility Clinic 
Yes 83 Reference   
No 68 0.62 0.24 1.62 
Normal (Fertile) Post-Treatment Semen Analysis 
No 52 Reference  
Yes 26 0.39 0.10 1.52 
Under Active Haematology or Oncology Follow Up 
No 64 Reference   
Yes 50 0.43 0.13 1.41 
 
There was no significant difference in risk of recorded specialist mental 
health for individuals who had or hadn’t banked sperm, were or weren’t seen 
                                            
iii Adjusted for age at diagnosis, deprivation, ethnicity, stage at diagnosis, 
treatment type, tumour group, treatment at TYA unit, year of diagnosis 
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again in the fertility clinic, had a fertile or sub-fertile post treatment semen 
analysis or who were or weren’t under active follow up with haematology or 
oncology. 
With regards to recorded mental health diagnoses on inpatient HES, there 
was a significantly reduced risk of this amongst individuals who were still 
under active haematology or oncology follow up. Sperm banking or not, 
being seen again in the fertility clinic and results of post treatment semen 
analysis did not significantly impact risk of having a recorded mental health 
diagnosis on inpatient HES. 
When both indicators of mental ill health were combined, there was no 
difference in risk of recorded mental ill health between those who had or 
hadn’t banked sperm, those who were or weren’t seen again in the fertility 
clinic, those who had a fertile or sub-fertile post-treatment semen analysis 
result and those who were or weren’t under active haematology or oncology 
follow-up.  
Potential reasons for the findings in this chapter are explored in section 7.5, 
Discussion, Strengths and Limitations of the Fertility Preservation Work. 
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Chapter 7 Discussion 
This thesis has sought to examine the relationship between a diagnosis of 
cancer in childhood or young adulthood and future risk of mental ill health. 
Utilising a high quality population-based specialist cancer registry and data 
linkage methodologies, it was possible to determine the rate of specialist 
mental health services use amongst a cohort of long term CYP’s cancer 
survivors. 
7.1 Key findings 
The key findings of this thesis were: 
 CYP’s cancer survivors are more likely than the general population to 
have received specialist mental health care, as recorded on the 
MHMDS or MHLDDS. 
o 10.7% of CYP’s cancer survivors on the YSRCCYP had a 
recorded contact with specialist mental health care recorded 
on the MHMDS and/or MHLDDS 
o The standardised incidence ratio for specialist mental health 
contacts amongst CYP’s cancer survivors was 173.7 (95% CI 
165.6-182.1); i.e. cancer survivors are 73.7% more likely than 
the general population to have a recorded contact with 
specialist mental health care. 
 CYP’s cancer survivors are no more likely than the general population 
to have a recorded mental health diagnosis on inpatient HES 
o 12.5% of CYP’s cancer survivors on the YSRCCYP had a 
recorded mental health diagnosis on inpatient HES 
o The standardised incidence ratio for recorded mental health 
diagnosis on inpatient HES amongst CYP’s cancer survivors 
was 97 (95% CI 91-103); i.e. cancer survivors are 3% less 
likely than the general population to have a recorded mental 
health diagnosis on inpatient HES. 
 Individuals diagnosed during the teenage or young adult period (aged 
13 to 29 at the time of cancer diagnosis) were almost twice as likely 
as those diagnosed with cancer under the age of 13 to have access 
specialist mental health care (13-24 RR 1.92, 95% CI 1.67-2.21; 25-
29 RR 1.80, 95% CI 1.54-2.11). 
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 Individuals treated on specialist TYA units appeared to have more 
recorded mental ill health than those treated on standard wards (RR 
1.36, 95% CI 1.00-1.84), and this effect was more pronounced when 
only young people aged 18-24 were considered (RR 1.78, 95% CI 
1.20-2.64). 
 Individuals from more deprived backgrounds at the time of cancer 
diagnosis were significantly more likely to have future recorded 
mental ill health than those from less deprived backgrounds, with risk 
of recorded mental ill health increasing 5% (95% CI 3-7%) for each 1 
point increase in deprivation on the Townsend deprivation index. 
 Female survivors were 20% (95% CI 7-35%) more likely than males 
to have future recorded mental ill health. 
 Stage at time of diagnosis (for non-CNS solid tumours) and white cell 
count at diagnosis (for leukaemias) were not associated with differing 
risks of future recorded mental ill health. 
 Individuals with low grade CNS tumours were at increased risk of 
recorded mental ill health compared to those with high grade CNS 
tumours. 
 Amongst individuals diagnosed as children (aged 0-14 at diagnosis), 
survivors of low grade CNS tumours were at greater risk of future 
mental ill health than survivors of leukaemia (RR 1.43, 95% CI 1.07-
1.92). There was no significant increase in risk of future mental ill 
health amongst survivors of other tumour types. 
 Amongst individuals diagnosed as young adults (aged 15-29 at 
diagnosis), survivors of low grade CNS tumours appeared to be at 
greater risk of future mental ill health than survivors of germ cell 
tumours (RR 1.23, 95% CI 0.90-1.67). There was no significant 
increase in risk of future mental ill health amongst survivors of other 
tumour types. 
 Individuals treated with combined chemotherapy and radiotherapy 
appeared to be at lower risk of future specialist mental health services 
use compared to individuals treated with chemotherapy alone (RR 
1.18, 95% CI 0.99-1.41). 
 Individuals allocated NCSI level 3 were over twice as likely as those 
allocated NCSI level 2 to have recorded mental ill health (RR 2.39, 
95% CI 1.74-3.25).  
 Individuals diagnosed as children had an increased risk of recorded 
mental ill health if they were diagnosed longer ago, with those 
diagnosed during the period 1985-1989 appearing to be at greatest 
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risk (RR 2.90, 95% CI 1.95-4.33), Conversely, individuals diagnosed 
as young adults had an increased risk of recorded mental ill health if 
they were diagnosed more recently, with those diagnosed during the 
period 2010-2012 at greatest risk (RR 1.32, 95% CI 1.03-1.69). 
 Ethnicity did not appear to significantly impact likelihood of recorded 
mental ill health. 
 Males who had undergone semen cryopreservation appeared to be 
less likely to have future recorded mental ill health (RR 0.82, 95% CI 
0.47-1.42) than those who hadn’t undergone semen cryopreservation, 
although post-treatment fertility was not associated with risk of 
recorded mental ill health. 
7.2 Clinical Implications 
This thesis highlights the increased risk of contacts with specialist mental 
health services amongst long-term survivors of CYP’s cancer. Whilst 
patients who are under active follow-up often have the opportunity to 
complete holistic needs assessments369, which may identify potential mental 
health difficulties as they evolve, many long-term survivors will have been 
discharged from specialist follow-up, and others will be seen only 
infrequently99.  
Clinicians providing long-term follow-up or survivorship services, may feel 
less confident assessing and discussing mental health problems than they 
are in, for example, talking about risks of cardiac failure or secondary 
malignancy. It is therefore essential that clinicians in these roles have 
adequate training on both the assessment and recognition of mental health 
disorders, as well as the mental health support and treatment available 
locally, and the best ways for patients to access these services. In particular, 
clinicians should be aware of the increased risk of mental ill health amongst 
at risk groups, including those diagnosed with cancer as teenagers and 
young adults, females and those from deprived backgrounds.  
Currently, long-term follow-up care is determined largely by risk of physical 
late effects99. Whilst CYP’s cancer survivors with physical health problems 
are at increased risk of mental ill health157, not all individuals who may 
develop mental health problems will currently be routinely followed up in 
specialist care. Particular attention should be drawn to survivors of low-
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grade CNS tumours, and individuals treated with neither chemo- nor 
radiotherapy, who appear to be at considerable risk of mental ill health but 
who may not be monitored closely in long-term follow-up services. 
Low grade CNS tumours are associated with increased risk of future mental 
ill health. These tumours are common27 and, due to their generally good 
prognosis370, survivors of them account for a considerable proportion of the 
entire CYP’s cancer survivor population (27% of the cohort in this study had 
a low-grade CNS tumour). However, individuals with low-grade CNS 
tumours, may be treated with only surgery370, or even simple monitoring371. 
These individuals are thus at low risk of physical late effects and therefore 
likely to be discharged from specialist services99. This highlights the 
discrepancy between risk of physical late effects and risk of mental health 
sequalae. It may, therefore, be beneficial in future to ensure that survivors of 
CYP’s cancer are educated on potential mental health difficulties, and how 
and where to access support should these issues arise. Additionally, it may 
be that future risk-stratification systems take into account risk of mental 
health problems when deciding whether or not to discharge a patient from 
specialist cancer care. Treatment summaries should be sent to all primary 
care clinicians, and should clearly highlight risks of mental ill health which 
could be seen in cancer survivors, particularly amongst those who are no 
longer being followed up in specialist cancer services. 
Risk of future mental ill health is higher amongst female CYP’s cancer 
survivors. Although cancer is more common in boys than in girls, incidence 
is increasing more rapidly in girls, thus potentially narrowing this gap14. 
Amongst TYA, cancer is more common in females than males15. The 
increasing incidence of cancer in young girls may lead in future to a greater 
number of mental health problems in this cohort.  
7.3 Discussion, Strengths and Limitations of the Study 
Cohort 
The study cohort were selected from the YSRCCYP. The methods used to 
link MH episodes to the YSRCCYP are described in detail in section 3.1: 
The Yorkshire Specialist Register of Cancer in Children and Young People. 
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The cohort are described and compared with the Yorkshire population in 
Chapter 4: Cohort Description. 
7.3.1 The Yorkshire Specialist Register of Cancer in Children and 
Young People Cohort 
A major strength of this cohort was that they were population-based, rather 
than opt-in, meaning that all individuals on the YSRCCYP who had survived 
over 5 years were included and not just a self-selecting group who had 
returned questionnaires or agreed to further follow up. This compares to 
other, large cohorts which have explored the long-term mental health of 
cancer survivors108,161,262,267. Population-based registers have the advantage 
of including all individuals who have had a cancer diagnosis and avoid 
potential issues with non-response bias, which may occur with 
questionnaire-based or opt-in cohorts.  
Additionally, the YSRCCYP includes data on TYA diagnosed under the age 
of 30, whilst other cohorts only look at children, excluding those young 
people diagnosed over the age of 15267 or 21 years108. Historically, TYA 
have been excluded from the majority of studies into cancer314. The 
systematic review aspect of this work found only 5 of 67 studies focussing 
on TYA. It is therefore an important strength of this study that this group 
have been included. 
A further strength of the YSRCCYP is that treatment data is included for all 
individuals, so it is possible to look at the long-term impact of specific 
chemotherapy and radiotherapy treatment as well as surgical interventions. 
An initial analysis of the cohort looked at the assignment of NCSI levels 
which are described in Chapter 4: Cohort Description. It was observed that 
NCSI levels were more likely to be assigned to patients who were younger at 
the time of diagnosis. This may be down to differences in referral rates to 
long term follow up services between paediatric and adult oncologists.  It 
may also reflect the fact that a higher percentage of older patients are 
treated outside of LTHT and are thus not being seen within the LTHT follow-
up services. 
The use of Onomap software to impute absent ethnicities to the YSRCCYP 
meant that ethnicity data in this cohort was almost complete, and allowed 
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ethnic group to be explored as a potentially important factor. Data on 
deprivation status and diagnosis were also complete, which enhanced the 
quality of analyses looking at these factors. 
Cancer diagnoses were classified according to the ICCC and Birch 
classification systems, which are described in full in section 1.1.3: Cancer 
Classification. Although these are robust, validated systems25,26, alternative 
classification systems exist and have slight differences. As well as the 
advantages associated with being well established and validated systems, 
there are also benefits when comparing work with internationally published 
results, which is much simpler and easier if the same classification systems 
are used. The Barr Classification Scheme for Adolescent and Young Adult 
Cancer is another system which is sometimes used, although this is very 
similar to the Birch system. The major categories most used by 
epidemiological studies are the same, and thus comparisons between 
studies using the Birch and Barr systems are possible and likely to be 
valid372.However, there are also drawbacks. Some groups are extremely 
heterogeneous, for example CNS tumours, and it is consequently difficult to 
draw conclusions about such a varied population. For the purposes of this 
thesis, the distinction was made between high- and low-grade tumours, but 
this is not always the case. Conversely, groups such as retinoblastoma 
account for such small numbers of individuals that it is very difficult to 
reliably analyse them in detail without major international collaboration. 
7.3.2 Population Data 
Similarities and differences between the YSRCCYP and also described in 
Chapter 4: Cohort Description. The YSRCCYP cohort had a similar ethnic 
make-up to the Yorkshire population as a whole, and patterns of deprivation 
were also similar. However, the YSRCCYP had many more males (59.8% of 
YSRCCYP cohort compared to 49.2% of the whole Yorkshire population). 
This likely reflects the fact that cancer diagnoses in childhood are more 
common in males14. Although cancer diagnoses in the TYA age group are 
more common in females15, the YSRCCYP collected data on childhood 
cancer (diagnosed under the age of 15 years) for 16 years before data on 
older CYP (aged 15-29 at diagnosis) was collected, which likely explains the 
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gender difference. The similarities between the ethnic and deprivation mixes 
seen in the YSRCCYP cohort and the whole Yorkshire population are a 
strength of this work. However, gender differences between the YSRCCYP 
cohort and the Yorkshire population may limit the generalisability of this 
work, although the calculations used to look at differences in rates of 
recorded mental ill health did take into account the gender mix of the 
populations.  
The data provided on the Yorkshire population was limited to an aggregated 
table of data, rather than individual-level data. This was due to difficulties 
obtaining data from NHS Digital, and concerns regarding potential 
identifiability of individuals. Despite multiple conversations with the data 
provider, it was not possible to obtain more granular data. Data was 
provided broken down by gender and age-bracket only. This limits the work, 
as it was impossible to adjust for factors such as deprivation status and 
ethnicity, which potentially could have impacted the results obtained. 
Socioeconomic status is causatively associated with childhood cancer risk, 
albeit as a probable proxy marker for factors such as parental smoking373, as 
are gender28 and ethnicity374, and it would therefore have been important to 
adjust for socioeconomic status and ethnicity if possible. A further limitation 
to data being provided in this format was that it wasn’t possible to know 
whether individuals had had multiple mental health service contacts or 
recorded mental health diagnoses on inpatient HES in different years. Whilst 
it was possible to look at the number of individuals with a mental health 
services contact or recorded mental health diagnosis on inpatient HES for 
each year, it wasn’t possible to work out what proportion of the population 
had any contact over the time period for which data were available. It is 
possible that there are differences in the way mental health services are 
accessed between the YSRCCYP cohort and the rest of the population, for 
example in one group there may have been lots of contacts made by 
individuals who were seen only once or twice whilst in the other there may 
have been a similar number of contacts but made by a smaller number of 
individuals who had multiple interactions with mental health care. The lack of 
individual-level population data means that this could not be explored in this 
thesis. Equally, it is possible that a similar number of individuals had 
- 241 - 
 
contacts but that individuals in one group had far more contacts than in the 
other, and again this could not be explored without having individual-level 
population data. 
Yorkshire is a large area, with a population of 5.3 million349. It does have 
some differences compared to the overall population of the United Kingdom. 
Yorkshire has a slightly larger white population than the U.K. as a whole, 
with 88% compared to 86% of the population identifying as white. Individuals 
of South Asian ethnicity make up 5.3% of the population of the U.K., 
compared to 6.0% of the Yorkshire population. There are also areas of the 
U.K. with much higher proportions of Black and East Asian individuals than 
are seen within Yorkshire349. These differences probably don’t markedly limit 
the applicability of the data to the U.K. as a whole, but may mean it isn’t 
applicable to specific smaller regions with a very different ethnic make-up. 
Yorkshire is also more deprived than the rest of the U.K., with around a 
quarter of the population living in areas within the most deprived quintile375, 
whilst in the U.K. as a whole the population are equally distributed 
throughout the quintiles. This difference in deprivation may also limit the 
applicability of the results of this work to the rest of the UK.  
7.4 Discussion, Strength and Limitations of the Mental 
Health Work 
The work exploring the risk of mental ill health amongst survivors of 
childhood and young adult cancers demonstrated an increased risk of 
specialist mental health services use in this cohort. This is in keeping with 
work from other centres, which have suggested increased mental ill health 
amongst survivors of CYP’s cancers161,267, including a previous Canadian 
population-based study322. Survivors of CYP cancer were no more likely 
than population controls to have recorded mental health diagnoses on 
inpatient HES. This may reflect that fact that co-morbidities are not always 
well recorded on such datasets, and that if the mental health diagnosis if not 
the primary reason for admission, this may well not be recorded376. This 
limitation is explored further in section 7.5.1 Mental Health Data Sets. It is 
suspected that this lack of difference represents poor recording for both 
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cancer survivors and controls, and it is not possible to make any statement 
about risk of mental illness as a result. 
The reasons for increased mental health services use are likely to be 
multifactorial. The increased prevalence of physical health problems which 
would be expected in this cohort may well be a contributory factor, as the 
link between physical and mental health is well documented210,211. The 
emotional impact of a cancer diagnosis is again well recognised, and at least 
some of the increased mental health problems seen may directly result from 
this, with PTSD being a direct result of the cancer diagnosis for some 
individuals294,321. Equally, some issues may result from treatment itself 
having direct effects on the brain and impacting on future mental health, 
particularly cranial radiotherapy or intrathecal chemotherapy256, or from the 
tumour itself in the case of CNS tumours. 
Individuals diagnosed during the TYA period were at greater risk of future 
mental health difficulties than those diagnosed as children. This finding was 
in keeping with literature which has suggested an increased risk of mental ill 
health in those diagnosed with cancer during the TYA age group240,265,322. 
This is likely to be explained by the already-known association between 
physical ill health during adolescence and mental ill health210–212, and the 
the considerable burden of adjusting to a life-changing illness in 
adolescence215, with similar patterns seen in other serious illnesses affecting 
young people377. The increased risk of mental health contacts seen in those 
treated on specialist TYA units, however, was unexpected. Young adults 
treated on specialist TYA units are more satisfied with many aspects of their 
care, including having company of a similar age, provision of space to study, 
and leisure facilities378, and it was anticipated that these factors would have 
led to a reduction in risk of long-term mental ill health. Additionally, those 
young people treated in adult facilities report negative experiences relating 
to isolation, lack of empathy from staff, and inappropriate treatment 
environment379, which could be expected to contribute to greater risk of 
future mental health problems. However, there may be some downsides to 
being treated in an apparently age-appropriate unit. Relationships may be 
forged with fellow young people, some of whom will not survive their illness, 
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which could lead to both natural grief reactions, and survivors’ guilt380. 
Forging close friendships with other cancer patients may also lead to 
jealously from existing friends and neglect of those relationships, leading to 
difficulty reintegrating into previous social circles after treatment. Young 
people treated on specialist TYA units also receive considerable support 
from specialist nurses and youth support workers, which often continues 
long after treatment finishes381. These specialist workers may be able to help 
young people navigate the healthcare system, encouraging them to seek 
medical advice for any difficulties, communicating with general practitioners 
and other professionals about any concerns, and assisting in obtaining 
onward referrals where these are appropriate. It is unclear, therefore, 
whether the increased risk of specialist mental health services use 
represents a true increase in disease prevalence, or whether these 
individuals have better healthcare support and are therefore better at 
accessing specialist services when they are required.  
The increased risk of mental ill health amongst individuals from more 
deprived backgrounds also reflects risk factors seen in the general 
population, with greater mental health problems seen among individuals 
from more deprived backgrounds generally382,383. 
Females in the general population are at higher risk of mental health 
difficulties than males384, and this pattern was reflected in CYP’s cancer 
survivors. There is some evidence that females appear more susceptible to 
earlier stressors than males, which may partially explain this result385,386. 
It was unexpected that there was no increased risk of mental ill health seen 
in those with higher stage disease at presentation. This may be a result of 
smaller numbers of survivors of more advanced disease meaning that a 
difference is not detected, or it may be that individuals with more advanced 
disease are given more intensive support which ameliorates some of the 
impact of their disease and treatment. 
The increased risk of mental ill health seen in survivors of low-grade CNS 
tumours was also unexpected, as it was hypothesised that survivors of high-
grade CNS tumours would have worse mental health as a result of intensive 
treatment and residual disability. These survivors made up a notable 
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proportion of the study cohort, and so it is unlikely to be due to small 
numbers. It may, however, be a result of reduced support offered to 
individuals who are perceived to have had less intensive treatments.  
The decreased risk of mental ill health seen in individuals treated with 
combined chemo- and radiotherapy was also surprising, but may explain 
why individuals with more advanced disease didn’t have the increase in 
mental ill health which had been initially expected, and may also explain why 
survivors of low-grade, rather than high-grade, CNS tumours, had increased 
risk of mental ill health.  
It was, however, counter-intuitive that those allocated NCSI level 3 had 
higher risk of specialist mental health services use, as these are likely to be 
some of the same individuals who received both chemo- and radiotherapy. 
However, because NCSI levels were not available for all individuals, smaller 
sample sizes may have impacted on the reliability of these results. 
Additionally, like those treated on specialist TYA units, those allocated NCSI 
level 3 were likely to be receiving more healthcare support and thus it may 
be that they were better at accessing the specialist care they required, rather 
than having a genuinely increased disease prevalence. 
The effects of time period of diagnosis were also somewhat unexpected, as 
it was anticipated that individuals diagnosed longer ago would be at greatest 
risk of mental ill health regardless of age at diagnosis, due to the more 
intensive treatments used longer ago. However, as previously stated, 
treatment intensity may not correlate well with mental health risk. 
Additionally, in those diagnosed as teenagers, it may be that their mental 
health difficulties emerged more quickly and thus were seen before they 
reached the 5 year period where they were classed as long-term survivors.  
7.4.1 Mental Health Data Sets 
The MHMDS and MHLDDS have the major strength that they are recording 
use of specialist mental health services, and thus all individuals with a 
recorded contact on these data sets will have been assessed as having a 
mental health condition requiring specialist care by a healthcare 
professional. This is an advantage over much work in this field which relies 
on self-reported mental health difficulties172,259,262,280,282,290 or implies 
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diagnoses from prescribing data156,258,265. The converse of this is that these 
data sets only record specialist mental health care, and not individuals who 
are treated in primary care, or those with mental health problems who are 
either undiagnosed or who are not undergoing active treatment. 
Data from the MHMDS and MHLDDS were only available for a relatively 
short time period, from 2006 to 2016, meaning that mental health services 
use out with this period would not have been captured in the analysis in this 
thesis. 
A potentially important limitation of the MHMDS and MHLDDS is that they 
depend on accurate data being recorded and coded. Although the quality of 
coding on HES records in general has improved noticeably in recent years, 
there is always the possibility that a diagnosis or admission has been 
recorded inaccurately330. Additionally, linkage errors may mean that records 
are not identified accurately. Work looking at Paediatric Intensive Care 
admissions has shown a low false match rate of 0.2%, but quite a high 
missed match rate of 4.1%387; if similar rates occurred when the YSRCCYP 
was linked to the MHMDS and MHLDDS then the true prevalence of mental 
health services use amongst CYP’s cancer survivors would have been 
underestimated. 
Another major limitation of the data sets used was that, for the time periods 
where we were able to obtain data, use of mental health care services 
specifically for children and adolescents were not included. These services 
have been included in HES mental health data sets more recently and future 
analyses of these data sets which do include young people’s mental health 
services would be a useful addition to this work. Children diagnosed with 
cancer very early in life may develop mental health problems many years 
after their treatment finishes, but still be classed as “children” at this time and 
thus be treated within children’s services. It is therefore an important 
limitation that the datasets provided did not include the services who would 
have provided care for these young people. 
The exploration of recorded mental health diagnoses on the inpatient HES 
database made some attempt to identify individuals who have a mental 
health diagnosis but who were not necessarily in receipt of specialist mental 
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healthcare. However, these are limited by only being available for individuals 
who had at least one inpatient hospital stay during the period for which data 
were available. Although the high rate of physical health problems amongst 
CYP’s cancer survivors111,184,275 means that many will have had at least one 
admission, there will still have been a considerable number who were never 
an inpatient. There have also been concerns that recording of co-morbidity 
lacks accuracy and has a particularly poor negative predictive value, 
meaning that the absence of a recorded co-morbidity does not mean that it 
is not present376. Inpatient HES data, however, was available for a longer 
period (1998-2017) than the mental health specific data sets. The inclusion 
of these records will have captured individuals who had an inpatient stay for 
a mental health issue between 1998 and 2006 and from 2016 to 2017, who 
would not have been included in the mental health data sets. However, 
looking solely at inpatient mental health stays would not have captured all 
specialist mental health services use in these time periods. The availability 
of this data over a longer time period may explain why a greater percentage 
of survivors had a mental health record on inpatient HES than on the 
MHMDS and/or MHLDDS (12.5% vs 10.7%). Additionally, the fact that this 
dataset may have captured some mental health issues which may not have 
been severe enough to warrant specialist care could also explain the 
increased number of contacts. 
Overall, at the present time, the specific mental health datasets (MHMDS 
and MHLDDS) are likely to be considerably more useful when assessing 
mental illness rates than the inpatient HES database. 
An additional potential limitation is the fact that a small number of individuals 
will opt out of their data being recorded and shared by NHSDigital, through 
the National Data Opt-Out Programme388. As of 2019, 2.74% of the 
population had opted out of having their data shared in this way388. Data 
from these individuals will not appear on any extracts from NHSDigital. This 
should not be a big limitation, as it would be assumed that roughly equal 
proportions of the registry population and whole Yorkshire population would 
have opted out. Additionally, the highest rates of opt-out are in the over 
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60s388, who would not have been included in the work done as part of this 
thesis. 
7.4.2 Primary Care Data 
A notable limitation to this work is the absence of data from primary care. It 
is known that the majority of mental health care is provided in general 
practice163, and one of the main conclusions of the systematic review of the 
literature was that inclusion of data regarding primary care access for mental 
health problems would be beneficial. Although there are considerable 
difficulties identifying mental health problems from primary care records due 
to issues with coding389, this research would have been considerably 
strengthened if primary care data could have been included, despite its 
presumed limitations. 
7.4.2.1 Reasons for Lack of Primary Care Data 
At the start of the study period for this Doctor of Philosophy, it was hoped 
that data would be available from primary care. Unfortunately, despite work 
to request these data and gain ethical approval to use it beginning in early 
2017, data wasn’t received by the University of Leeds until late 2019. There 
were then further delays as University systems did not sufficiently meet data 
security levels to allow the data to be accessed. Data were only available in 
an accessible format in November 2019, however with the period of study for 
this Doctor of Philosophy ending in January 2020, it was not considered 
feasible to analyse these data for inclusion in this thesis. 
7.5 Discussion, Strengths and Limitations of the Fertility 
Preservation Work 
Considerably fewer patients aged 13-17 at diagnosis had banked semen 
compared to those aged 18 and over. This is likely to reflect the fact that 
many younger patients have not reached sexual maturity and are unable to 
produce a sample with sufficient spermatozoa to bank; in a large 
multinational study of adolescents undergoing fertility preservation, likelihood 
of producing an azoospermic sample was inversely correlated with age390. 
Patients under 18 are also likely to be accompanied to their appointment by 
a parent or guardian, and there is evidence that the presence of an 
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accompanying adult reduces the likelihood of producing a sample, probably 
as a result of embarrassment around masturbation391. 
The semen banking rate amongst individuals with CNS tumours was very 
low compared to all other tumour groups. This may be due to the fact that 
many CNS tumours are not treated with gonadotoxic therapies and thus 
there would be no indication to refer for fertility preservation. 
There was a notably lower rate of semen banking amongst those in the 
middle deprivation fifth. This is an unusual finding for which there is no 
obvious explanation, and this may be a result of the small numbers in this 
study. 
As suggested by a previous study, it is likely that fertility preservation is 
associated with decreased mental distress regarding sub-fertility368 and this 
may explain why fewer men who had stored semen had recorded mental ill 
health. Although a significant difference was not seen for recorded contact 
with specialist mental health services between those who had and hadn’t 
banked semen, there was a suggestion of reduced risk in those who had 
stored semen (OR 0.54, 95% CI 0.26-1.16).  
It was also anticipated that having a normal semen analysis following 
treatment would also lead to a reduction in incidence of mental ill health 
requiring specialist treatment, and this was not seen in this study. This may 
reflect the relatively small number of patients for whom we had post-
treatment data rather than a genuine lack of effect. Indeed, one of the major 
limitations to this chapter was the small number of individuals for whom data 
were available, and it is difficult to draw any robust conclusions based on 
such small numbers. The large confidence intervals are almost certainly a 
result of such small numbers, and it may be that a larger study would find 
results which achieved statistical significance. 
A relatively low number of our cohort had banked sperm compared to other 
reports. Even studies looking solely at younger patients reported banking 
rates from 43.8% to 83%392,393. However, the higher rate was seen in a study 
recruiting patients who had already been referred to fertility services and it is 
unclear how many of the overall number of patients diagnosed with cancer 
would have been included. It is also worth noting that rates of semen 
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cryopreservation have been increasing year on year393, and an older paper 
reported lower rates of 28.1%, which are much lower than the rate we 
found394. A paper reporting solely on lymphoma patients, who made up a 
large proportion of our cohort, reported lower rates of 40%, which is 
comparable to our findings395.  
Data were not available on how many of our cohort were referred for fertility 
preservation but were either unable to produce a sample or produced an 
azoospermic sample unsuitable for freezing. Patients with testicular tumours 
and Hodgkin’s lymphoma, who account for a notable number of our cohort, 
have previously been shown to produce poorer quality semen396 and it may 
be that a number of samples which were unsuitable for freezing accounted 
in some part for the low overall banking numbers in this cohort. Additionally, 
a number of the younger patients in our cohort may not have completed 
puberty and may not have been sexually mature enough to actually produce 
a suitable sample397. 
Despite the small number of patients banking sperm being an obvious 
limitation of this work, a major strength is that over 50% of patients who did 
bank semen had had a post-treatment semen sample analysed. This 
compares of rates of 40-42% in other studies395,396. 
Despite the relatively small nature of this study, we have shown that having 
undergone fertility preservation is associated with decreased risk of mental ill 
health requiring specialist care in long-term cancer survivors. This is further 
evidence to support the routine referral of young men with cancer to fertility 
services prior to undergoing cancer treatment where it is safe to do so. 
7.6 Future Work 
7.6.1 Recommendations for the Yorkshire Specialist Register of 
Cancer in Children and Young People 
The YSRCCYP has been an invaluable data source throughout this work. 
Nonetheless, future work could be enhanced by the inclusion of additional 
data.  
A reliable indicator of whether or not an individual has undergone HSCT, 
whether this was an autograft or an allograft, and details on the donor 
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(match status, related or unrelated) would be extremely valuable. The 
intensity of treatment for HSCT may pre-dispose individuals undergoing it to 
multiple future problems, which may include mental health and fertility 
issues, and being able to readily identify them so that they can be studied as 
a separate group would be potentially very useful. The number of individuals 
treated with HSCT has been reported in other cohort studies108,267,292, and 
thus there is a need for this information to be collected. 
More reliable, detailed data on the treatment received by individuals, 
including cumulative dose of high-risk drugs such as anthracyclines and total 
radiotherapy doses, would be helpful and would allow more detailed 
exploration of the links between treatment and future outcomes. At the 
present time, another PhD student is looking at using data linkage between 
the YSRCCYP and electronic hospital records to provide this data, so it may 
be that in future, this data is much more readily available. 
It would also be useful to be able to explore whether being under regular 
specialist oncology or haematology follow-up impacted future risk of mental 
ill health. Therefore, a reliable marker of when an individual was last 
reviewed by specialist services would be a helpful thing for the YSRCCYP to 
include. 
In addition to data on follow-up, if it were possible to access data on physical 
health and late effects, this would allow testing of the hypothesis that at least 
some of the increased mental ill health seen in cancer survivors was related 
to increased physical health difficulties. Although it may be difficult from a 
practical point of view, if the registry were able to maintain a list of ongoing 
late effects, this would allow more exploration of the link between physical 
and mental ill health. This is likely to be a difficult thing to do in practice due 
to data regulation laws not allowing the registry to keep linked data from 
HES, which has previously been used to explore cardiovascular and 
respiratory health problems111,398, in the registry itself.  
7.6.2 Mental Health 
As previously described, the inclusion of primary care data would have 
greatly enhanced this thesis. Work exploring mental health diagnoses, 
prescriptions of drugs for mental health disorders and referrals to specialist 
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services would be extremely valuable and has the potential to form the basis 
of a future thesis. 
Future analysis of the newer mental health data set (the MHSDS), which 
includes data on use of services specifically for children and adolescents 
(i.e. the Child and Adolescent Mental Health Service, or CAMHS), would be 
valuable and would be of particular interest when looking at the long-term 
mental health of those diagnosed with cancer at a very young age.  It is 
important that these young people are not overlooked in future analyses. 
Given the relationship between mental health difficulties early in life and 
future mental health outcomes189,190,204, it is important that use of CAMHS 
services amongst cancer survivors can to be fully explored. 
More granular data on the mental health of the Yorkshire population, 
including individualised data to allow for adjustment for socioeconomic 
status as well as age and sex would also enhance any future work. This 
would also allow comparisons between the ways mental health services are 
accessed so that number of contacts per individual could be explored, 
allowing more in-depth analysis of the potential differences between the 
ways in which cancer survivors and the wider population access specialist 
mental health care.  
7.6.3 Fertility 
The work looking at the impact of fertility preservation on mental health 
services use suggested a decreased risk of mental ill health in individuals 
who had undergone semen cryopreservation. Further work should focus on 
attempting to replicate this study on a larger scale.  
Prospective cohort studies which also record data on referrals to fertility 
services and patients who either decline to produce semen or are unable to 
produce a sample suitable for cryopreservation would be an important next 
step. It would be useful to record both the demographic and disease 
characteristics of these individuals. Analysis should focus not only on the 
differences between those who did and did not undergo fertility preservation, 
but on potential differences between those who chose not to bank semen 
and those who would have chosen to but who were unable to.  
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Additionally, future work should include analysis of the impact of fertility 
preservation work in females, including both oocyte and ovarian tissue 
storage. 
7.7 Conclusion 
This thesis has illustrated the increased risk of specialist mental health 
services use amongst survivors of childhood and young adult cancers 
compared to the wider population in Yorkshire. Groups at particular risk of 
mental ill health have also been highlighted, and include females, those 
diagnosed as teenagers and young adults, those from more deprived 
backgrounds, survivors of low-grade CNS tumours, and those treated 
without chemo- or radiotherapy. Future work should explore the reasons 
behind these associations, and should include the analysis of primary-care 
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Appendix A: List of Fields Recorded in the Yorkshire 
Specialist Registry of Cancer in Children and Young People 
This appendix lists all available fields from the YSRCCYP, which is 
described in Chapter 3: Methods and Data Sources. 
 General details 
o Patient ID 
o NHS number 
o Date of birth 




o Record complete 
o Reason not complete 
o Sex 
o Ethnicity 
o Source details 
o Seen at Leeds Paediatric Oncology department? 
o Seen/tretated at TCT ward? 
o MDT meeting type 
o Comments (free text) 
o Register status 
o Reason not registered (if applicable) 
 Diagnosis 
o Pathology number 






o White blood cell count 
o Height (cm) at diagnosis 
o Weight (kg) at diagnosis 




o Verified address?  
o Time at address 
 Surgery details 
o Date of surgery 
o Did patient refuse surgery? 
o OPCS code 
o Outcome code 
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 Radiotherapy details 
o Date of radiotherapy 
o Did patient refuse radiotherapy? 
o Has patient had RIAT? 
o Has patient had TBI? 
o Is the treatment curative? 
o Is the treatment completed? 
o Site 
o Total dose 
o Gray 
o Fractions 
 Chemotherapy details 
o Date of chemo 
o Did patient refuse chemo? 
o Is the treatment completed? 
o Is there a clinical trial? 
o Which trial? 
o Trial arm 
o Regimen 
o Drug names  
 Relapse details 
o Date of relapse 
o Topography 
 Hospital details 
o Hospital type (treating/referring/other) 
o Hospital address 
o Consultant 
o Unit number 
 Follow up details 
o Date of follow up 
o Imputed? 
o Comments (free text) 
o No treatment? 
o Reason for no treatment 
o Hospital 
o GP/Consultant 
 Follow up status 
o Last known status 
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Appendix B: List of Fields Available from the Mental Health 
Minimum Dataset and Mental Health and Learning 
Disabilities Dataset 
This appendix lists all provided fields from the MHMDS and MHLDDS, which 
are described in Chapter 3: Methods and Data Sources. 
Mental Health Minimum Dataset 
 Dataset ID  
 Unique Record ID  
 Provider Organisation Code 
 Commissioner Code 
 Reporting Period  
 Start Date of Reporting Period 
 End Date of Reporting Period 
 Electoral ward of usual address 
 Primary Care Trust of Residence 
 Gender 
 Marital Status 
 Primary Care Trust of GP Practice 
 Ethnicity 
 Year of First Known Psychiatric Contact 
 Care Spell Identifier 
 Spell Identifier 
 Number of Spells in Reporting Period  
 Specialty Function Code  
 Episode Start Date  
 Source of Referral  
 Episode End Date 
 Spell End Code  
 Spell Days Within Reporting Period 
 Suspended Days in Reporting Period 
 Suspension Reason 
 Care Programme Approach Standard Days 
 Care Programme Approach Enhanced Days 
 Care Programme Level 
 Occupation of Care Co-ordinator 
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 Date Care Programme Approach Care Co-Ordinator Last Seen 
 Marker of Mental Health Care Without Patient Consent 
 Number of Social Services Statutory Assessments for Community 
Care 
 HONOS assessment First Score  
 Date of First HONOS Assessment 
 HONOS assessment Most Recent Score  
 Date of Most Recent HONOS Assessment 
 Worst Ever HONOS Assessment Score 
 Date of Worst Ever Score on HONOS Assessment 
 Best HONOS Assessment Score in Last 12 Months 
 Date of Best Score in Last 12 Months on HONOS Assessment 
 Mental Health Bed Days 
 Mental Health Medium Security Bed Days 
 Intensive Mental Health Care Days 
 Acute Home Based Mental Health Care Days 
 NHS Community Care Bed Days 
 Indicator of Stay in non-NHS Residential Community Care 
 Day Care Attendances (NHS Sites) 
 Day Care Attendances (non-NHS Sites) 
 Indicator of Attendance at Sheltered Work Facility 
 Out-Patient Consultant Attendance 
 Community Psychiatry Contact 
 Clinical Psychology Contact 
 Occupational Therapy Contact 
 Marker of Mental Health Social Worker Involvement 
 Home Help Visit 
 Electroconvulsive Therapy Treatments  
 Number of Admissions 
 Number of Discharges 
 Type of Service/Team Patient Referred To 
 Physiotherapy Contact 
 Consultant Psychotherapy Contact 
 Social Worker Contact  
 Outpatient Did Not Attend 
 Day Care Did Not Attend 
 Contacts with NHS Direct for Mental Health 
 Care Programme Approach Review 
 Method of Ascertaining Spell Start and End Date 
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 Postcode District  
 Age at Start of Mental Health Care Spell 
 Age at End of Mental Health Care Spell 
 Age at Start of Reporting Period 
 Age at End of Reporting Period 
 Age at Date of First Inpatient Review  
 Age at Date of Last Review in Reporting Period 
 Age at Date Last Seen by Care Programme Approach Team 
 Age at Date of Detention under Mental Health Act 
 Age at Date of First Electroconvulsive Therapy Treatment 
 Age at Date of Admission 
 Age at Date of Discharge 
 Age at Date of First HONOS Assessment 
 Age at Most Recent HONOS Assessment 
 Number of Concurrent Legal Statuses 
 Number of Concurrent Mental Statuses 
 Care Spell Number in Reporting Period 
 Calculated Out-Patient Attendances 
 Calculated Out-Patient Did Not Attends 
 Calculated Day Care Attendances 
 Calculated Day Care Did Not Attends 
 First, Most Recent ICD Diagnosis 
 Employment Status 
 Weekly Hours Worked 
 Settled Accommodation Indicator  
 Accommodation Status 
 Valid NHS Number Flag  
 Valid Postcode Flag  
 LSOA 
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Mental Health and Learning Disabilities Dataset 
 Electoral ward of usual address 
 Gender 
 Marital status 
 GP Practise Code 
 Ethnicity 
 Year of First Known Psychiatric Care 
 Episode Start Date 
 Episode End Date 
 Postcode District 
 Reason for End of Healthcare Spell 
 Spell ID 
 Person ID 
 Provider Organisation Code 
 Valid NHS Number Flag  
 Valid Postcode Flag  
 LSOA  
 County  
 Local Authority District/Unitary Authority  
 Age  
 Date of first noticeable change in behaviour or mental state 
 Date of first positive psychotic symptom 
 Date at which positive psychotic symptom has lasted for one week  
 Emergent Psychosis Date 
 Psychosis Treatment Start Date  
 Crisis Plan Creation Date  
 Crisis Plan Last Update Date  
 Ethnic Code Category (Cleansed) 
 Total Number of Days Between Start and End of Ward Stay 
 Total Number of Days Between Start and End of Ward Stay 
(Cleansed) 
 Total Number of Days Between Start and End of Ward Stay, Minus 
Home Leave 
 Organisation Code (Residence Responsibility) 
 Organisation Code (GP Practice Responsibility)  
 Clinical Commissioning Group of GP  
 Indicator of Open Care Programme Approach Episode at End of 
Reporting Period 
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 Indicator of Open MHA Episode at End of Reporting Period  
 Indicator of Open SCT Episode at End of Reporting Period  
 Indicator of Open Recall Episode at End of Reporting Period, where 
Recall Has Not Expired 
 Indicator of Open Spell at End of Reporting Period, with Valid 
Recorded Primary Diagnosis within the Previous 12 Months  
 Employment Status of Most Recent Event 
 Settled Accommodation Status of Most Recent Event   
 Settled Accommodation Indicator for Most Recent Event 
 Indicator of Open Spell at End of Reporting Period and Care 
Programme Approach Review within the Previous 12 Months  
 Indicator of Open EIT Team Episode at End of Reporting Period 
 Indicator of Open AOT Team Episode at End of Reporting Period 
 Indicator of Open WRDST or PROSP Episode at End of Reporting 
Period 
 Length of Spell (in Days)  
 Cluster Code for Most Recent Open Cluster Episode 
 Indicator of Open Care Approach Episode for More Than 365 Days  
 Number of Mental Health Act Admissions  
 Total Number of Discharges in the Reporting Period 
 Total Number of Healthcare Provider Contacts in the Reporting 
Period 
 Number of Attended Healthcare Provider Contacts in the Reporting 
Period 
 Number of Days Between The Start and End of a Delayed Discharge 
Episode 
 Number of Distinct Mental Health Commissioner Codes  
 Total Number of Day Attendance Contacts 
 Number of Attended Day Attendance Contacts 
 Indicator of AWOL Episode 
 Legal Status Classification Code (Cleansed)  
 Most Restrictive Legal Classification During Episode  
 Month ID the Record was Given  
 Financial Year of Episode  
 Marker of Inactive Episode   
 Marker of Open Ward Spell at the End of a Period of Learning 
Disability Care, Plus Intensity of Care 
 Marker of Open Episode with Learning Disability Team  
 Marker of Open Episode with Learning Disability Specialty  
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 Marker of Open Episode with Learning Disability Treatment Function 
 Marker That Patient is Limited by Memory or Concentration, and that 
Symptoms Began Before the Age of 18 years  
 Indicator That HONOS Assessment was Carried Out in Past 12 
Months 
 Indicator That Patient Had a Learning Disability at the Start of the 
Reporting Period 
 Indicator of Open Episode with Learning Disability Services  
 Indicator That Patient Had a Mental Health Issue at the Start of the 
Reporting Period 
 Indicator of Open Episode with Mental Health Services  
 Trace Status of NHS Number 
 Organisation Code of Organisation that Assigned Local Patient 
Identifier 
 Date Smoking Status Recorded  
 Date Disability Questionnaire Completed  
 Smoking Status 
 Answer to Disability Question  
 Answer to Behavioural and Emotional Question 
 Answer to Hearing Question   
 Answer to Manual Dexterity Question 
 Answer to Memory or Ability to Learn Concentrate or Understand 
Question (if Under 18 at Symptom Onset) 
 Answer to Memory or Ability to Learn Concentrate or Understand 
Question (if 18 or Over at Symptom Onset) 
 Answer to Mobility and Gross Motor Question   
 Answer to Perception of Physical Danger Question 
 Answer to Personal, Self-Care and Continence Question   
 Answer to Progressive Conditions and Physical Health Question  
 Answer to Sight Question   
 Answer to Speech Question   
 Answer to Autism Spectrum Conditions Question  
 Answer to Other Question 
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Appendix C: Directed acyclic Graphs 
This appendix shows DAGs with each possible exposure highlighted as the 
primary exposure. 
Figure C1: A Directed acyclic Graph describing the causal relationship 
between risk of mental health hospitalisation and “deprivation” 
highlighted as the primary risk factor of interest (exposure), together 
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Figure C2: A Directed acyclic Graph describing the causal relationship 
between risk of mental health hospitalisation and “ethnicity” highlighted 
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Figure C3: A Directed acyclic Graph describing the causal relationship 
between risk of mental health hospitalisation and “gender” highlighted 
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Figure C4: A Directed acyclic Graph describing the causal relationship 
between risk of mental health hospitalisation and “stage at diagnosis” 
highlighted as the primary risk factor of interest (exposure), together 
with all other variables. 
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Figure C5: A Directed acyclic Graph describing the causal relationship 
between risk of mental health hospitalisation and “treatment at 
specialist TYA unit” highlighted as the primary risk factor of interest 
(exposure), together with all other variables. 
 
  
- 311 - 
 
Figure C6: A Directed acyclic Graph describing the causal relationship 
between risk of mental health hospitalisation and “tumour type” 
highlighted as the primary risk factor of interest (exposure), together 
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Figure C7: A Directed acyclic Graph describing the causal relationship 
between risk of mental health hospitalisation and “year of diagnosis” 
highlighted as the primary risk factor of interest (exposure), together 
with all other variables. 
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Appendix D: Mental Health Contacts Per Financial Year 2006-07 to 2015-16 
This appendix gives full details of the data described in section 5.4: Comparison between Mental Health Services Use amongst 
Individuals on the Yorkshire Specialist Register of Cancer in Children and Young People and the Yorkshire Population as a Whole. 
Data in these tables are broken down by age (5 year age groups) and sex. To ensure anonymity of patients, population data was 
small number suppressed, so an asterisk (*) denotes fewer than 5 individuals in that specific group. 
Table Da Characteristics of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire population, and 


























Male 5 to 9 155287 255 285 1 164 351 
Male 10 to 14 169833 350 506 2 206 395 
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Male 15 to 19 176746 1,535 451 11 868 2439 
Male 20 to 24 188020 2,600 713 7 1383 982 
Male 25 to 29 162529 3,255 745 4 2003 537 
Male 30 to 34 165102 3,715 617 0 2250 0 
Male 35 to 39 192276 3,885 274 0 2021 0 
Male 40 to 44 195660 3,705 267 0 1894 0 
Male 45 to 49 178394 3,135 24 0 1757 0 
Male 50 to 54 159359 2,545 0 0 1597 - 
Male 55 to 59 170719 2,485 0 0 1456 - 
Female 5 to 9 149673 105 228 0 70 0 
Female 10 to 14 162669 235 305 9 144 2951 
Female 15 to 19 171816 1,885 381 26 1097 6824 
Female 20 to 24 185259 2,915 470 25 1573 5319 
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Female 25 to 29 160653 3,120 468 19 1942 4060 
Female 30 to 34 167326 3,545 390 18 2119 4615 
Female 35 to 39 196070 4,070 274 11 2076 4015 
Female 40 to 44 198015 3,975 113 5 2007 4425 
Female 45 to 49 179552 3,315 18 1 1846 5556 
Female 50 to 54 159385 2,815 0 0 1766 - 
Female 55 to 59 173071 2,610 0 0 1508 - 
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Table Db Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 152629 20 253 2 13 791 
Male 10 to 14 167718 80 396 9 48 2273 
Male 15 to 19 178028 1995 473 22 1121 4651 
Male 20 to 24 190703 3460 697 25 1814 3587 
Male 25 to 29 169510 4285 750 21 2528 2800 
Male 30 to 34 159057 4605 621 25 2895 4026 
Male 35 to 39 190695 5200 514 20 2727 3891 
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Male 40 to 44 196751 5030 266 5 2557 1880 
Male 45 to 49 181841 4245 47 1 2334 2128 
Male 50 to 54 161756 3530 0 0 2182 - 
Male 55 to 59 162327 3225 0 0 1987 - 
Female 5 to 9 146978 10 205 0 7 0 
Female 10 to 14 160760 85 283 4 53 1413 
Female 15 to 19 173169 2475 364 20 1429 5495 
Female 20 to 24 187645 3945 474 35 2102 7384 
Female 25 to 29 167284 4320 475 12 2582 2526 
Female 30 to 34 159724 4615 385 13 2889 3377 
Female 35 to 39 194370 5525 312 13 2843 4167 
Female 40 to 44 198929 5440 139 9 2735 6475 
Female 45 to 49 183922 4760 29 0 2588 0 
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Female 50 to 54 161844 3890 0 0 2404 - 
Female 55 to 59 164705 3585 0 0 2177 - 
 
Table Dc Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 150910 5 239 2 3 837 
Male 10 to 14 165492 55 362 6 33 1657 
Male 15 to 19 179588 2395 448 20 1334 4464 
Male 20 to 24 191194 3950 660 17 2066 2576 
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Male 25 to 29 175853 4655 759 17 2647 2240 
Male 30 to 34 156394 4810 644 21 3076 3261 
Male 35 to 39 187248 5640 559 14 3012 2504 
Male 40 to 44 196919 5325 297 9 2704 3030 
Male 45 to 49 185638 4540 88 1 2446 1136 
Male 50 to 54 165051 3790 0 0 2296 - 
Male 55 to 59 157879 3255 0 0 2062 - 
Female 5 to 9 145122 * 190 1 <3 526 
Female 10 to 14 159211 95 270 2 60 741 
Female 15 to 19 173163 2960 351 13 1709 3704 
Female 20 to 24 190667 4170 445 27 2187 6067 
Female 25 to 29 172876 4620 492 17 2672 3455 
Female 30 to 34 155939 4550 392 14 2918 3571 
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Female 35 to 39 190677 5535 354 8 2903 2260 
Female 40 to 44 198375 5710 163 7 2878 4294 
Female 45 to 49 187538 4970 46 1 2650 2174 
Female 50 to 54 165584 4155 0 0 2509 - 
Female 55 to 59 159282 3530 0 0 2216 - 
 
Table Dd Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 150699 10 240 2 7 833 
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Male 10 to 14 163658 50 325 3 31 923 
Male 15 to 19 181011 2400 432 11 1326 2546 
Male 20 to 24 189068 3975 586 22 2102 3754 
Male 25 to 29 176419 4365 780 15 2474 1923 
Male 30 to 34 158376 4725 644 12 2983 1863 
Male 35 to 39 181703 5395 612 11 2969 1797 
Male 40 to 44 196070 5370 331 7 2739 2115 
Male 45 to 49 189784 4690 141 3 2471 2128 
Male 50 to 54 167675 3840 1 0 2290 0 
Male 55 to 59 156201 3190 0 0 2042 - 
Female 5 to 9 144927 * 168 1 <3 595 
Female 10 to 14 157153 80 254 1 51 394 
Female 15 to 19 174399 2785 324 9 1597 2778 
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Female 20 to 24 190457 4335 425 21 2276 4941 
Female 25 to 29 174848 4430 499 13 2534 2605 
Female 30 to 34 155785 4425 410 12 2840 2927 
Female 35 to 39 184624 5365 378 7 2906 1852 
Female 40 to 44 197932 5590 189 4 2824 2116 
Female 45 to 49 191479 5010 72 4 2616 5556 
Female 50 to 54 168712 4210 1 0 2495 0 
Female 55 to 59 157503 3455 0 0 2194 - 
 
Table De Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 



















100,000)  of 
YSRCCYP 
Population with 






Male 5 to 9 151812 10 214 1 7 467 
Male 10 to 14 161736 25 308 1 15 325 
Male 15 to 19 180251 2345 430 14 1301 3256 
Male 20 to 24 191756 4070 539 21 2122 3896 
Male 25 to 29 175949 4285 738 13 2435 1762 
Male 30 to 34 161810 4775 695 18 2951 2590 
Male 35 to 39 176893 5465 623 15 3089 2408 
Male 40 to 44 194540 5380 384 12 2765 3125 
Male 45 to 49 193017 4905 185 6 2541 3243 
Male 50 to 54 171703 3855 6 0 2245 0 
Male 55 to 59 155273 3280 0 0 2112 - 
Female 5 to 9 146333 5 148 1 3 676 
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Female 10 to 14 155789 45 238 1 29 420 
Female 15 to 19 173107 2910 306 4 1681 1307 
Female 20 to 24 190828 4380 419 24 2295 5728 
Female 25 to 29 176440 4410 476 13 2499 2731 
Female 30 to 34 159453 4490 429 15 2816 3497 
Female 35 to 39 178136 5255 396 10 2950 2525 
Female 40 to 44 196611 5625 233 1 2861 429 
Female 45 to 49 194412 5230 84 3 2690 3571 
Female 50 to 54 173153 4280 7 0 2472 0 
Female 55 to 59 155741 3535 0 0 2270 - 
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Table Df Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 155272 5 201 0 3 0 
Male 10 to 14 158335 30 285 1 19 351 
Male 15 to 19 178838 2430 405 10 1359 2469 
Male 20 to 24 196830 5590 510 14 2840 2745 
Male 25 to 29 176818 5390 706 17 3048 2408 
Male 30 to 34 165170 5900 740 19 3572 2568 
Male 35 to 39 170345 6160 613 14 3616 2284 
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Male 40 to 44 194396 6830 449 10 3513 2227 
Male 45 to 49 195079 6225 227 8 3191 3524 
Male 50 to 54 175586 4970 24 1 2831 4167 
Male 55 to 59 156029 4135 0 0 2650 - 
Female 5 to 9 149374 * 136 1 <3 735 
Female 10 to 14 152693 70 228 0 46 0 
Female 15 to 19 172391 3265 304 8 1894 2632 
Female 20 to 24 193090 6540 379 26 3387 6860 
Female 25 to 29 176796 6350 469 18 3592 3838 
Female 30 to 34 163631 6215 464 11 3798 2371 
Female 35 to 39 170086 6330 381 10 3722 2625 
Female 40 to 44 196674 7300 276 7 3712 2536 
Female 45 to 49 196128 7000 111 3 3569 2703 
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Female 50 to 54 177520 5830 18 1 3284 5556 
Female 55 to 59 156652 4720 0 0 3013 - 
 
Table Dg Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 159108 105 192 0 66 0 
Male 10 to 14 155203 180 253 1 116 395 
Male 15 to 19 177400 2375 396 13 1339 3283 
Male 20 to 24 201574 5705 472 16 2830 3390 
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Male 25 to 29 176774 5380 691 18 3043 2605 
Male 30 to 34 168397 5635 743 18 3346 2423 
Male 35 to 39 163311 5925 617 21 3628 3404 
Male 40 to 44 191554 6640 511 15 3466 2935 
Male 45 to 49 195772 6320 265 7 3228 2642 
Male 50 to 54 179699 5325 47 2 2963 4255 
Male 55 to 59 158532 4260 0 0 2687 - 
Female 5 to 9 153322 30 140 1 20 714 
Female 10 to 14 149604 150 204 0 100 0 
Female 15 to 19 170110 3030 282 5 1781 1773 
Female 20 to 24 195408 6455 363 23 3303 6336 
Female 25 to 29 177270 6070 472 20 3424 4237 
Female 30 to 34 168344 6060 472 16 3600 3390 
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Female 35 to 39 162306 5835 388 11 3595 2835 
Female 40 to 44 194673 6980 308 8 3585 2597 
Female 45 to 49 196790 6840 135 4 3476 2963 
Female 50 to 54 181893 5815 29 1 3197 3448 
Female 55 to 59 159177 4820 0 0 3028 - 
 
Table Dh Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 161093 20 184 0 12 0 
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Male 10 to 14 150126 75 238 1 50 420 
Male 15 to 19 170259 2320 362 9 1363 2486 
Male 20 to 24 200000 5880 387 16 2940 4134 
Male 25 to 29 175559 5695 654 16 3244 2446 
Male 30 to 34 168436 5685 750 22 3375 2933 
Male 35 to 39 155377 5890 641 19 3791 2964 
Male 40 to 44 184123 6660 556 11 3617 1978 
Male 45 to 49 191154 6630 295 14 3468 4746 
Male 50 to 54 179297 5640 88 1 3146 1136 
Male 55 to 59 157524 4585 0 0 2911 - 
Female 5 to 9 154677 5 134 0 3 0 
Female 10 to 14 144720 110 189 0 76 0 
Female 15 to 19 163717 3225 268 2 1970 746 
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Female 20 to 24 192024 6785 350 15 3533 4286 
Female 25 to 29 176174 6545 452 19 3715 4204 
Female 30 to 34 169881 6440 488 18 3791 3689 
Female 35 to 39 154220 5950 385 9 3858 2338 
Female 40 to 44 186781 6980 352 8 3737 2273 
Female 45 to 49 192575 6890 161 2 3578 1242 
Female 50 to 54 181300 6195 46 3 3417 6522 
Female 55 to 59 159243 5070 0 0 3184 - 
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Table Di Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 167988 40 169 0 24 0 
Male 10 to 14 152590 265 235 1 174 426 
Male 15 to 19 171781 3330 325 8 1939 2462 
Male 20 to 24 202804 7420 430 17 3659 3953 
Male 25 to 29 179330 6800 583 23 3792 3945 
Male 30 to 34 171509 6540 773 23 3813 2975 
Male 35 to 39 157911 6330 639 12 4009 1878 
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Male 40 to 44 182022 7070 609 14 3884 2299 
Male 45 to 49 194112 7100 330 6 3658 1818 
Male 50 to 54 187732 6340 140 3 3377 2143 
Male 55 to 59 163387 5140 1 0 3146 0 
Female 5 to 9 161195 15 124 0 9 0 
Female 10 to 14 147039 370 168 0 252 0 
Female 15 to 19 165108 4280 251 5 2592 1992 
Female 20 to 24 194267 7850 324 11 4041 3395 
Female 25 to 29 179142 7365 423 20 4111 4728 
Female 30 to 34 174326 7075 495 18 4058 3636 
Female 35 to 39 156859 6695 403 16 4268 3970 
Female 40 to 44 184299 7300 315 8 3961 2540 
Female 45 to 49 196669 7500 188 6 3814 3191 
- 334 - 
 
Female 50 to 54 189415 6940 71 3 3664 4225 
Female 55 to 59 166149 5490 1 0 3304 0 
 
Table Dj Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 171839 25 148 0 15 0 
Male 10 to 14 153766 55 211 1 36 474 
Male 15 to 19 170728 2985 307 1 1748 326 
Male 20 to 24 201670 6790 425 5 3367 1176 
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Male 25 to 29 182668 6205 537 5 3397 931 
Male 30 to 34 171910 5810 733 6 3380 819 
Male 35 to 39 159967 5575 691 6 3485 868 
Male 40 to 44 176292 6100 618 8 3460 1294 
Male 45 to 49 192672 6185 382 12 3210 3141 
Male 50 to 54 190939 5545 184 1 2904 543 
Male 55 to 59 167866 4605 6 0 2743 0 
Female 5 to 9 164525 10 120 0 6 0 
Female 10 to 14 148329 115 148 1 78 676 
Female 15 to 19 163858 3500 236 1 2136 424 
Female 20 to 24 193226 7000 306 3 3623 980 
Female 25 to 29 179938 6595 418 7 3665 1675 
Female 30 to 34 175653 6150 472 4 3501 847 
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Female 35 to 39 160071 5720 423 6 3573 1418 
Female 40 to 44 177771 6040 392 5 3398 1276 
Female 45 to 49 195697 6475 233 2 3309 858 
Female 50 to 54 192841 6075 83 2 3150 2410 
Female 55 to 59 170980 4935 7 0 2886 0 
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Appendix E: Mental Health Co-Morbidity Per Financial Year 1997-98 to 2016-17 
This appendix gives full details of the data described in section 5.5: Comparison between Mental Health Co-Morbidity amongst 
Individuals on the Yorkshire Specialist Register of Cancer in Children and Young People and the Yorkshire Population. Data in these 
tables are broken down by age (5 year age groups) and sex. 
Table Ea Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 172875             30  479 0 17  0  
Male 10 to 14 164457            121  701 1 74  143  
Male 15 to 19 153988            499  752 0 324  0  
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Male 20 to 24 156350         1,014  625 2 649  320  
Male 25 to 29 179797         1,104  521 2 614  384  
Male 30 to 34 190822         1,020  274 2 535  730  
Male 35 to 39 178780            926  47 0 518  0  
Male 40 to 44 160788            499  0 0 310   0 
Female 5 to 9 165852               11  368 0 7  0  
Female 10 to 14 156937               94  477 0 60  0  
Female 15 to 19 149528            498  478 0 333  0  
Female 20 to 24 152605            699  400 2 458  500  
Female 25 to 29 181367            819  316 0 385  0  
Female 30 to 34 194057            909  143 0 422  0  
Female 35 to 39 181294            761  31 0 501  0  
Female 40 to 44 161112            681  0 0 472   0 
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Table Eb Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 171797 46 451 0 27 0  
Male 10 to 14 167233 207 665 0 124 0  
Male 15 to 19 155948 740 764 0 475 0  
Male 20 to 24 150378 1340 646 2 891 310  
Male 25 to 29 175072 1492 570 0 852 0  
Male 30 to 34 189141 1453 303 5 768 1650  
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Male 35 to 39 182078 1331 89 2 731 2247  
Male 40 to 44 163527 1151 0 0 704  0 
Female 5 to 9 165852 164038 9 353 15 0 
Female 10 to 14 156937 159654 104 449 166 2 
Female 15 to 19 149528 151359 464 495 703 2 
Female 20 to 24 152605 147161 610 396 898 2 
Female 25 to 29 181367 177037 595 361 1054 0 
Female 30 to 34 194057 192628 588 167 1132 0 
Female 35 to 39 181294 184516 572 49 1056 0 
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Table Ec Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 170305 52 434 0 31 0 
Male 10 to 14 168947 235 592 2 139 338 
Male 15 to 19 158069 818 786 2 517 254 
Male 20 to 24 149566 1313 646 3 878 464 
Male 25 to 29 165670 1456 621 1 879 161 
Male 30 to 34 186171 1420 337 1 763 297 
Male 35 to 39 184315 1288 145 0 699 0 
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Male 40 to 44 166019 1118 1 0 673 0 
Female 5 to 9 162796 21 325 0 13 0 
Female 10 to 14 162148 214 430 0 132 0 
Female 15 to 19 154542 647 502 0 419 0 
Female 20 to 24 146763 765 415 1 521 241 
Female 25 to 29 169112 847 387 1 501 258 
Female 30 to 34 189959 978 194 0 515 0 
Female 35 to 39 188074 975 194 0 518 0 
Female 40 to 44 167348 948 74 0 566 0 
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Table Ed Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 167546               54  432 0 32  0  
Male 10 to 14 169929            193  545 0 114  0  
Male 15 to 19 160085            795  746 1 497  134  
Male 20 to 24 149711         1,332  700 3 890  429  
Male 25 to 29 158937         1,535  631 3 966  475  
Male 30 to 34 182967         1,513  389 3 827  771  
Male 35 to 39 186511         1,553  189 2 833  1058  
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Male 40 to 44 169753         1,203  6 0 709  0  
Female 5 to 9 159686               13  308 0 8  0  
Female 10 to 14 163310            212  424 0 130  0  
Female 15 to 19 155011            602  478 4 388  837  
Female 20 to 24 149181            824  436 1 552  229  
Female 25 to 29 162858         1,002  406 0 615  0  
Female 30 to 34 188007            953  238 0 507  0  
Female 35 to 39 190943         1,261  87 0 660  0  
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Table Ee Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 164178 63 406 0 38 0 
Male 10 to 14 171854 210 515 1 122 194 
Male 15 to 19 163711 724 716 2 442 279 
Male 20 to 24 153034 1230 154 7 804 4545 
Male 25 to 29 151923 1510 621 6 994 966 
Male 30 to 34 181755 1599 456 1 880 219 
Male 35 to 39 188097 1571 228 0 835 0 
- 346 - 
 
Male 40 to 44 173558 1361 24 0 784 0 
Female 5 to 9 156839 23 305 0 15 0 
Female 10 to 14 165354 214 384 0 129 0 
Female 15 to 19 157813 577 471 2 366 425 
Female 20 to 24 154001 824 471 5 535 1062 
Female 25 to 29 156249 937 392 2 600 510 
Female 30 to 34 187561 1046 281 0 558 0 
Female 35 to 39 192490 1182 115 0 614 0 
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Table Ef Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 165074 63 396 0 38 0 
Male 10 to 14 175138 173 477 1 99 210 
Male 15 to 19 170083 695 700 0 409 0 
Male 20 to 24 161830 1279 752 3 790 399 
Male 25 to 29 148244 1602 624 2 1081 321 
Male 30 to 34 182911 1813 518 0 991 0 
Male 35 to 39 193480 1698 268 0 878 0 
- 348 - 
 
Male 40 to 44 181624 1441 47 1 793 2128 
Female 5 to 9 157965 14 283 0 9 0 
Female 10 to 14 168847 188 366 0 111 0 
Female 15 to 19 163361 672 475 2 411 421 
Female 20 to 24 164822 886 476 2 538 420 
Female 25 to 29 151920 987 398 1 650 251 
Female 30 to 34 190095 1181 315 1 621 317 
Female 35 to 39 198154 1261 141 0 636 0 
Female 40 to 44 184138 1175 30 0 638 0 
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Table Eg Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 162947 67 362 1 41 276 
Male 10 to 14 174125 223 450 1 128 222 
Male 15 to 19 173536 635 662 0 366 0 
Male 20 to 24 168427 1372 763 3 815 393 
Male 25 to 29 144840 1544 646 5 1066 774 
Male 30 to 34 179062 1772 565 1 990 177 
Male 35 to 39 193556 1782 299 2 921 669 
- 350 - 
 
Male 40 to 44 185654 1583 88 0 853 0 
Female 5 to 9 156660 15 270 0 10 0 
Female 10 to 14 167375 220 351 1 131 285 
Female 15 to 19 167955 593 447 0 353 0 
Female 20 to 24 171591 938 493 4 547 811 
Female 25 to 29 148205 986 394 1 665 254 
Female 30 to 34 186623 1210 359 1 648 279 
Female 35 to 39 197992 1293 166 0 653 0 
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Table Eh Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 161285 84 325 0 52 0 
Male 10 to 14 173880 226 433 1 130 231 
Male 15 to 19 174545 741 589 2 425 340 
Male 20 to 24 178294 1261 785 2 707 255 
Male 25 to 29 148412 1513 646 3 1019 464 
Male 30 to 34 174828 1836 617 2 1050 324 
Male 35 to 39 193215 1900 334 1 983 299 
- 352 - 
 
Male 40 to 44 190067 1717 142 1 903 704 
Female 5 to 9 154826 20 254 0 13 0 
Female 10 to 14 166436 260 325 0 156 0 
Female 15 to 19 169637 688 428 2 406 467 
Female 20 to 24 176551 993 500 2 562 400 
Female 25 to 29 149169 1069 413 1 717 242 
Female 30 to 34 180559 1233 385 0 683 0 
Female 35 to 39 197713 1359 193 0 687 0 
Female 40 to 44 192880 1717 73 0 890 0 
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Table Ei Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 158967 67 308 1 42 325 
Male 10 to 14 172505 220 431 2 128 464 
Male 15 to 19 175352 741 542 0 423 0 
Male 20 to 24 185633 1381 745 1 744 134 
Male 25 to 29 156791 1569 700 4 1001 571 
Male 30 to 34 171243 1812 626 1 1058 160 
Male 35 to 39 193120 1922 384 2 995 521 
- 354 - 
 
Male 40 to 44 194136 1870 187 1 963 535 
Female 5 to 9 152994 22 238 0 14 0 
Female 10 to 14 164583 272 308 1 165 325 
Female 15 to 19 171115 658 422 4 385 948 
Female 20 to 24 182278 1067 476 0 585 0 
Female 25 to 29 154961 1069 433 4 690 924 
Female 30 to 34 174863 1380 405 3 789 741 
Female 35 to 39 196412 1405 237 0 715 0 
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Table Ej Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 155287 86 285 0 55 0 
Male 10 to 14 169833 279 506 2 164 395 
Male 15 to 19 176746 767 451 3 434 665 
Male 20 to 24 188020 1358 713 3 722 421 
Male 25 to 29 162529 1630 745 2 1003 268 
Male 30 to 34 165102 1891 617 4 1145 648 
Male 35 to 39 192276 2037 274 2 1059 730 
Male 40 to 44 195660 1964 267 0 1004 0 
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Female 5 to 9 149673 21 228 0 14 0 
Female 10 to 14 162669 259 305 0 159 0 
Female 15 to 19 171816 723 381 2 421 525 
Female 20 to 24 185259 1095 470 1 591 213 
Female 25 to 29 160653 1239 468 0 771 0 
Female 30 to 34 167326 1289 390 4 770 1026 
Female 35 to 39 196070 1490 274 0 760 0 
Female 40 to 44 198015 1664 113 1 840 885 
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Table Ek Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 152629 97 253 0 64 0 
Male 10 to 14 167718 230 396 0 137 0 
Male 15 to 19 178028 755 473 1 424 211 
Male 20 to 24 190703 1202 697 2 630 287 
Male 25 to 29 169510 1599 750 4 943 533 
Male 30 to 34 159057 1740 621 1 1094 161 
Male 35 to 39 190695 2019 514 1 1059 195 
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Male 40 to 44 196751 2129 266 0 1082 0 
Female 5 to 9 146978 31 205 0 21 0 
Female 10 to 14 160760 295 283 0 184 0 
Female 15 to 19 173169 698 364 4 403 1099 
Female 20 to 24 187645 1085 474 2 578 422 
Female 25 to 29 167284 1316 475 2 787 421 
Female 30 to 34 159724 1370 385 4 858 1039 
Female 35 to 39 194370 1479 312 1 761 321 
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Table El Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 150910 127 239 1 84 418 
Male 10 to 14 165492 300 362 1 181 276 
Male 15 to 19 179588 765 448 4 426 893 
Male 20 to 24 191194 1311 660 4 686 606 
Male 25 to 29 175853 1621 759 4 922 527 
Male 30 to 34 156394 1893 644 1 1210 155 
Male 35 to 39 187248 2227 559 3 1189 537 
- 360 - 
 
Male 40 to 44 196919 2334 297 0 1185 0 
Female 5 to 9 145122 81 190 1 56 526 
Female 10 to 14 159211 290 270 0 182 0 
Female 15 to 19 173163 795 351 4 459 1140 
Female 20 to 24 190667 1185 445 5 622 1124 
Female 25 to 29 172876 1412 492 2 817 407 
Female 30 to 34 155939 1384 392 3 888 765 
Female 35 to 39 190677 1743 354 2 914 565 
Female 40 to 44 198375 1915 163 0 965 0 
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Table Em Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 150699 121 240 1 80 417 
Male 10 to 14 163658 316 325 1 193 308 
Male 15 to 19 181011 835 432 2 461 463 
Male 20 to 24 189068 1512 586 3 800 512 
Male 25 to 29 176419 1866 780 4 1058 513 
Male 30 to 34 158376 2108 644 2 1331 311 
Male 35 to 39 181703 2488 612 3 1369 490 
- 362 - 
 
Male 40 to 44 196070 2727 331 1 1391 302 
Male 45 to 49 189784 544 141 4 287 2837 
Female 5 to 9 144927 85 168 0 59 0 
Female 10 to 14 157153 332 254 2 211 787 
Female 15 to 19 174399 1067 324 3 612 926 
Female 20 to 24 190457 1621 425 3 851 706 
Female 25 to 29 174848 1822 499 6 1042 1202 
Female 30 to 34 155785 1779 410 5 1142 1220 
Female 35 to 39 184624 2079 378 0 1126 0 
Female 40 to 44 197932 2217 189 0 1120 0 
Female 45 to 49 191479 386 72 0 202 0 
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Table En Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 151812 193 214 1 127 467 
Male 10 to 14 161736 342 308 2 211 649 
Male 15 to 19 180251 1058 430 5 587 1163 
Male 20 to 24 191756 1860 539 7 970 1299 
Male 25 to 29 175949 2254 738 3 1281 407 
Male 30 to 34 161810 2613 695 6 1615 863 
Male 35 to 39 176893 3260 623 4 1843 642 
- 364 - 
 
Male 40 to 44 194540 3405 384 3 1750 781 
Male 45 to 49 193017 657 185 0 340 0 
Female 5 to 9 146333 143 148 2 98 1351 
Female 10 to 14 155789 362 238 1 232 420 
Female 15 to 19 173107 1296 306 1 749 327 
Female 20 to 24 190828 2196 419 7 1151 1671 
Female 25 to 29 176440 2383 476 3 1351 630 
Female 30 to 34 159453 2459 429 5 1542 1166 
Female 35 to 39 178136 2807 396 6 1576 1515 
Female 40 to 44 196611 3058 233 2 1555 858 
Female 45 to 49 194412 604 84 0 311 0 
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Table Eo Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 155272 180 201 1 116 498 
Male 10 to 14 158335 373 285 6 236 2105 
Male 15 to 19 178838 2047 405 3 1145 741 
Male 20 to 24 196830 4448 510 14 2260 2745 
Male 25 to 29 176818 4723 706 19 2671 2691 
Male 30 to 34 165170 4963 740 12 3005 1622 
Male 35 to 39 170345 5947 613 9 3491 1468 
- 366 - 
 
Male 40 to 44 194396 6872 449 9 3535 2004 
Male 45 to 49 195079 5855 227 3 3001 1322 
Male 50 to 54 175586 5222 24 0 2974 0 
Male 55 to 59 156029 4833 0 0 3098  0 
Female 5 to 9 149374 112 136 0 75 0 
Female 10 to 14 152693 439 228 0 288 0 
Female 15 to 19 172391 4071 304 2 2361 658 
Female 20 to 24 193090 7836 379 12 4058 3166 
Female 25 to 29 176796 7074 469 16 4001 3412 
Female 30 to 34 163631 5944 464 12 3633 2586 
Female 35 to 39 170086 5951 381 10 3499 2625 
Female 40 to 44 196674 6540 276 4 3325 1449 
Female 45 to 49 196128 6022 111 1 3070 901 
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Female 50 to 54 177520 5151 18 0 2902 0 
Female 55 to 59 156652 4254 0  0 2716 0  
 
Table Ep Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 159108 201 192 1 126 521 
Male 10 to 14 155203 339 253 1 218 395 
Male 15 to 19 177400 2323 396 9 1309 2273 
Male 20 to 24 201574 5127 472 20 2543 4237 
- 368 - 
 
Male 25 to 29 176774 5310 691 11 3004 1592 
Male 30 to 34 168397 5975 743 6 3548 808 
Male 35 to 39 163311 6411 617 10 3926 1621 
Male 40 to 44 191554 7703 511 2 4021 391 
Male 45 to 49 195772 7568 265 2 3866 755 
Male 50 to 54 179699 7294 47 0 4059 0 
Male 55 to 59 158532 6416 0  0 4047 0  
Female 5 to 9 153322 101 140 1 66 714 
Female 10 to 14 149604 417 204 0 279 0 
Female 15 to 19 170110 4857 282 10 2855 3546 
Female 20 to 24 195408 9899 363 10 5066 2755 
Female 25 to 29 177270 9244 472 9 5215 1907 
Female 30 to 34 168344 7586 472 12 4506 2542 
- 369 - 
 
Female 35 to 39 162306 6690 388 7 4122 1804 
Female 40 to 44 194673 7967 308 6 4093 1948 
Female 45 to 49 196790 8057 135 2 4094 1481 
Female 50 to 54 181893 7593 29 0 4174 0 
Female 55 to 59 159177 6084 0  0 3822 0  
 
Table Eq Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 161093 203 184 2 126 1087 
- 370 - 
 
Male 10 to 14 150126 394 238 0 262 0 
Male 15 to 19 170259 2462 362 7 1446 1934 
Male 20 to 24 200000 5413 387 6 2707 1550 
Male 25 to 29 175559 6025 654 12 3432 1835 
Male 30 to 34 168436 6437 750 8 3822 1067 
Male 35 to 39 155377 6523 641 12 4198 1872 
Male 40 to 44 184123 7917 556 8 4300 1439 
Male 45 to 49 191154 7939 295 5 4153 1695 
Male 50 to 54 179297 7993 88 1 4458 1136 
Male 55 to 59 157524 7154 0  0 4542 0  
Female 5 to 9 154677 125 134 1 81 746 
Female 10 to 14 144720 509 189 1 352 529 
Female 15 to 19 163717 5151 268 7 3146 2612 
- 371 - 
 
Female 20 to 24 192024 11023 350 10 5740 2857 
Female 25 to 29 176174 10182 452 17 5780 3761 
Female 30 to 34 169881 8752 488 6 5152 1230 
Female 35 to 39 154220 7051 385 5 4572 1299 
Female 40 to 44 186781 8474 352 10 4537 2841 
Female 45 to 49 192575 8813 161 1 4576 621 
Female 50 to 54 181300 8266 46 0 4559 0 
Female 55 to 59 159243 6906 0  0 4337 0 
 
Table Er Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 
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Male 5 to 9 167988 220 169 2 131 1183 
Male 10 to 14 152590 416 235 3 273 1277 
Male 15 to 19 171781 2520 325 4 1467 1231 
Male 20 to 24 202804 5683 430 5 2802 1163 
Male 25 to 29 179330 6296 583 14 3511 2401 
Male 30 to 34 171509 6577 773 8 3835 1035 
Male 35 to 39 157911 6704 639 9 4245 1408 
Male 40 to 44 182022 8188 609 8 4498 1314 
Male 45 to 49 194112 8779 330 10 4523 3030 
Male 50 to 54 187732 8591 140 2 4576 1429 
Male 55 to 59 163387 7499 1 0 4590 0 
Female 5 to 9 161195 146 124 0 91 0 
- 373 - 
 
Female 10 to 14 147039 513 168 1 349 595 
Female 15 to 19 165108 5359 251 6 3246 2390 
Female 20 to 24 194267 11361 324 7 5848 2160 
Female 25 to 29 179142 11108 423 5 6201 1182 
Female 30 to 34 174326 9839 495 10 5644 2020 
Female 35 to 39 156859 7698 403 2 4908 496 
Female 40 to 44 184299 9062 315 11 4917 3492 
Female 45 to 49 196669 9568 188 4 4865 2128 
Female 50 to 54 189415 9315 71 0 4918 0 
Female 55 to 59 166149 7719 1 0 4646 0 
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Table Es Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 171839 263 148 0 153 0 
Male 10 to 14 153766 437 211 0 284 0 
Male 15 to 19 170728 2450 307 0 1435 0 
Male 20 to 24 201670 5675 425 4 2814 941 
Male 25 to 29 182668 6403 537 6 3505 1117 
Male 30 to 34 171910 6854 733 10 3987 1364 
Male 35 to 39 159967 6611 691 10 4133 1447 
- 375 - 
 
Male 40 to 44 176292 7989 618 7 4532 1133 
Male 45 to 49 192672 8918 382 5 4629 1309 
Male 50 to 54 190939 8631 184 0 4520 0 
Male 55 to 59 167866 8099 6 0 4825 0 
Female 5 to 9 164525 196 120 0 119 0 
Female 10 to 14 148329 535 148 0 361 0 
Female 15 to 19 163858 5282 236 2 3224 847 
Female 20 to 24 193226 11665 306 9 6037 2941 
Female 25 to 29 179938 11874 418 8 6599 1914 
Female 30 to 34 175653 10198 472 8 5806 1695 
Female 35 to 39 160071 8200 423 8 5123 1891 
Female 40 to 44 177771 8991 392 12 5058 3061 
Female 45 to 49 195697 9871 233 1 5044 429 
- 376 - 
 
Female 50 to 54 192841 10073 83 2 5223 2410 
Female 55 to 59 170980 8344 7 0 4880 0 
 
Table Et Populations of the Yorkshire Specialist Register of Cancer in Children and Young People and Yorkshire and number of 


























Male 5 to 9 5 to 9 171383 165 117 283 2 
Male 10 to 14 10 to 14 154781 279 199 432 1 
Male 15 to 19 15 to 19 164448 1470 284 2417 3 
Male 20 to 24 20 to 24 197034 2876 402 5667 4 
- 377 - 
 
Male 25 to 29 25 to 29 185133 3738 506 6921 9 
Male 30 to 34 30 to 34 170656 4093 704 6985 13 
Male 35 to 39 35 to 39 160032 4440 734 7106 13 
Male 40 to 44 40 to 44 165352 4828 611 7983 11 
Male 45 to 49 45 to 49 188542 4751 446 8957 5 
Male 50 to 54 50 to 54 188456 4884 224 9204 2 
Male 55 to 59 55 to 59 168292 5000 24 8414 0 
Female 5 to 9 5 to 9 163594 81 93 132 0 
Female 10 to 14 10 to 14 148740 361 136 537 0 
Female 15 to 19 15 to 19 158176 3537 227 5595 4 
Female 20 to 24 20 to 24 188347 6689 303 12598 3 
Female 25 to 29 25 to 29 179967 7410 378 13336 18 
Female 30 to 34 30 to 34 173525 6519 467 11312 10 
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Female 35 to 39 35 to 39 161104 5638 459 9083 10 
Female 40 to 44 40 to 44 166626 5418 407 9028 10 
Female 45 to 49 45 to 49 191763 5543 276 10629 6 
Female 50 to 54 50 to 54 190431 5592 110 10648 1 
Female 55 to 59 55 to 59 171507 5437 18 9325 0 
 
 
